Immunoregulatory proteases in systemic lupus erythematosus and lupus nephritis by Rupanagudi, Khader Valli
 
 
 
 
 
Aus der Medizinischen Klinik und Poliklinik IV  
der Ludwig-Maximilians-Universität München  
Direktor: Prof. Dr. med. Martin Reincke  
 
 
 
Immunoregulatory Proteases in 
Systemic Lupus Erythematosus and Lupus Nephritis 
 
 
 
 
 
 
 
Dissertation 
zum Erwerb des Doktorgrades der Humanbiologie 
an der Medizinischen Fakultät der 
Ludwig-Maximilians-Universität zu München 
 
 
 
 
 
 
 
Vorgelegt von 
 
Khader Valli Rupanagudi 
aus 
Proddatur, India 
2013 
 
 
 
 
 
Mit Genehmigung der Medizinischen Fakultät 
der Universität München 
  
  
   
1. Berichterstatter:                   Prof. Dr. med. Hans-Joachim Anders  
  
              
1. Mitberichterstatter:               Prof. Dr. Dr. Christian Sommerhoff         
          
2. Mitberichterstatter:                  Priv. Doz. Dr. Bianca Schaub  
 
3. Mitberichterstatter:                  Prof. Dr. jӧrg Christoph Prinz 
 
Mitbetreuung durch den 
Promovierten Mitarbeiter:            Dr. med. Julia Lichtnekert     
 
Dekan:                                      Prof. Dr. med. Dr. h.c. M. Reiser, FACR, FRCR  
  
 
Tag der mündlichen Prüfung:  12.11.2013     
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Dedicated to 
 
My wife Mrs. Sunitha Rupanagudi 
My sons - Mahesh Rupanagudi & 
Krishna Teja Rupanagudi 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Khader Valli Rupanagudi M. Sc.  
Medizinische Klinik und Poliklinik IV,  
Klinikum der Universität Muenchen, 
Nephrologisches Zentrum, 
Arbeitsgruppe Klinische Biochemie,  
Schillerstraße-42, Munich-80336, Germany.  
Tel. 0049/89/2180-75857 
khaderbio@gmail.com  
  
DECLARATION  
 
I hereby declare that the present work embodied in this thesis was carried out by me under the 
supervision of Prof. Hans Joachim Anders, Medizinische Klinik und Poliklinik IV- Innenstadt, 
Klinikum der Universität München. This work has not been submitted in part or full to any other 
university or institute for any degree or diploma.  
 
Publications 
 
Julia Lichtnekert, Khader Valli Rupanagudi, Onkar P. Kulkarni, Murthy Narayana  Darisipudi, 
Ramanjaneyulu Allam and Hans-Joachim Anders. Activated Protein C Attenuates Systemic Lupus 
Erythematosus and Lupus Nephritis in MRL-Fas(lpr) Mice. The Journal of Immunology, 2011 Sep 
15; 187(6):3413-21.  
 
Khader Valli Rupanagudi, Onkar P. Kulkarni, Julia Lichtnekert, Murthy Narayana Darisipudi, 
Shrikant R. Mulay, Brigitte Schott, Sabine Gruner, Wolfgang Haap, Guido Hartmann and Hans-
Joachim Anders. Cathepsin S inhibition abrogates immune complex glomerulonephritis because 
cathepsin S is essential for MHC class II-mediated CD4 T cell and B cell priming. (submitted) 
 
 
Poster presentation 
 
Julia Lichtnekert, Khader Valli Rupanagudi, Onkar Kulkarni and Hans J. Anders. Activated Protein 
C Attenuates Systemic Lupus Erythematosus and Lupus Nephritis in MRL-Fas(lpr) Mice - 
Presented at ASN Kidney Week 2011, November 8 - 13, 2011, Philadelphia, USA. 
 
Khader Valli Rupanagudi, Onkar P. Kulkarni, Julia Lichtnekert, Murthy Narayana Darisipudi, 
Shrikant R. Mulay, Brigitte Schott, Sabine Gruner, Wolfgang Haap, Guido Hartmann and Hans-
Joachim Anders. Cathepsin S inhibition abrogates immune complex glomerulonephritis because 
cathepsin S is essential for MHC class II-mediated CD4 T cell and B cell priming. (Submitted to 
ERA-EDTA 50TH Congress, which will be held in May 2013, Istanbul, Turkey) 
 
Part of the work was done by collaborators, as mentioned below:  
 
Dr. Guido Hartmann and Dr. Brigitte Schott, Roche Pharmaceuticals, Basel, Switzerland.  
They have provided in-situ hybridization images, in-vitro enzyme inhibition assay data, plasma 
levels of R05461111 data, as well as R05461111 dose dependent p10 accumulation data. These 
data are presented in the results part II (table 7, figure 21 and 23) of this thesis. 
 
 
 
Khader Valli Rupanagudi.  
Date: 5-3-2013 
 
 
 
 
 
Acknowledgements  
 
First and foremost, I am deeply grateful to my advisor Prof. Hans-Joachim Anders who has guided 
me in a constructive manner by providing crucial inputs and encouraging ideas, in making my 
thesis. I am thankful for his support, both financial and academic, contribution of time, in making 
my Ph.D. experience more productive and outstanding. The joy and enthusiasm he has for research 
is contagious and motivated me to pursue my research work with a similar attitude. His ability to 
select and approach compelling research problems, high scientific standards, and hard work set an 
example in my research work.  
 
I would like to express my heartfelt thanks to Dr. Julia Lichtnekert, for providing me the platform 
to do research in this laboratory as a Ph.D. fellow. To work with her has been a real pleasure to me. 
 
My special thanks to Dr. Ramanjaneyulu Allam for being my friend for so many years, without 
whose support I would not have achieved my dream. My sincere thanks to Dr. Onkar Kulkarni for 
his help and support. 
 
I wish to thank all the staff members and colleagues of the department of Klinische Biochemie for 
their help, cooperation and for providing a friendly environment. I would like to thank Dr. Volker 
Vielhauer, Dr. Bruno Luckow and Dr. Peter Nelson for their constant encouragement and 
suggestions. My special thanks to Katharina for her help. I would like to acknowledge the skillful 
technical assistance provided by Dan Draganovici and Janina Mandelbaum.  
 
I have been surrounded by wonderful colleagues, and I would like to thank them, who have been 
extremely supportive whilst pursuing my PhD studies. I would like to thank my past and current 
colleagues of my lab - Narayana Murthy Darisipudi, Shrikant Mulay, Santosh Kumar, Kirstin 
Andersen, Nuru Eltrich, Maciej Lech, Sufyan Sayyed, Adriana Migliorini, Simone Romoli, Mi 
Ryu, Heni Eka Susanti, Dana Thomasova, Ewa Radomska, Stephanie Käser, Anne Kuhn, Christina 
Scherbaum, Jan Henrik Hagemann, Georg Lorenz, Marc Weidenbusch, Martin Bernhard Müller, 
Ingo Hartter, Andrei Bideak, Hauke Bruns, Roman Günthner, John Hoppe for their valuable help, 
support and friendly attitude.  
 
This thesis would not be possible without the love and support of my family. I would like to thank 
my wife Mrs Sunitha Rupanagudi for her love and encouragement. Many thanks to my mother, 
brother and sister for their love and support. My heartfelt thanks to all of them.  
 
I am indebted to many people for making the time working on my Ph.D. an unforgettable 
experience. My time in Munich was made enjoyable in large part due to the many friends Sudhakar 
Reddy, Naresh, Vignesh, Vidhya Sankar, Harish, Satish and Praneeth. I am grateful to my friends 
who spent valuable time with me during my memorable trips in and around Germany. I would like 
take this opportunity to thank my friends Raghavan Vallur, Shahul Hameed, Vivek Sharma and 
Praseeda for their support in providing scientific papers to write my thesis. 
 
I am grateful to everybody who has been part of my life and helped in some way or the other, may 
I failed to mention any of their names, I still thank each and every one of them. It is my duty to 
express my tearful acknowledgement to the animals, which have been sacrificed for the betterment 
of human being. 
 
And last, but not the least, I am grateful to Prof. Vijayalakshmi Ravindranath for rekindling my 
dreams. I thank her from the bottom of my heart for her support and encouragement. 
 
 
Khader Valli Rupanagudi, 2013 
 
 
 
 
 
Table of contents 
 
1              Introduction  1  
1.1           Systemic lupus erythematosus  1  
1.1.1        Predisposing factors associated with SLE 6  
1.1.2        Cell death: Implications in SLE and Lupus nephritis 9  
1.1.3        Role of dendritic cells in SLE  11  
1.1.4        Role of T cells in SLE  13 
1.1.5        Role of B cells in SLE  16  
1.1.6        Autoantibodies in SLE  18  
1.1.7        Role of Complement in SLE  21 
1.1.8        Role of cytokines and chemokines in SLE 22 
1.2           Current therapies of SLE  25  
1.3           Role of proteases  30 
1.3.1        Activated protein C  30  
1.3.2        Cathepsin S  34 
1.4           MRL-Fas(lpr) mice- mouse model of SLE 39 
 
2.             Research objectives  41  
 
3.             Materials and Methods  42 
 
3.1           Materials  42 
3.2           Methods  45 
3.2.1        Animals experiments  45  
3.2.2        Quantification of activated protein C levels 46 
3.2.3        Cathepsin S inhibitor R05461111  46 
3.2.4        Morphological evaluation  47 
3.2.5        In situ hybridization  48 
3.2.6        Plasma cytokines  48  
3.2.7        Serological analysis  49  
3.2.8        Antinuclear antibody and Crithidia staining 50 
3.2.9        Western blotting  51  
3.2.10      Renal function analysis  52 
3.2.11      Flow cytometry  55 
3.2.12      RNA isolation, cDNA synthesis and real-time PCR 56  
3.2.13      Statistical analysis  60 
 
 
 
 
 
 
4.             Results  61  
4.1           Part I - Activated protein C in SLE  61 
4.1.1        Activated protein C suppresses renal pathology 61  
4.1.2        Activated protein C reduces renal immune complex disease 62 
4.1.3        Activated protein C reduces intrarenal inflammation 64 
4.1.4        Activated protein C improves cutaneous lupus 64 
4.1.5        Activated protein C improves lung disease 67 
4.1.6        Activated protein C suppresses the abnormal humoral immunity 68  
4.1.7        Activated protein C suppresses the activation of antigen presenting cells 71  
4.1.8        Activated protein C suppresses systemic inflammation 71 
 
4.2           Part II - Cathepsin S in SLE  74  
4.2.1        Cathepsins expression in MRL-Fas(lpr) mice 74 
4.2.2        Pharmacodynamics and pharmacokinetics of RO5461111 in mice 77  
4.2.3        Plasma levels of IL-10 and TNF  80 
4.2.4        Activation and expansion of splenic dendritic cells 81  
4.2.5        Activation and expansion of splenic CD4 and autoreactive T cells 83  
4.2.6        Activation and expansion of splenic B cells and plasma cells 84 
4.2.7        RO5461111 disrupts germinal centers  84 
4.2.8        RO5461111 reduces hypergammaglobulinemia 87 
4.2.9        RO5461111 reduces autoantibody production 87 
4.2.10      RO5461111 improves lupus nephritis  91 
4.2.11      RO5461111 reduces lung inflammation  94 
 
5.             Discussion  97 
5.1           Part I - Activated protein C in SLE  97 
5.2           Part II - Cathepsin S in SLE  101 
 
6.             Summary and Conclusion  106 
7.             Zusammenfassung und Fazit  109  
8.             References  112 
9.             Abbreviations  121  
10            Appendix  122  
11.           Curriculum Vitae  123 
 
Introduction 
 
 
Page | 1  
 
1. Introduction 
1.1 Systemic lupus erythematosus 
 
  Systemic lupus erythematosus (SLE) is an autoimmune disease that is 
characterized by the loss of tolerance to nuclear self-antigens, the production of pathogenic 
autoantibodies and damage to multiple organ systems. SLE was first described by the 
French dermatologist Beitt in 18281. Lupus is characterized by flares and remissions and 
affects at least 5 million people worldwide. The disease can affect all ages but most 
commonly between 20-45 years of age. Statistics demonstrate that lupus is somewhat more 
frequent in African Americans and people of Chinese and Japanese descent. People with 
SLE can develop different combinations of symptoms and organ involvement. The clinical 
manifestations of SLE include autoimmune inflammation of the skin, joints, kidney, lungs, 
heart, blood vessels, nervous system, intestine, liver, etc. Common symptoms include 
fatigue, low-grade fever, headache, anemia, loss of appetite, muscle aches, hair loss 
(alopecia), arthritis, ulcers of the mouth and nose, facial rash ("butterfly rash"), unusual 
sensitivity to sunlight (photosensitivity), inflammation of the lining that surrounds the 
lungs (pleuritis) and the heart (pericarditis) and poor circulation to the fingers and toes 
with cold exposure (Raynaud's phenomenon). It is more common in women. The female to 
male ratio in adults is approximately 9:1. The impact of SLE on pregnancies can be severe. 
A meta-analysis calculated that 16% of pregnancies in women with SLE resulted in 
spontaneous abortion and 6.1% resulted in stillbirth or neonatal death2. 
 
 One of the most challenging issues for people with SLE is receiving a timely and 
accurate diagnosis. Misdiagnosis is common, and there can be a 2-year delay between the 
onset of symptoms and a diagnosis of SLE. Since individuals with SLE can have a wide 
variety of symptoms and different combinations of organ involvement, no single test 
establishes the diagnosis of systemic lupus. The American Rheumatism Association 
established 11 classification criteria, which are closely related to the symptoms discussed 
above (Table 1). When a person has four or more of these criteria, the diagnosis of SLE is 
strongly suggested. Until March 2011, the only drugs that were approved by the Food and 
Drug Administration (FDA) for the treatment of lupus were corticosteroids (1955), 
hydroxychloroquine (1955) and aspirin (1948). The recent breakthrough in the treatment 
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Table 1. American college of Rheumatology criteria for the diagnosis of systemic 
lupus erythematosus 
Criterion Definition 
Malar rash A rash on the cheeks and nose, often in the shape of a 
butterfly 
Discoid rash A rash that appears as red, raised, disk-shaped patches 
Photosensitivity  A reaction to sunlight that causes a rash to appear or get 
worse 
Oral ulcers Sores in the mouth 
Arthritis Joint pain and swelling of two or more joints 
Serositis Inflammation of the lining around the lungs (pleuritis) or 
inflammation of the lining around the heart that causes chest 
pain, which is worse with deep breathing (pericarditis) 
Kidney disorder Persistent protein or cellular casts in the urine 
Neurological disorder Seizures or psychosis 
Blood disorder Anemia (low red cell count), leukopenia (low white cell 
count), lymphopenia (low level of specific white cells), or 
thrombocytopenia (low platelet count) 
Immunologic disorder Positive test for anti–double stranded DNA, anti-Sm,  
or antiphospholipid antibodies 
Abnormal antinuclear  
Antibodies 
Positive antinuclear-antibody test 
Four of the 11 criteria are needed for the formal diagnosis of SLE. 
Adapted from Rahman et al.3 
 
of lupus was the approval of belimumab by the FDA in 2011. Current therapeutic regimen 
for SLE mainly comprised of corticosteroids, antimalarials, nonsteroidal anti-inflammatory 
drugs (NSAIDS) and immune-suppressive drugs4. In milder, non-organ threatening 
disease, antimalarials, NSAIDS and lower dose steroids are usually effective. For an organ 
threatening disease that is not responding to steroids, immunosuppressants are initiated. 
Survival of patients with SLE has improved substantially in the past 5 decades as a result 
of earlier disease detection and advances in the treatment. Five-year survival in patients 
with SLE has improved from approximately 50% in the 1950s to >90% in the 2000s5. 
However, overall survival of patients with SLE has not improved much since the 1980s; 
the mortality still remains high compared with the general population. The most common 
causes of death in SLE include, SLE induced complications and immunosuppressant 
induced infections. Management of refractory disease, especially nephritis, cutaneous and 
neuropsychiatric manifestations, remains unsatisfactory.  
 
Pathogenesis of SLE 
       The major immunological features of lupus are, loss of self-tolerance to autoantigens, 
the presence of autoreactive B and T cells, with polyclonal activation of B-cells, the conse- 
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Figure 1. Pathogenesis of SLE. Increased production of autoantigens because of increased rates of 
apoptotic cell death coupled with defects in their removal contributes to lymphocyte hyperactivity 
and production of pathogenic autoantibodies. (The image was kindly provided by Dr. Maciej Lech) 
 
 
quent production of autoantibodies by plasma cells (Figure 1). Anti-double stranded DNA 
antibodies (anti-dsDNA) are probably the most pathogenic type of antibody produced. The 
formation of immune complexes, the activation of the complement pathway and the 
defective clearance of immune complexes also play an important role in the pathogenesis 
of lupus. A more recent link between the innate and adaptive immune system in SLE 
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includes the neutrophil, which can be primed by interferon-α and autoantibodies to release 
neutrophil extracellular traps as an additional source of immunogenic DNA, histones, and 
neutrophil proteins. In SLE, three main immune pathways have been identified: aberrant 
clearance of nucleic acid containing debris and immune complexes, excessive innate 
immune activation involving Toll like receptors (TLRs) and type I interferons (IFNs) and 
abnormal T and B lymphocyte activation. Research has demonstrated evidence that a key 
enzyme's failure to dispose of dying cells may contribute to the development of SLE. The 
enzyme, DNase1 normally eliminates DNA by chopping them into tiny fragments for 
easier disposal and mice without DNase1 showed signs of SLE6. Thus, a genetic mutation 
in a gene that could disrupt the body's cellular waste disposal may be involved in the 
initiation of SLE. Autoantigens are released by both necrotic and apoptotic cells. Defects 
in the clearance of apoptotic cells have been described in this disorder and these defects 
could lead to aberrant uptake by macrophages, which then present the self-antigens to T 
and B cells, thus driving the autoimmune process. There are a few drugs that have been 
reported to trigger SLE. However, more than 90% of cases of "drug-induced lupus" occurs 
as a side effect of one of the following six drugs: hydralazine, quinidine, procainamide, 
phenytoin, isoniazid and d-penicillamine. These drugs are known to stimulate the immune 
system and cause SLE. Fortunately, drug-induced SLE is infrequent (accounting for less 
than 5% of all people with SLE) and usually resolves when the medications are 
discontinued7. 
Treatments of SLE aim to relieve symptoms and protect organs mainly by 
suppressing the underlying abnormal immune activation, systemic inflammation, and 
immunopathology of affected organs. To date, SLE treatment still depends on unspecific 
immunosuppressive or immunomodulatory agents. Despite this armamentarium, several 
problems still remain. First, all of the aforementioned drugs can have significant side 
effects and potent immunosuppression, as it is necessary to treat highly active or life-
threatening SLE, which is often associated with serious infectious complications. Second, 
even intense immunosuppressive regimens are often unable to suppress highly active SLE. 
For example, when the Aspreva Lupus Management Study trial compared high-dose 
cyclophosphamide plus steroids with high-dose mycophenolate mofetil plus steroids in 
patients with diffuse proliferative lupus nephritis, >40% of patients in both groups did not 
reach partial remission with either of the treatments8. Therefore, finding novel drugs that 
can suppress SLE and lupus nephritis without major side effects are important.  
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Lupus nephritis 
Lupus nephritis is a common manifestation of SLE and affects 50% of patients 
with significant impact on morbidity and mortality. Lupus nephritis is more prevalent and 
more aggressive in Afro-Americans and Hispanics, who exhibit a greater incidence of 
proliferative nephritis than Caucasians. Standard treatment includes corticosteroids such as 
prednisone or prednisolone, to reduce inflammation in the kidneys. The treatment of lupus 
nephritis has improved over the last few decades. Mycophenolate mofetil or 
cyclophosphamide are usually used as the first line treatment for nephritis, and in either 
case, corticosteroids are added. For maintenance therapy, either mycophenolate mofetil or 
azathioprine is preferred. Although effective in the majority of patients, cyclophosphamide 
was associated with serious adverse effects including infections, malignancy and 
infertility. Novel drugs that more specifically interfere with the disease pathomechanisms 
are needed to improve lupus nephritis management. By light and immunofluorescence 
microscopy, renal biopsies in patients with SLE display mesangial cell proliferation, 
inflammation, basement membrane abnormalities, and immune complex deposition, with 
immunoglobulins and complement components9. On electron microscopy, these deposits 
can be visualized in the mesangium and the subendothelial or subepithelial surface of the 
basement membrane. The International Society of Nephrology (ISN) classified the various 
forms of lupus nephritis according to the light, immunofluorescent and electron 
microscopic changes (Table 2). 
 
Recent reports have identified some of the inflammatory mediators which play 
important role in chronic tissue inflammation associated with SLE. We assume that 
targeting inflammatory mediators without affecting systemic immunity can be an excellent 
therapeutic approach for SLE. In this study we evaluated the effect of two different 
proteases on murine lupus. In the first study we administered serine protease activated 
protein C (aPC) to the MRL-Fas(lpr) mice, a murine model of SLE. In the second study we 
inhibited cysteine protease Cathepsin S (Cat S) using a specific inhibitor R05461111 in 
MRL-Fas(lpr). Before describing the observed findings of the study, known details of SLE 
pathogenesis and current therapy, followed by a brief introduction on aPC and Cat S are 
reviewed in this introductory section.  
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Table 2. International Society of Nephrology/Renal Pathology Society (ISN/RPS) 2003 
classification of lupus nephritis 
Class I Minimal mesangial lupus nephritis 
Normal glomeruli by light microscopy, mesangial immune deposits by 
immunofluorescence 
Class II Mesangial proliferative lupus nephritis 
Mesangial hypercellularity or matrix expansion, with mesangial immune 
deposits on immunofluorescence 
Class III 
 
Class III (A) 
Class III (A/C) 
 
Class III (C) 
Focal lupus nephritis 
Glomerulonephritis involving <50% of glomeruli, typically with 
subendothelial immune deposits 
Active lesions: focal proliferative lupus nephritis 
Active and chronic lesions: focal proliferative and sclerosing lupus 
nephritis 
Chronic inactive lesions with glomerular scars: focal sclerosing lupus 
nephritis 
Class IV 
 
Class IV-S (A) 
Class IV-G (A) 
Class IV-S (A/C) 
 
Class IV-G (A/C) 
 
Class IV-S (C) 
 
Class IV-G (C) 
Diffuse lupus nephritis 
Glomerulonephritis involving >50% of glomeruli, typically with 
subendothelial immune deposits. Can be segmental of global. 
Active lesions: diffuse segmental proliferative lupus nephritis 
Active lesions: diffuse global proliferative lupus nephritis 
Active and chronic lesions: diffuse segmental proliferative and sclerosing 
lupus nephritis 
Active and chronic lesions: diffuse global proliferative and sclerosing 
lupus nephritis 
Chronic inactive lesions with scars: diffuse segmental sclerosing lupus 
nephritis 
Chronic inactive lesions with scars: diffuse global sclerosing lupus 
nephritis 
Class V 
 
Membranous lupus nephritis 
Global of segmental sub-epithelial immune deposits 
Class VI Advanced sclerosing lupus nephritis 
>90% of glomeruli globally sclerosed without residual activity 
 Adapted and modified from Weening et al.10 
 
1.1.1 Predisposing factors associated with SLE 
 
A search of the precise immunopathogenesis of SLE has remained a challenge to 
many research groups all around the globe. Several mechanisms lead to a loss of self-
tolerance and organ dysfunction in SLE. This has led to lots of conceptual theories which 
are published in recent times. Several studies in humans and several murine models of SLE 
have shown that a variety of predisposing factors play important roles in the pathogenesis 
of SLE. Predisposing factors that may increase risk of SLE include genetic, environmental, 
sex and hormonal factors. 
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Genetic factors  
SLE is considered to be complex multi-genetic autoimmune disease. Genetic 
factors confer a predisposition to the development of SLE. Genes that contribute to the 
pathogenesis of systemic lupus are classified as follows: 1) Genes that cause a break in 
tolerance for the self-antigens. 2) Genes that lead to immune dysregulation. It is also 
suggested that multiple mutations (inherited or somatic) may be needed before a self-
reactive clone B and T lymphocytes bypasses sequential tolerance check points resulting in 
the emergence of autoimmune disease4. CCL5 is important for the recruitment of 
lymphocytes, monocytes and eosinophils to the sites of inflammation. In a study of 146 
Han Chinese patients with SLE, CCL5 polymorphism (–403 G/G) was found to be 
considerably more frequent in those with renal damage than in those without (79% versus 
33%)11. Although in rare cases SLE may be associated with the deficiency of a single gene 
(e.g., the complement components C1q and C4), the disease more commonly results from 
the combined effect of variants in a large number of genes. Lack of C4 has been linked to 
decreased elimination of self-reactive B cells, whereas lack of C1q leads to deficient 
elimination of necrotic (waste) material. Each allele contributes only minimally, and the 
cumulative effect of several genes is necessary to substantially increase the risk of SLE.  
 
Certain single nucleotide polymorphisms (SNPs) linked to SLE were reported for 
genes whose products may contribute to abnormal T-cell function in SLE (CD3-ζ12 and 
PP2Ac13). HLA antigens and genes (particularly HLA class II) have been associated with 
SLE. Graham et al. have identified haplotypes carrying the HLA class II alleles 
DRB1*0301 and DRB1*1501 are clearly associated with SLE14. Recent genome-wide 
association study identified two novel genetic loci C8orf13-BLK and ITGAM-ITGAX that 
contribute to the risk of SLE15. A recent large scale replication study confirmed some of 
these associations and identified TNIP1, PRDM1, JAZF1, UHRF1BP1, and IL-10 as risk 
loci for SLE. Another large study of individuals and multi-case families with SLE 
suggested that an SNP within the programmed cell death 1 gene (PDCD1) is associated 
with the development of lupus in both European and Mexican populations16. Although 
these findings are promising, the loci identified so far can account for only about 15% of 
the heritability of SLE17. Polymorphisms in the low-affinity Fcγ receptors have been 
associated with susceptibility to a number of autoimmune diseases, including SLE. Low 
copy number of FCGR3B18 gene has been associated with SLE.  
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Environmental factors  
Sunlight is the most obvious environmental factor that may exacerbate SLE. 
Ultraviolet light (UV) induces apoptosis of keratinocytes and has been implicated in the 
skin manifestations of lupus. Drugs like procainamide, hydralazine and quinidine can lead 
to drug-induced lupus erythematosus. Epigenetic changes such as DNA hypomethylation 
have been attributed to medications known to cause SLE. Sulfonamide antibiotics can 
induce idiopathic SLE. Subacute cutaneous lupus erythematosus (SCLE) is associated with 
thiazides, calcium channel blockers and angiotensin-converting enzyme inhibitors. The 
possibility that viruses may trigger SLE has been considered during the past 40 years. 
Epstein Barr virus (EBV) has also been identified as a possible factor in the development 
of lupus. EBV may reside in and interact with B cells. To enter B cells, viral glycoprotein 
gp350 binds to cellular receptor CD21. Then, viral glycoprotein gp42 interacts with 
cellular HLA class II molecules. This triggers fusion of the viral envelope with the cell 
membrane, allowing EBV to enter the B cell. Gross et al.19 found a high frequency of EBV 
infected B cells in lupus patients compared to controls and these infected cells are 
predominantly memory B cells. Amongst the other factors which are also associated with 
SLE are toxic exposures to silica and mercury20. 
 
Sex and Hormonal factors  
SLE is a disease affecting women of childbearing age and there have been many 
anecdotal reports of exogenous estrogens exacerbating lupus or increasing the risk of 
developing this disorder. Oral contraceptive use in the Nurses’ Health Study21 was 
associated with a slightly increased risk of disease with a relative risk for users versus 
never users of 1·9. Sex hormones were shown to affect T cells and B cells. In particular 
estrogen has been suggested to predispose women to SLE. Estrogen has multiple effects on 
the immune system, which upregulates Bcl2, thus blocking tolerance induction of naive B 
cells22. Either an increase in estrogen or prolactin can break tolerance of high-affinity 
DNA-reactive B cells. Estrogen promotes the survival and activation of the T-independent 
marginal zone B cell subset23. In SLE T cells estrogen increases expression of the 
calcineurin24, which promotes the proliferation and activation of T cells. The topical 
calcineurin inhibitors, tacrolimus and pimecrolimus, have been used to treat resistant 
cutaneous lupus. Estrogen can activate DCs25. Thus, estrogen may facilitate the maturation 
of pathogenic naive autoreactive B cells, whereas hampering a potentially protective 
autoreactive B-cell repertoire26. 
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Hormones (estrogen, progesterone) contribute through unknown mechanisms to the 
increased prevalence of SLE among women. The X chromosome may contribute 
independently from hormones because in castrated female and male mice that have been 
genetically manipulated to express XX, XO (female), XY, or XXY (male) combinations, 
the presence of two X chromosomes increases the severity of SLE27. The X-chromosome 
has many genes involved in immune functions such as TLR7, FOXP3, Bruton’s tyrosine 
kinase (BTK), CD40L, IRAK128 which contribute to the onset of SLE. High estrogen 
levels resulting from pregnancy may aggravate SLE. DHEA (dehydroepiandrosterone) is a 
hormone secreted by the adrenal gland. DHEA serves as a precursor to male and female 
sex hormones, treatment with DHEA significantly reduced the number of SLE flares29. 
 
1.1.2 Cell death: Implications in SLE and Lupus nephritis 
 
Cell death is the most likely phenomenon to supply autoantigens. There are many 
different types of cell death mechanisms in living organisms, but the major types of cell 
death are apoptosis and necrosis. Apoptosis is an active, programmed cellular process, 
which appears under both physiological and pathological conditions in all tissues. One of 
the hallmarks of apoptosis is that the cell membrane stays intact. In healthy individuals, 
apoptotic cells are efficiently removed by macrophages before debris can be formed, 
without eliciting inflammation, whereas in SLE patients the clearance of apoptotic cells by 
macrophages is impaired. Clearance deficiency results in the initiation and maintenance of 
the systemic autoimmune reactions and ensuing chronic inflammation in SLE. There is 
growing evidence for a clearance deficiency of early apoptotic cells in mouse models of 
SLE30 and in humans31. 
 
 If apoptotic cells are not cleared on time, they lose their membrane integrity and 
enter the stage of secondary necrosis. Secondary necrotic cells can release DNA-
containing nucleosomes together with dangerous inflammatory signals towards immune 
system cells32. Apoptotic bodies are a source of self-antigen, which in turn leads to release 
of pathogenic autoantibodies into the circulation. Autoantibodies then form immune 
complexes and get deposited in various organs that leads to tissue inflammation. 
Disordered regulation of both apoptosis and the clearance of apoptotic products have been 
implicated in the pathogenesis of SLE and lupus nephritis33.  
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Under normal circumstances, activity against self-antigens is prevented by several 
mechanisms, including the Fas pathway of apoptosis, which was shown to be involved in 
the process of immune tolerance by deletion of unwanted autoreactive T cells and B 
cells34. Defective apoptosis leading to the prolonged survival of lymphocytes, particularly 
autoreactive lymphocytes was thought to be one disease mechanism for SLE. This 
hypothesis was supported by observations in murine lupus models. Defective Fas mediated 
apoptosis in MRL-Fas(lpr) mice results in massive lymphoproliferation and the 
development of a severe lupus-like disease with immune glomerulonephritis (GN). 
However, there are several problems with this model. First, the massive 
lymphoproliferation resulting from defective apoptosis seen in the MRL-Fas(lpr) mice is 
not characteristic of human SLE, which conversely is often associated with profound 
lymphopenia. Second, the expression of both Fas and FasL is normal in patients with SLE. 
Lastly, apoptosis of peripheral lymphocytes in patients with SLE has been shown to be 
increased compared with controls. 
 
The reasons for the defective clearance of apoptotic cells in SLE are not clear. It 
could be the result of quantitative or qualitative defects of the early complement proteins, 
such as C2, C4, or C1q. Patients with homozygous deficiencies in these complement 
components develop a severe lupus-like disease early in life. The C1q receptors on the 
surface of phagocytes constitute an extremely important mechanism for the clearance of 
apoptotic cells. Patients or mice with homozygous C1q deficiency develop autoantibodies 
and a lupus-like syndrome apparently because of the inability to eliminate apoptotic cells.  
 
So we know that apoptotic bodies are one of the major sources of autoantigens. If 
we look at the physiology of cell, every cell undergoes apoptosis, but at the same time in a 
healthy individual clearing mechanisms are appropriately placed to clear the debris. In 
addition to that, healthy immune system is tolerant to self. But in SLE the immune system 
is deregulated and increased generation of autoreactive B and T cells takes place along 
with the reduction of regulatory T cells. Circulating autoantigens or immune-complexes 
which are non-antigenic in healthy conditions are recognized as danger signals, which 
further lead to excessive activation of immune system in SLE4,35. The SLE patients have 
greater levels of circulating nucleosomes than in normal healthy individuals36. Increased 
rates of apoptosis and/or reduced clearance of neoantigens created by apoptosis might lead 
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to increased autoantibody production. One mechanism by which direct renal damage might 
occur in lupus nephritis is by increased rates of apoptosis among resident cells. In a murine 
model of lupus nephritis, caspase inhibitor therapy reduced glomerular injury37. 
 
Cell death by necrosis, on the other hand, occurs when external factors strike cells. 
Necrotic cell death is characterized by cytoplasmic and organelle swelling, followed by the 
loss of cell membrane integrity and release of the cellular contents into the surrounding 
extracellular space. This phenomenon is often triggered by an infectious agent, heat, 
ischemia, low ATP levels or a mechanical injury. No matter if cells die through apoptosis 
or necrosis, they must quickly be eliminated from tissues in order to prevent further 
damage. Early apoptotic cells are cleared by phagocytosis without eliciting either 
inflammation or immune response. Necrotic cells induce inflammation and favour the 
initiation of immune responses38. HMGB1 is passively released from necrotic cells and 
mediates inflammation and immune activation. In contrast, during apoptotic cell death, 
nuclear HMGB1 becomes tightly attached to hypo-acetylated chromatin and is not released 
into the extracellular milieu, thereby preventing an inflammatory response39. 
 
1.1.3 Role of dendritic cells in SLE 
 
Dendritic cells (DCs) are a heterogeneous group of bone marrow-derived cells that 
function in immunosurveillance, antigen presentation and tolerance. The general categories 
of DCs are the conventional dendritic cells (cDC) and the plasmacytoid dendritic cells 
(pDC). The cDC include those found in the skin, in secondary lymph nodes and the spleen. 
One of the most studied cDCs is the skin DCs, known as Langerhans cells. Upon exposure 
to pathogens or insult, immature DC can recognize foreign material and phagocytize them. 
This phagocytosis is not as efficient as professional phagocytes such as macrophages; 
however, the main function of DCs carrying antigenic cargo is to migrate to secondary 
lymph nodes to activate T cells, particularly naïve T cells. pDCs have the prominent 
feature of producing type I interferons (IFNs) and specifically they are the major producers 
of IFN-α. Accumulating evidence has highlighted pDCs as the culprit for SLE 
pathogenesis, mainly through type I interferons production. In SLE patients, immune 
complexes consisting of autoantibodies bound to self-DNA and RNA can stimulate 
production of type I IFNs through TLR7 and TLR9 signaling of pDCs. Guiducci et al.40 
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have suggested that inhibitors of TLR7 and 9 signalling could be effective corticosteroid-
sparing drugs. The primary anti-inflammatory mechanism of glucocorticoids is thought to 
be NF-kB inhibition. Chronic stimulation of pDCs through TLR7 and 9 by nucleic acid-
containing immune complexes activates the NF-kB pathway essential for pDC survival. 
Glucocorticoids do not affect NF-kB activation in pDCs, preventing glucocorticoid 
induction of pDC death and the consequent reduction of systemic IFN-α levels. The 
pathogenic role of type I IFN in SLE is mediated in part by its ability to induce immune 
activation, including a positive feedback loop that induces plasma cell maturation and 
increases autoantibody formation41. pDCs infiltrating inflamed peripheral tissues represent 
the main source of type I IFNs in patients with SLE. 
 
DCs in general are highly phagocytic and serve as sentinels to continuously detect 
danger signals from the environment. They uniquely express a plethora of innate pattern-
recognition receptors (PRRs) including TLRs, C-type lectin receptors (CLRs), RIG-I-like 
receptors and NOD-like receptors (NLRs) which capture antigens through binding to the 
pathogen-associated molecular patterns (PAMPs) of microbes or damage-associated 
molecular patterns (DAMPs) of endogenous tissues. In humans, mDCs are classically 
characterized by the high expression of CD11c, CD1a and HLA-DR with the 
distinguishing morphology of protruding dendrites. pDCs, as suggested by its name, are 
plasma-cell like, negative for both CD11c and CD1a and express the comparatively lower 
level of HLA-DR.  
 
DCs could influence SLE in several ways: presentation of self-antigen to 
autoreactive T cells; secretion of proinflammatory cytokines; and promotion of B cell 
autoantibody production, either directly or indirectly. DCs are widely considered to be 
critical for initiating T cell responses in infections42. Based on this notion, it could be 
assumed that they are the primary antigen-presenting cells (APCs) to induce T cell 
autoimmunity. However, depending on their activation state, DCs might also support 
peripheral T cell self-tolerance instead of T cell immunity. During the onset of 
autoimmunity, DCs are thought to be critical for priming of self-reactive T cells that have 
escaped tolerance induction. However, DCs can also induce T cell tolerance and DC-
depleted mice showed increased frequencies of CD4+ thymocytes and infiltration of CD4+ 
T cells into peripheral tissues. These mice developed spontaneous autoimmunity 
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characterized by reduced body weight, splenomegaly, autoantibody formation, 
neutrophilia, high numbers of Th1 and Th17 cells, and inflammatory bowel disease43. 
 
1.1.4 Role of T cells in SLE 
 
 T cells contribute to the initiation and perpetuation of autoimmunity in SLE. T 
cells play an important role, because the production of pathogenic autoantibodies in SLE is 
a T-cell-dependent process44. As major contributors to the disease, T cells in SLE display 
multiple abnormalities that reflect and partly explain some aspects of the complex disease 
process. The cytokine expression pattern is uniquely characterized by decreased expression 
of interleukin (IL)-2 and increased production of IL-17 and related cytokines. Moreover 
SLE T cells show inappropriate tissue homing and promote inflammation by secreting 
cytokines and activating DCs and B cells. T cells provide excessive help to B cells in SLE 
and mount inflammatory responses. 
 
T cells are functionally and phenotypically heterogeneous, and can be divided into 
subgroups. On the basis of the expression of the CD4 and CD8 antigens, thymocytes could 
be subdivided into several subpopulations: ~5% express neither CD4 nor CD8 (double-
negative T cells); ~80% express both CD4 and CD8 (double-positive T cells); ~10% 
express only CD4 (CD4+ T cells); and ~5% express only CD8 (CD8+ T cells). Double-
negative T cells are significantly expanded in patients with SLE and induce anti-DNA 
antibody production by autoreactive B-cells. Recent studies showed that they also secrete 
other cytokines such as IL-1β and IL-17, and are found in the kidneys of patients with 
lupus nephritis. T cells can also be divided into regulatory T cells and effector T cells. 
Regulatory T cells suppress the activation or effector activities of other immune cells, 
especially self-reactive T cells; they are low and functionally abnormal in patients with 
SLE. In contrast, effector T cells proliferate in response to antigen stimulation, secrete 
cytokines and help the function of cytotoxic T cells or B cells for the production of 
antibodies. Effector T cells are divided into T helper (Th) 1, Th2 and Th17 cells, 
depending on the major cytokines that they produce (Figure 2). Th1 cells mainly produce 
IFN-γ, but also IL-2, tumor necrosis factor-α (TNF-α) and lymphotoxin (which favour the 
elimination of pathogens). Th2 cells produce IL-4, IL-5, IL-6, IL-10 and IL-13 (which 
associate with allergy and humoral immunity, especially in B cell activation and 
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immunoglobulin class switch) and Th17 cells play a role in host defense against 
extracellular pathogens and produce the proinflammatory cytokine IL-17.  
 
CD4+ T cells and their cytokines play a crucial role in the induction and 
propagation of the inflammatory conditions. With the help of T cells, activated B cells 
migrate into lymphoid follicles of lymphoid organs and form germinal centers (GC). 
Recently, follicular helper T (Tfh) cells, a novel CD4+ T subset, have been found to be 
present in GCs, which regulate the development of antigen-specific B-cells. Tfh cells 
provide help to GC B cells and play an essential role in mediating long-lived antibody 
responses.  
 
Administration of antibodies that non-specifically deplete or inactivate helper 
CD4+ T cells suppresses the production of antibodies to DNA and prevents or reverses 
glomerulonephritis in mice with SLE45. Inhibition of co-stimulation between APCs and T 
cells has therapeutic potential in SLE. CD86 and CD80 are expressed on activated antigen 
presenting cells (APCs) including B cells, DCs and macrophages. The interaction of 
CD86/80 with its ligands CD28 and CD152 (CTLA4) plays a critical role in the induction 
and regulation of immune responses. Binding of CD86/80 to CD28 on T cells results in the 
transaction of costimulatory signals required for activation or proliferation of T cells. In 
contrast, binding of CD86 to CTLA4 regulates T-cell activation and diminishes the 
immune response. Abatacept (CTLA4–Ig) prevents the CD28–CD80/86 interaction and 
shown to be effective in improving disease activity in lupus-prone mice46,47, but failed in 
human clinical trials. Critical interactions between APCs that express CD40 and T cells 
expressing the CD40L are thought to provide important co-stimulatory signals required for 
activation and survival of B cells, enhanced APC function and T-cell activation. 
Monoclonal antibodies to CD40L have been used to treat patients with SLE, but 
enthusiasm for their use has been tempered by the tendency for patients treated with this 
antibody to experience thromboembolic complications48. 
 
Spontaneous apoptosis is increased in T cells from SLE patients. On the other 
hand, upon exposure to oxidizing agents, SLE T cells undergo necrosis rather than 
apoptosis. Increased T cell necrosis and apoptosis represents a source of nuclear material, 
which amplifies the inflammatory response in patients with SLE. T cells display various 
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Figure 2. Helper T cell differentiation (adapted and modified from O'Shea et al.49) 
 
chemokine receptors that allow them to respond to inflammatory signals and migrate out 
of the circulation into the tissue. SLE T cells show altered migratory activity in states of 
inflammation. For example, the migration of T cells in response to CXCL12 is faster in 
SLE50. This may be due to increased expression of CXCR4, the receptor for CXCL12. In 
addition, kidneys from patients with lupus nephritis show high levels of CXCL12, further 
supporting the role of the CXCR4/CXCL12 axis in T cell homing to the kidney. 
 
The CD8+ T cells in SLE are impaired. Most of the disturbed T cell homeostasis in 
SLE seems to depend on aberrant mechanisms of peripheral control, and it is generally 
thought that central tolerance may not be affected or can only partly influence T cell 
autoimmunity in SLE51,52. SLE T cells display spontaneously increased activation 
associated with a reduced threshold of activation to self-antigens, yet they are 
hyporesponsive to further antigenic stimulation53. At the molecular level, T cell receptor 
(TCR) stimulation in SLE T cells associates with an increased signaling protein 
phosphorylation and a sustained increase in free intracellular Ca++ compared to control T 
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cells54. Additional molecular mechanisms that could contribute to impaired T-cell 
functions in SLE include histone acetylation and methylation, as shown by the finding that 
treatment with histone deacetylase inhibitors can suppress murine lupus55. 
 
 
1.1.5 Role of B cells in SLE 
 
Growing evidence shows that B cells not only produce antibodies but also secrete 
interleukins (IL), act as antigen-presenting cells (APCs), contribute to T-cell activation, 
and modulate DCs. Several abnormalities in SLE B-cell populations have been identified, 
supporting the hypothesis that B cells play a central role in the pathogenesis of this 
disease. Thus, recent advances in SLE treatment have evolved to target B cells in the 
expectation that patients would have fewer side-effects than those which cause generalized  
immunosuppression. B cell hyperactivity has significant effects on SLE pathogenesis via 
autoantibody production, antigen presentation to T cells, production of cytokines including 
IL-10 and IL-6, and abnormal B cell signaling. 
 
Recent findings in both human and mouse models suggest that TLR7 and TLR9 
may play a central role in the progression of the disease by activating B cells to produce 
autoantibodies56. The role of the B cell in the pathogenesis of immune mediated 
glomerulonephritis has traditionally been viewed as limited to that of antibody producer. 
However, it is increasingly appreciated that B cells contribute to the pathogenesis of 
glomerulonephritis in many other ways. They can function as potent antigen-presenting 
cells (APCs), regulate T cells and DCs through the production of cytokines. Evidence for 
an antibody-independent role for B cells comes from animal models, lupus prone MRL-
Fas(lpr) mouse with nonsecretory plasma cells (without antibody production) developed 
SLE57, whereas B cell-deficient MRL-Fas(lpr) mice did not58. The role of the B 
lymphocyte as an APC is also likely to be essential in the development of 
autoimmunity57,59. 
 
To investigate the role of B cells in lpr-induced autoimmunity, Shlomchik et al.58 
crossed the "Jh knockout" mutation onto the autoimmune MRL-Fas(lpr) background. As 
expected, these animals lack B cells and show no signs of autoimmune kidney destruction 
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or vasculitis, in spite of carrying the lpr/lpr mutation. In contrast, lpr/lpr littermates that 
had B cells had severe nephritis and vasculitis, as well as autoantibodies. These results 
demonstrate a primary role for B cells and/or (auto) antibodies in initiating several types of 
autoimmune manifestations in MRL-Fas(lpr) mice. Another B-cell-related functions likely 
to be important in the pathogenesis of SLE is cytokine release, particularly IL-10, TNF-α, 
IL-6 and BLyS/BAFF (B lymphocyte stimulator/B-cell activating factor) are produced in 
high levels in SLE60. Ultimately, activated B cells can aggregate into ectopic lymph node-
like structures containing plasmablasts, memory B cells, and plasma cells are observed in 
sites with chronic inflammation.  
 
Several strategies that target B cells are currently available. The approaches include 
mainly inhibition of survival factors, interruption of co-stimulatory factors and depletion 
of B cells. Rituximab is a genetically engineered chimeric monoclonal antibody that 
targets B-lymphocyte surface marker CD20 (Figure 3). The mechanisms by which 
rituximab induces depletion probably include antibody-dependent cell-mediated 
cytotoxicity (ADCC), complement-dependent cytotoxicity (CDC) and apoptosis61. 
Because CD20 is only expressed from the pre-B stage to the mature B cells, rituximab 
spares haematopoietic stem cells, pro-B and plasma cells, allowing B-cell regeneration. 
Given the generally encouraging results in the open-labeled studies, it was most 
disappointing to learn that the EXPLORER study in the USA, comparing rituximab with 
placebo in non-renal lupus, did not reach its primary endpoints.  
 
In contrast to rituximab, the experience with the use of epratuzumab in SLE is very 
limited. Epratuzumab is a humanized recombinant monoclonal antibody that targets CD22 
(Figure 3), which is a co-receptor of the B-cell-antigen receptor (BCR) that regulates B-
cell activation and interaction with T cells. It is expressed in pro-B, pre-B and mature B 
cells, but is absent from plasma cells. This drug has shown safety in short-term studies and 
potential for clinical efficacy, and warrants further exploration for the treatment of SLE62. 
 
B-lymphocyte stimulator (BLyS) is a cytokine that is involved in the survival of B 
cells, GC formation, and T cell-dependent and T cell-independent immunoglobulin-class 
switching. It binds to the surface of B cells and acts with the B-cell receptor in signal 
transduction. Studies in mice have shown a role of BLyS in the expression of lupus63. 
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Figure 3. Strategies for B‑cell targeting in SLE (adapted from Sanz et al.64). 
 
Blockade of BLyS with an anti-BLyS antibody resulted in a significant beneficial clinical 
effect within the first year of treatment in patients with mild or moderate disease. This 
antibody (belimumab) was approved by the Food and Drug Administration for use in the 
treatment of lupus. 
 
1.1.6 Autoantibodies in SLE 
 
Autoantibodies are antibodies that react with self-antigens. Self-antigens are 
internalized by APCs such as, DCs, macrophages and B cells. After internalization, APCs 
present self-antigens to CD4+ T cells via major histocompatibility complex class II (MHC-
II) molecules and activate the adaptive immune system in lupus. SLE is characterized by 
autoantibodies (Table 3), especially against nuclear antigens such as anti-dsDNA 
antibodies and anti-histone antibodies. Increased production of anti-dsDNA antibodies 
predicts periods of active clinical disease. 
 
Anti-DNA antibodies constitute a subgroup of antinuclear antibodies (ANA) that 
bind single stranded DNA (ss-DNA), ds-DNA, or both. Antibodies targeted against ds-
DNA were first described in 195765. They might be IgM antibodies or any of the 
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subclasses of IgG antibodies. Anti-dsDNA antibodies are thought to play a crucial role in 
the pathogenesis of lupus nephritis66. In many patients with SLE, increased renal disease 
activity is associated with rising titers of anti-DNA antibodies. Although anti-dsDNA was 
once thought to cause glomerulonephritis by forming complexes with DNA that are 
passively trapped in the glomeruli, many investigators now believe that anti dsDNA 
antibodies are pathogenic to the kidney via direct (cross-reactivity) or indirect (via a 
nuclear antigen bridge) binding to glomerular structures. A series of studies by Chan et 
al.67,68 have shed light on the potential pathogenicity of anti-DNA binding to glomerular 
cells in lupus nephritis. Subsets of anti-DNA antibodies from patients with SLE were 
shown to bind to human mesangial cells and endothelial cells, and the cellular binding of 
these autoantibodies correlated with disease activity. 
 
In addition to cell binding, there is convincing evidence to show that anti-dsDNA 
antibodies penetrate into living cells. Administration of certain anti-dsDNA antibodies to 
non-autoimmune mice in vivo leads to cell penetration and intranuclear Ig deposits in the 
kidney and other organs69. Apart from glomerular cells, renal tubular cells, hepatocytes, 
neuronal cells, fibroblasts and mononuclear cells are all susceptible to penetration by anti-
dsDNA antibodies. One intracellular effect of anti-DNA antibodies is to enhance cell 
growth and proliferation, or conversely induce apoptosis70. Madaio et al.71 reported that 
nuclear localizing anti-DNA antibodies bind to DNAse I in living cells and inhibit the 
activity of this enzyme, making the cells more resistant to apoptosis. This observation 
might explain the finding of glomerular hypercellularity in mice injected with penetrating 
antibodies. Abetimus (LJP-394) is an intravenously administered tetrameric 
oligonucleotide conjugate that safely reduces anti-dsDNA antibodies. Anti-dsDNA 
antibodies are present in the majority of lupus patients and have been linked to the 
pathogenesis of LN. Abetimus is composed of four identical strands of anti-dsDNA and it 
is supposed to bind to the circulating anti-dsDNA antibodies. 
 
Generation of nucleosomes in vivo requires apoptosis72. These nucleosomes and 
intracellular debris appear as blebs on apoptotic cell surfaces, and might incite T cell-
driven stimulation of B cells. The injection of syngeneic apoptotic cells into normal mice 
has been shown to generate antinuclear antibodies and immune deposition in kidneys73. 
Kalaaji et al. have shown exposed glomerular basement membrane-associated 
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nucleosomes as target structures for nephritogenic autoantibodies in vivo74,75. It would be 
reasonable to assume that nucleosomes are one of the major autoantigens in lupus 
nephritis. 
 
The presence of anti-Ro antibodies, anti-La antibodies, or both during pregnancy of 
lupus patients confers a 1 to 2% risk of fetal heart block. Ro antigens are exposed on the 
surface of fetal (but not maternal) cardiac myocytes as the heart undergoes remodeling by 
apoptosis, and maternal anti-Ro antibodies that cross the placenta interact with these 
antigens. Both anti-Ro and anti-nucleosome antibodies may play a role in cutaneous lupus. 
Anti-Ro antibodies are associated with an increased risk of the development of a 
photosensitive rash. Anti-Sm is an antibody specific against Sm, a ribonucleoprotein found 
in the cell nucleus. Anti-Sm antibodies are usually found only in SLE patients. 
 
Antibodies against the N-methyl-d-aspartate receptor (NMDAR) may be important 
in central nervous system lupus. NMDA is an excitatory amino acid released by neurons. 
Kowal et al. have shown that in patients with lupus, the serum with antibodies against 
DNA and NMDA receptors caused cognitive impairment and hippocampal damage when 
given intravenously to mice. They also showed that anti-NMDA-receptor antibodies are 
present in the brain tissue of patients with cerebral lupus76. Antibodies against complement 
component C1q are associated with SLE and LN disease activity. 
 
 
Table 3 – Pathogenic autoantibodies in SLE 
Antigen specificity Prevalence % Main clinical effects 
Anti-dsDNA 70-80 Kidney disease, skin disease 
Nucleosomes 60-90 Kidney disease, skin disease 
Ro 30-40 Skin disease, kidney disease, fetal 
heart problems 
La 15-20 Fetal heart problems 
Sm 10-30 Kidney disease 
NMDA receptor 33-50 Brain disease 
Phospholipids 20-30 Thrombosis, pregnancy loss 
α-Actinin 20 Kidney disease 
C1q 40-50 Kidney disease 
* Modified from Rahman et al.3 
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1.1.7 Role of Complement in SLE  
 
The role of complement in the pathogenesis of SLE is paradoxical. On the one 
hand, complement components appear to mediate autoantibody-initiated tissue damage. On 
the other hand, the complement system appears to have protective features as hereditary 
deficiencies of some complement components are associated with an increased risk for 
SLE. The kidney is an important source of complement synthesis. Activation of 
complements by immune complexes through classical pathway is supposed to be the main 
mechanism of tissue injury. Blocking the final common pathway C5-C9 of both the 
classical complement pathway and the alternative complement pathway could be an 
attractive approach for treating patients with SLE because both these pathways are 
activated in this disease. Moreover, those patients with hereditary deficiencies of 
complement proteins of the classical pathway are at increased risk for systemic lupus 
erythematosus. Wang et al. demonstrated decreased renal disease and increased survival in 
NZB/W F1 mice, a mouse model of SLE, after treatment with a monoclonal antibody 
specific for C5 component of complement. This antibody blocks the cleavage of C5 and 
thus prevents the generation of the potent proinflammatory factors C5a and C5b-977.  
 
The involvement of the complement system in SLE occurs in three steps, known as 
the ‘waste disposal hypothesis’. The first step is the failure to clear autoantigens i.e. 
defective waste disposal78. This is the stage at which complement deficiency might have a 
pathogenic role. The second step is the uptake of autoantigen by immature DCs in the 
presence of inflammatory cytokines, which causes these cells to mature into antigen-
presenting cells, allowing the presentation of autoantigens to T cells. The third step is the 
pathogenesis of lupus nephritis provision of help by T cells to autoreactive B cells, which 
have taken up autoantigen by means of their immunoglobulin receptors. Such B cells 
mature into plasma cells that secrete autoantibodies. It is likely that in the majority of 
patients, SLE develops only in the presence of abnormalities in more than one of these 
steps.  
 
The formation of an antibody–antigen complex (immune complex) is the principal 
way of activating the classical pathway of the complement system. C1q, an integral part of 
the first component of complement (C1), triggers the activation process when it docks onto 
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antibodies within these immune complexes. In this way, C1q acts to bridge the innate and 
adaptive immune systems. It has been widely accepted that the activation of complement 
by immune complexes is an important contributor to tissue injury in patients with SLE. 
 
At the same time hereditary deficiencies in the complement components of the 
classical pathway increase the risk of lupus and lupus like disease. Deficiencies in C1, C2, 
C4 and CR1 predispose an individual to the development of SLE. For example, the 
complement component C1q eliminates necrotic cellular waste (apoptotic material) in 
healthy individuals. In patients with SLE, a possible deficiency of the C1q component can 
lead to disease expression. C1q-deficient mice developed renal injury with vascular 
thrombosis, proteinuria and renal failure. The increased IgG deposits and apoptotic cells in 
the glomeruli of C1q-deficient mice suggest that the exacerbation of disease may be due to 
a defect in the clearance of immune complexes from the kidneys79. Animal studies have 
produced conflicting data as to whether C3 confers protective or harmful effects80,81. A 
second example of genetic variance is a possible deficiency of the C4 complement, a 
component identified in the elimination of self-reactive B cells. At present, it is difficult to 
reconcile the potential positive and negative impacts of complement in SLE.  
 
1.1.8 Role of cytokines and chemokines in SLE 
 
Cytokines and chemokines may act as key players in the immunopathogenesis of 
SLE. Some cytokines and chemokines levels correlate with SLE disease activity. Certain 
cytokines such as the IL-6, IL-10, IL-17A, BLys, type I IFNs, TNF-α and chemokines 
such as CCL2, CCL5, CXCL10, CXCL12 are closely linked to the pathogenesis of SLE. 
The delineation of the role played by these cytokines and chemokines not only fosters our 
understanding of this disease but also provides a sound rationale for various therapeutic 
approaches. 
 
Cytokines 
Serum levels of interferon-α are also elevated in patients with active lupus82, and 
microarray studies showed that 13 genes regulated by interferon were up-regulated in 
peripheral-blood mononuclear cells from patients with lupus, as compared with similar 
cells from healthy controls83. In studies of lupus-prone NZB/W F1 mice, nephritis 
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developed 15 to 20 weeks earlier in mice continuously exposed to IFN-α from a young age 
than in control mice not subject to this exposure84. 
 
Serum and urine levels of IL-6 were significantly elevated in active SLE patients 
and correlated with the SLE activity index. Monocytes secrete IL-6, which, together with 
transforming growth factor (TGF) β, promotes the differentiation of TH17 cells. IL-6 is 
very important in the stimulation of differentiation and proliferation of B-cells85. It has 
been shown that activated B cells express IL-6 receptors and IL-6 induces the 
differentiation to plasma cells86. Inhibition of IL-6 or IL-6 receptor (IL-6R) using specific 
antibodies resulted in clinical improvements in lupus-prone mice. The fully humanized 
monoclonal anti-IL6R antibody tocilizumab has shown promise in a phase I trial of SLE. 
SLE patients produce abnormally large amounts of IL-10 that correlate with disease 
activity87. IL-10 is produced by activated macrophages and CD4+ T cells. IL-10 has a 
number of biologic effects, including stimulation of polyclonal populations of B 
lymphocytes. Blocking this cytokine could reduce the production of pathogenic 
autoantibodies. In a SLE mouse model, anti-IL-10 mAb treatment led to a significant 
reduction in autoantibody production. A small trial with a single injection of the anti-IL-10 
mAb, B-N10, was conducted in lupus patients with active disease. Although there was an 
overall improvement in disease activity, all patients developed anti-murine antibodies88. 
 
The role of TNF-α in lupus is controversial. This cytokine may be protective in 
patients with lupus, since giving TNF-α to lupus-prone NZB/W F1 mice delayed the 
development of lupus89. The protective effect is specific to that mouse strain, and the 
mechanism is unknown. In some patients with rheumatoid arthritis who were treated with 
anti–TNF-α antibodies, anti–dsDNA antibodies developed90, and lupus erythematosus 
developed in a few of these patients91. TGF-β could exert a bidirectional effect similar to 
the effects of the classical Th2 cytokines, with less inflammation on the one hand, but 
more fibrosis on the other. TGF-β may also play a role for regulatory T cell action. In 
lupus nephritis, Increased expression of TGF-β isoforms (TGF-β1, TGF-β2 and TGF-β3) 
were found in glomeruli and the tubulointerstitium92. In MRL lpr/lpr mice, where TGF-β is 
likewise over expressed, additional TGF-β was beneficial with regard to autoantibody 
formation, kidney disease and survival93, but its role in fibrosis has been suggested to be 
critical. 
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Elevated serum levels of IL-17A and increased numbers of T cells secreting IL-17 
have been detected in SLE patients and in murine lupus models94. IL-17A is a potent 
neutrophil chemoattractant and it is the primary form of IL-17 secreted by Th17 cells. In 
lupus, Th17 cells traffic to inflamed tissues, such as the kidney and promote inflammation 
by enhancing cytokine production, which can in turn activate B cell antibody production, 
activate DCs, and stimulate resident cells in the target tissues. 
 
IL-1α and IL-1β are primarily synthesized by activated monocytes and 
macrophages. IL-1 induces activation of T cells and promotes chemotaxis of 
polymorphonuclear cells, leukocytes, lymphocytes and monocytes and enhances the 
infiltration of these molecules into inflamed tissue. High levels of IL-1β were reported in 
the sera and cerebrospinal fluid of lupus patients. Anakinra, a recombinant human IL-1 
receptor antagonist, is used in the treatment of rheumatoid arthritis. Two very small 
uncontrolled studies of three and four SLE patients suggested that anakinra might have 
beneficial effects on lupus-related manifestations. IL-18, belongs to the IL-1 cytokine 
family, has a variety of effects on DCs, T cells and natural killer (NK) cells. IL-18 was 
associated with the pathogenesis of systemic lupus erythematosus. 
 
The B-lymphocyte stimulator (BLyS) is a member of the TNF-ligand superfamily. 
It promotes the proliferation and survival of B lymphocytes. Circulating levels of BLyS 
are elevated in several other conditions, including rheumatoid arthritis and Sjögren’s 
syndrome, as well as in lupus. The overexpression of BLyS has been detected in both 
humans with lupus and lupus-prone mice63. 
 
Chemokines 
 The regulatory role of chemokines in leukocyte recruitment during inflammatory 
tissue injury has gained more interest over the last decade. In the kidney, all types of renal 
cells have been shown to produce inflammatory chemokines such as CCL2, CCL5, 
CXCL10 and CXCL12 upon various kinds of injury. Local production of these 
chemokines initiates recruitment of macrophages and T cell subsets, which leads to 
subsequent glomerulonephritis and interstitial nephritis. Autoimmune mice with targeted 
deletion of certain chemokines or chemokine receptors, moreover interventional studies 
with specific antagonists are protected from renal autoimmune tissue injury.  
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CCL2 (MCP-1), a potent chemoattractant for monocytes and T cells, and is 
secreted from many kinds of cells. A significant number of T cells and macrophages 
infiltrate the kidneys of patients with lupus nephritis. There is an increasing body of 
evidence that CCL2 plays a major role in the pathogenesis of lupus nephritis. Deletion of 
the CCL2 gene dramatically reduces lupus nephritis in MRL-Fas(lpr) mice95. Inhibition of 
CCL2 ameliorates lupus nephritis in MRL-Fas(lpr) mice96. These findings suggest that 
overexpression of CCL2 plays an important role in the pathogenesis of lupus nephritis in 
humans and in animal models. Serum CCL5 levels are significantly elevated in SLE 
patients when compared with normal controls. CCL5 is critical for glomerular macrophage 
recruitment, as CCL5 blockade reduces glomerular macrophage counts during immune 
complex glomerulonephritis97. CXCL10 is a chemokine that binds to the receptor CXCR3 
and regulates immune responses through the activation and recruitment of leukocytes, such 
as, T cells, eosinophils, and monocytes. Elevated serum CXCL10 levels were observed in 
SLE patients. CXCL12 (SDF-1) is a chemokine that attracts T cells, B cells, pre-B cells 
and monocytes. Its receptor, CXCR4, is the most broadly expressed chemokine receptor, 
as it is present on the surface of T cells, B cells, monocytes, neutrophils and DCs. 
Monoclonal antibodies against CXCL12 hampered autoantibody production and 
development of nephritis in NZB/W mice. Blocking the CXCR4/CXCL12 axis represents 
another possible therapeutic approach for SLE treatment, and this has already shown some 
promise in mouse models of disease98. 
 
1.2 Current therapies of SLE 
 
There is no cure for systemic lupus erythematosus. The goal of treatment is to 
relieve symptoms and protect the organs by decreasing inflammation and/or the level of 
autoimmune activity in the body. The precise treatment is decided on an individual basis. 
Mild flares are treated with nonsteroidal anti-inflammatory drugs and anti-malarials, while 
more serious flares are treated with corticosteroids and immunosuppressants. 
 
Pain and inflammation are common problems in patients with SLE, and NSAIDs 
are usually the drugs of choice for patients with mild SLE with little or no organ 
involvement. NSAIDs are helpful in reducing inflammation, pain and fever. Examples 
include aspirin, ibuprofen, naproxen and sulindac. Since the individual response to 
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NSAIDs varies, it is common for a doctor to try different NSAIDs to find the most 
effective one with the fewest side effects. The most common side effects are stomach 
upset, abdominal pain, ulcers, and even ulcer bleeding.  
 
Corticosteroids are hormones secreted by the cortex of the adrenal gland and are 
more potent than NSAIDs in reducing inflammation and restoring function when the 
disease is active. These drugs are used to treat many of the symptoms of lupus that result 
from inflammation. Administration of corticosteroids results in rapid depletion of 
circulating T-cells. Corticosteroids are particularly helpful when internal organs are 
affected. Prednisone is a corticosteroid that is often used to treat lupus. Unfortunately, 
corticosteroids have serious side effects when given in high doses over prolonged periods. 
Side effects of corticosteroids include weight gain, thinning of the bones, infection and 
diabetes. Although corticosteroids have potentially serious side effects, they are highly 
effective in reducing inflammation, pain, high blood pressure, fatigue, and suppressing the 
immune system. Corticosteroid creams are available to treat skin rashes caused by lupus.  
 
Hydroxychloroquine (plaquenil), chloroquine and mepacrine are antimalarial drugs 
that are used to treat lupus. Hydroxychloroquine is the most commonly used antimalarial. 
These drugs are particularly useful for those patients with skin rashes, joint pain, fever, 
fatigue, pleurisy and especially those patients with discoid lupus. They may provide 
sufficient lupus treatment for a patient with moderately active lupus to avoid steroids. 
Consistently taking plaquenil can prevent flare-ups of lupus. Side effects include diarrhea, 
indigestion and may impair vision. Hydroxychloroquine is considered to be safe for use in 
pregnancy and breast feeding period. Antimalarials are not a sufficient treatment for more 
severe lupus symptoms such as kidney disease and nervous system. Antimalarial 
medications help to control lupus in several ways by modulating the immune system 
without predisposing you to infection. Antimalarial drugs are one of the mainstays of 
treatment for SLE as multiple studies have shown they can delay onset of SLE, reduce the 
symptoms, and prevent flares99. 
 
Immunosuppressives are medications that help suppress the immune system and 
are used for treating people with more severe manifestations of SLE, such as damage to 
internal organ(s). They are almost always taken along with corticosteroids and, in fact, are 
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Table 4. Medications for the management of SLE 
Drug Suggested dose 
NSAIDs 
Ibuprofen 20-40 mg/kg per day 
Naproxen 10-25 mg/kg per day 
Aspirin 3.6 - 5.4 g/day 
Corticosteroids 
Prednisone Up to 2 mg/kg per day 
Methyl prednisone (intravenous) 10-30mg per dose 
Methyl prednisone (oral) Up to 2 mg/kg per day 
Antimalarials 
Hydroxychloroquine 5-7 mg/kg per day 
Chloroquine 250 mg per day 
Immunosuppressants 
Cyclophosphamide (oral) 0.5-2 mg/kg per day 
Cyclophosphamide (intravenous) 500-1000 mg/m2 
Cyclosporine 2.5-4.5 mg/kg per day 
Azathioprine 0.5-2.5 mg/kg per day 
Rituximab 375 mg/m2  per dose 
Methotrexate 15-20 mg/kg per day 
Belimumab 10 mg/kg 
Others 
Mycophenolate mofetil 0.5-3 g/day 
 
 
often used to help gradually reduce the dose of corticosteroids. Examples of 
immunosuppressive medications include methotrexate, leflunomide, azathioprine, 
cyclophosphamide, chlorambucil, cyclosporine, rituximab and belimumab. One of the 
most widely used immunosuppressive drugs for lupus, azathioprine works by blocking 
immune cell function. Side effects can include nausea, lowered blood cell counts, and liver 
inflammation. Methotrexate is used to control skin rash and joint pain caused by lupus and 
not recommended for severe lupus. Cyclosporine modifies the immune system without 
decreasing blood cell counts. Leflunomide is an anti-inflammatory medication that can 
help to reduce the pain and swelling of joints. Cyclophosphamide inhibits cell division and 
growth, and it is a strong immunosuppressive drug. Cyclophosphamide in lupus treatment 
is reserved for very serious kidney disease or other internal organ involvement. All 
immunosuppressive medications can seriously depress blood-cell counts and increase risks 
of infection, bleeding, liver damage, decreased fertility and an increased risk of cancer.  
 
Despite the fact that the mortality and morbidity of patients with SLE has improved 
significantly during the last few decades, mortality rates remain approximately three times 
those of the age-matched and sex-matched population in most studies. The need for more 
Introduction 
 
 
Page | 28  
 
effective therapies with less toxic side effects has propelled interest in targeted biologic 
therapies based on an expanding understanding about SLE disease pathogenesis. B cells 
play a central role in the pathogenesis of lupus, making them a logical therapeutic target. 
The BAFF (B-cell-activating factor) is a critical survival factor for transitional and mature 
B cells. Belimumab (monoclonal antibody against BAFF) blocks the stimulation of the B 
cells and is indicated for the treatment of adult patients with active, autoantibody-positive 
SLE who are receiving standard therapy. It is important to note that the efficacy of 
belimumab has not been evaluated in patients with severe active lupus nephritis. Side 
effects include nausea, diarrhea and fever. Belimumab was approved by the FDA and the 
European medicines agency (EMA) for the treatment of SLE in 2011. Most recent research 
is indicating benefits of rituximab in treating lupus. Rituximab is a genetically engineered 
chimeric monoclonal antibody that targets B-lymphocyte surface marker CD20. Rituximab 
suppresses the B cells by decreasing their number in the circulation. Because rituximab 
does not eliminate plasma cells, it does not markedly reduce immunoglobulin levels. A 
large number of open-label studies documented the efficacy of rituximab in refractory 
lupus nephritis. Unfortunately, the placebo-controlled Phase II/III EXPLORER and 
LUNAR trials of rituximab in SLE failed to meet the primary and secondary endpoints.  
In recent years, mycophenolate mofetil (CellCept) has been used as an effective 
medication for lupus, particularly when it is associated with kidney disease. Its lower side-
effect profile has advantage over traditional immunosuppressive medications. In SLE 
patients with serious lupus cerebritis or lupus nephritis, plasmapheresis is sometimes used 
to remove antibodies and other immune substances from the blood to suppress immunity. 
Plasmapheresis is a process of removing blood and passing the blood through a filtering 
machine, then returning the blood to the body with its antibodies removed. End-stage 
kidney damage from SLE requires dialysis and/or a kidney transplant. 
SLE treatment has moved from the use of conventional drugs such as 
hydroxychloroquine, NSAIDS, corticosteroids and non-specific immunosuppressants to 
targeting selective components of the immune system in the hope that they can be more 
effective and reduce undesired side-effects. Our increased understanding of SLE 
immunopathogenesis has led to the introduction of several new agents over the last 10 
years, a move from therapeutic serendipity to sense. Biological agents targeting B cells and 
T cells are under development. Drugs under current research in SLE are directed against B 
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cell surface molecules (CD20, CD22 and CD19), co-stimulation (CTLA-4, CD40/CD40L, 
ICOS/B7-H2), complement inhibition, toleragens, TLR inhibitors, as well as cytokines and 
chemokines.  
 
People with lupus are more likely to experience infection and infection-related 
complications. This is because their immune system is weakened by both the disease and 
the medications used to treat it. In particular corticosteroids and immunosuppressive drugs, 
affect the immune system. The most common infections in people with lupus include those 
of the respiratory tract, skin and urinary system. Immunosuppressive drugs used to treat 
lupus can also enhance the risk of cancer. Thus the main goal of research is to find drugs to 
treat lupus more specifically, without systemically suppressing the immune system. The 
development of targeted therapies that specifically address disease pathogenesis and 
progression has lagged, resulting in a limited therapeutic armamentarium of broad 
spectrum immuno-suppressive agents that have substantial toxicities and are not always 
adequate to control symptoms or prevent disease flares. Recent clinical trials based on 
rational hypotheses and robust preclinical effects on mouse SLE models have tested the 
efficacy of new biologic drugs in combination with standard-of-care therapies but have 
met with only limited success in recent years. Even though T cell and B cell targets seem 
to be promising, clinical trial results for these therapies do not look encouraging. This 
leaves scope for the development of new strategies to encounter SLE and lupus nephritis. 
Treatments, that are more specific in modifying particular subsets of immune cells (e.g. 
T/B cells), or the activity of cytokine they secrete have been gaining attention.  
 
The development and approval of new treatments for SLE remain a challenge for 
rheumatologists and healthcare providers as the disease is multisystemic, remitting and 
relapsing, and usually requires corticosteroids as baseline therapy. Previous clinical trials 
with promising new drugs, such as rituximab and abatacept, have failed. However, these 
medications are responsible for the untargeted immune suppression and may increase the 
risk of infections and bone marrow suppression, hepatotoxicity and other adverse events. 
The currently available treatments for lupus have been shown to be ineffective in 
inducing/maintaining a low disease activity state or remission in some patients. Thus, there 
are unmet needs in SLE treatment for new drugs that can target specific pathways and 
reduce or eliminate disease activity without predisposing to serious adverse events. 
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1.3 Role of Proteases 
 
Proteases are proteolytic enzymes that catalyze the breakdown of proteins by 
hydrolysis of peptide bonds. Proteases play a critical role in many physiological and 
pathophysiological processes by controlling the activation, synthesis and turnover of 
proteins. Proteases are involved in a large number of key physiological processes such as 
cell-cycle progression, cell proliferation, cell death, DNA replication, tissue remodeling, 
haemostasis, wound healing and immune responses. Different types of proteases have 
different biological functions. Proteases are mainly classified into five distinct classes: 
serine, cysteine, aspartic, threonine and metalloproteases; depending on the nature of the 
functional group at the active site.  
 
The scope of the thesis is to study in detail roles of a serine protease (Activated 
protein C) and a cysteine protease (Cathepsin S) in SLE and lupus nephritis. 
 
1.3.1 Activated protein C  
 
 Activated protein C (aPC), a vitamin K-dependent serine protease and is generated 
from the protein C (PC) zymogen by proteolytic activation by thrombin. Originally 
thought to be synthesized exclusively by the liver, recent reports have shown that PC is 
also produced by endothelial cells, smooth muscle cells, keratinocytes and some 
leukocytes. The molecule was discovered in 1976 by Johan Stenflo who purified a protein 
in pool C of a chromatography elute derived from bovine plasma100. The function of this 
protein was revealed a few years later when Charles Esmon and colleagues discovered that 
its activated form was a physiological anticoagulant. In contrast to the various 
procoagulant plasma factors, aPC has anticoagulant and cytoprotective activities. Normal 
activation of protein C by thrombin requires two membrane receptors, thrombomodulin 
and endothelial protein C receptor (EPCR). PC is activated on the endothelial surface 
when thrombin binds to thrombomodulin and cleaves the activation peptide (Figure 4). 
This conversion to aPC is augmented by the EPCR. Clinical studies reveal that deficiency 
of PC lead to microvascular thrombosis. PC circulates in plasma at 70 nM whereas aPC is 
present in much lower concentrations (40 pM or ~ 2.3 ng/ml).  
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aPC is a protein with multiple functions in the regulation of homeostasis. It acts as 
a natural anticoagulant by inactivating the coagulation factors Va and VIIIa. In addition to 
its anticoagulation functions, aPC also has cytoprotective effects such as anti-
inflammatory, pro-fibrinolytic, anti-apoptotic, and endothelial barrier protection. aPC has 
been shown to be protective in severe human sepsis. In fact, a recombinant form of human 
aPC (Drotrecogin Alfa activated; commercially known as Xigris; Lilly Deutschland, Bad 
Homburg, Germany) was approved in 2001 by the U.S. Food and Drug Administration for 
the treatment of severe sepsis associated with a high risk of mortality101. On October 25th, 
2011, Eli Lilly & Co. withdrew Xigris from the market after a major study (PROWESS-
SHOCK trial) showed no efficacy for the treatment of sepsis. As a consequence, the FDA 
has recommended that aPC treatment should not be started in new patients.   
 
There are four major moieties that make up the PC molecule; the Gla domain, two 
EGF-like regions, a small activation peptide, and the active serine protease domain. Upon 
binding with EPCR, thrombin-thrombomodulin complexes activate PC by removing 14 
amino acids100 from activation peptide (Figure 4). Cytoprotective actions generally require 
EPCR and protease activated receptor-1 (PAR-1). aPC has following cytoprotective 
activities. 
 
 
 
Figure 4. Structure of PC. GLA: γ-carboxy-glutamic acid-rich domain; EGF: epidermal growth 
factor-like moiety; S–S: disulphide bond. Crimson moiety represents the activation peptide. Bar 
shows approximate amino acid sequential numbers. (Adapted from Christopher J. Jackson and 
Meilang Xue100) 
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Anticoagulant activity 
In the presence of its cofactors such as protein S, phospholipids and 
glycosphingolipids aPC degrades the coagulation factor Va and VIIIa and inhibits 
thrombin generation. In addition, aPC promotes fibrinolysis by binding to plasminogen 
activator inhibitor which prevents inhibition of plasminogen conversion to plasmin. 
Anti-apoptotic activity 
Gene expression profiling pattern studies revealed modulation of gene expression 
by aPC for some major genes of inflammation and apoptosis, with the general effect of 
down-regulation of proinflammatory and pro-apoptotic pathways and up-regulation of anti-
inflammatory and anti-apoptotic pathways. Notably, aPC decreases pro-apoptotic p53 and 
Bax expression and increases expression of anti-apoptotic genes such as Bcl-2. 
Endothelial barrier stabilization 
aPC is well-known for its ability to protect the endothelial barrier, which is 
mediated by EPCR-dependent PAR-1 activation. aPC activated PAR-1 can stimulate 
sphingosine kinase-1 (SphK-1) and enhance sphingosine-1-phosphate (S1P) production, 
which is involved in endothelial barrier protection. PAR-1 activation by thrombin 
destabilizes the endothelial barrier, while activation of PAR-1 by aPC enhances barrier 
function. 
Anti-inflammatory activity 
aPC inhibits nuclear translocation of nuclear factor (NF)-kB, which blocks 
expression of downstream TNF-α, IL-6, IL-8, IL-1β, MCP-1 and TNF-α, and cell adhesion 
molecules, intracellular adhesion molecule 1, vascular cell adhesion molecule 1 and E-
selectin. In addition to downregulation of proinflammatory cytokines, aPC was shown to 
increase the expression of anti-inflammatory cytokine IL-10. Tissue factor (TF) is an 
important factor that links inflammation and coagulation, aPC decreases TF expression in 
an EPCR-dependent manner. Proinflammatory effects of the coagulation pathway are 
primarily mediated by thrombin, inhibition of thrombin formation indirectly by aPC 
through its inhibition of FVa and FVIIIa can reduce thrombin’s proinflammatory activities.  
 
Although aPC can be considered as a potentially useful clinical tool, its ugly side 
still remains (i.e. the bleeding risk associated with its anticoagulant activity). Site-directed 
mutagenesis has made it possible to engineer PC variants that are devoid of anticoagulant 
activity while preserving cell signaling properties. aPC variants with reduced anticoagulant  
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Figure 5. Proposed actions of activated protein C  
Infectious agents and inflammatory cytokines such as TNF-α and interleukin-1 activate coagulation 
by stimulating the release of tissue factor from monocytes and the endothelium. The presentation 
of tissue factor leads to the formation of thrombin and a fibrin clot. Inflammatory cytokines and 
thrombin can both impair the release of plasminogen-activator inhibitor 1 (PAI-1) from platelets 
and the endothelium. PAI-1 is a potent inhibitor of tissue plasminogen activator, the endogenous 
pathway for lysing a fibrin clot. In addition, the thrombin suppresses the endogenous fibrinolytic 
system by activating thrombin-activatable fibrinolysis inhibitor (TAFI). The conversion of protein 
C, by thrombin bound to thrombomodulin, to the aPC is impaired by the inflammatory response. 
aPC can intervene at multiple points during the systemic response to infection. It exerts an 
antithrombotic effect by inactivating factors Va and VIIIa, limiting the generation of thrombin. As 
a result of decreased thrombin levels, the inflammatory, procoagulant, and anti-fibrinolytic 
response induced by thrombin is reduced. aPC exerts an anti-inflammatory effect by inhibiting the 
production of inflammatory cytokines (TNF-α, IL-1, and IL-6) by monocytes and limiting the 
rolling of monocytes and neutrophils on injured endothelium by binding selectins. aPC indirectly 
increases the fibrinolytic response by inhibiting PAI-1. (Adapted from Bernard et al.101) 
 
 
action but normal cytoprotective actions hold the promise of reducing bleeding risk 
because of attenuated anticoagulant activity while reducing mortality based on 
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cytoprotective effects. For example, safe aPC variants with reduced bleeding risk may 
permit therapies using higher aPC doses for shorter times. Higher doses of aPC may 
stabilize stressed cells at risk for excessive inflammation or apoptosis and prevent organ 
failure. aPC variants have been successfully tested in endotoxemia, ALS and ischemic 
stroke models102,103. 
 
Studies in animal models have demonstrated that aPC shows promise in a variety 
of pathologies. Although the precise way of action has not yet been elucidated, the 
immunosuppressive and cytoprotective effects of aPC have now emerged as a potential 
treatment for a number of autoimmune and inflammatory diseases that are associated with 
excessive immune responses such as acute respiratory distress syndrome, multiple 
sclerosis, rheumatoid arthritis, brain injury, lung injury, spinal cord injury, asthma, stroke, 
and chronic wounds104. aPC appears to have protective effects against 
ischemia/reperfusion-induced renal injury not by inhibiting coagulation, but by inhibiting 
the activation of leukocytes. The mechanism of action of aPC in wound healing is 
complex, and involves a unique combination of inhibition of inflammation, stimulation of 
angiogenesis and re-epithelialisation as well as anti-apoptotic properties. A recent study 
reported that aPC was also effective in protecting from diabetic nephropathy by inhibiting 
endothelial and podocyte apoptosis, where it modulates the mitochondrial apoptosis 
pathway via the PAR-1 and the EPCR105. aPC also had protective effects on chronic 
inflammatory bowel disease by reducing intestinal microvascular inflammation106. Given 
these beneficial effects of aPC on multiple hyperinflammatory and autoimmune disease 
states, we speculated that aPC may also suppress SLE and lupus nephritis. To address this 
question, we treated autoimmune and nephritic MRL-Fas(lpr) mice with recombinant 
human aPC and characterized the therapeutic effects on systemic autoimmunity, lupus 
nephritis, and other organ manifestations of SLE.  
 
1.3.2 Cathepsin S 
 
Cathepsin S (Cat S) is a lysosomal cysteine protease, plays an important role in 
antigen presentation and matrix degradation. Cat S has also been suggested to be involved 
in the generation of certain antigenic epitopes107. It is mainly found in 
lysosomal/endosomal compartments of APCs, such as B cells, macrophages and DCs and 
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can also be induced in many types of cells including adipocytes and smooth muscle 
cells108. It is also found in the ‘non-professional’ APC such as epithelial cells. Among the 
lysosomal proteases, Cat S possesses special characteristics, including its tissue-specific 
constitutive expression, its IFN-γ-dependent transcriptional activation and its activity over 
a broad pH range that extends to alkaline pH109,110. Unlike some other cathepsins, which 
are ubiquitously expressed, Cat S has a restricted tissue distribution and it is expressed 
mostly in the spleen, lymph, heart and lung. These findings suggest a role in immune and 
inflammatory processes. Its inhibition is expected to result in immune-suppression, making 
this enzyme an attractive target to potentially treat autoimmune and inflammatory diseases.  
 
Cat S plays a major role in the degradation of the invariant peptide chain associated 
with the major histocompatibility complex and thus affects antigen presentation. Antigen 
presentation is the process whereby extracellular antigens, are taken up by professional and 
non-professional antigen presenting cells, and mostly degraded in the lysosomal 
compartment. The resulting peptides are displayed on the cell surface after the formation 
of MHC-II-peptide complexes. The molecular mechanism leading to the formation of class 
II peptide complexes and presentation of antigen on the cell surface begins with the 
synthesis of the class II α β heterodimers in the endoplasmic reticulum. These dimers are 
assembled together with the assistance of the Ii chaperone molecule to form a nanomeric 
complex αβ-Ii. This complex is then delivered to the endosomes where Ii is degraded in a 
stepwise fashion by the lysosomal proteases, allowing the antigen-binding site of MHC-II 
to be exposed. In B-cells and DCs, Cat S is the single enzyme that cleaves the Ii p10; a 10-
kDa fragment of the lysosomal MHC-II bound invariant chain to form 24 amino-acid CLIP 
fragments (Figure 6). HLA-DM in humans and H-2M in mice catalyze the replacement of 
the MHC-II bound CLIP peptide with an antigenic peptide111. 
 
Active Cat S was detected in B cells, DCs and peritoneal macrophages. By 
contrast, cathepsin L (Cat L) was detected only in macrophages and cortical thymic 
epithelial cells, where a defect resulted in severely impaired CD4+ T cell selection. In 
addition to Cat S, Cat L and cathepsin F (Cat F) have been implicated in Ii degradation and 
antigen presentation in alveolar macrophages. In macrophages, Cat S deficiency does not 
severely impair Ii degradation and antigen processing as Cat L and F can compensate for 
it112.  
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Figure 6. Role of cathepsin S in invariant chain processing. (Adapted from Virobay Inc. website) 
 
 
Cat S has emerged as an attractive target for inhibiting immune responses, as its 
prime target is the disruption of antigen presentation. The continuous presentation of 
antigenic self-peptides is thought to perpetuate the autoimmune disease process. Inhibitors 
of Cat S block the presentation of autoantigens and may hold great promise for a novel 
immunosuppressive therapy. In APCs, deficiency of the Cat S enzyme, as a result of gene 
knock-down or inhibition by a small molecular compound, reduces degradation of the 
invariant chain, a crucial chaperon which also blocks peptide-binding by MHC-II 
molecules, thereby decreasing antigen presentation to CD4+ T cells. Cat S deficient mice 
showed diminished activation of CD4+ T cells, reduced production of antibodies, and are 
resistant to collagen-induced arthritis (CIA)113. Similar findings are observed in mice and 
rats dosed with Cat S inhibitors. Such inhibition reduced antigen dependent pulmonary 
inflammation in mice and decreased inflammation in the rat adjuvant-induced arthritis 
model. Cat S inhibitors have been found to block the rise in immunoglobulin E titers and 
eosinophil infiltration in the lungs, in a mouse model of pulmonary hypersensitivity. This  
suggests that Cat S may be involved in asthma. The possibility of using a Cat S inhibitor to 
regulate overactive autoimmune responses was confirmed, with the use of Cat S inhibitor 
CLIK-60 in a murine model for Sjӧgren’s syndrome. Intraperitoneal administration of 
CLIK-60 showed elimination of the autoimmune manifestations by preventing the 
presentation of organ specific antigen α-fodrin by MHC-II114. In vivo, mice deficient in Cat 
S are healthy and normal in most respects but exhibit defects in immune function. 
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Furthermore, Cat S-deficient mice showed abnormal angiogenesis, defective microvessel 
development during wound healing. 
 
It has been shown that extracellular Cat S is critical for the initiation and/or 
maintenance of neuropathic pain in peripheral nerve injured mice and rats. Intrathecal 
delivery of an irreversible Cat S inhibitor, morpholinurea-leucine-homophenylalanine-
vinyl phenyl sulfone (LHVS) was anti-hyperalgesic and anti-allodynic in neuropathic rats 
and attenuated spinal microglia activation, leading to alleviation of chronic pain associated 
with spinal cord injury (SCI)115. Moreover, it was demonstrated that the pronociceptive 
role of extracellular Cat S might be mediated by the release of the transmembrane 
chemokine fractalkine in neurons. Cat S has a pivotal role in atherogenesis. Thus, a 
deficiency in Cat S has been shown to reduce atherosclerosis in mice, indicated by plaque 
size and stage of development116. In a novel potential therapeutic use of Cat S inhibitors, 
Novartis recently claimed their use for the treatment of chronic pain. The rationale is based 
on the discovery of Cat S mRNA upregulation in animal models of chronic pain and that 
inhibitors act as analgesics in these models. 
 
A huge unmet medical need exists for a safe, oral medication for the treatment of 
SLE. In searching for novel therapeutic options, it has become clear that intervention at the 
stage of antigen presentation may be a viable option. Cat S has a non-redundant role in 
antigen presentation that selectively affects CD4+ T cells and leaves CD8+ T cells largely 
intact. This should provide therapeutic advantages over non-selective immunosuppressive 
compounds. Current therapies for lupus are often only partially effective and are 
accompanied by undesirable side effects. Thus targeting the antigen presentation pathway, 
responsible for triggering autoimmune diseases such as SLE, may provide a novel 
immunotherapy. Cat S inhibitors are more specific, safe and effective than the inhibitors 
with broad specificity. 
 
Multiple genome-wide association studies performed on large cohorts of patients 
with lupus nephritis, membranous glomerulonephritis, or IgA nephropathy now confirmed 
that the pathogenesis of these common forms of immune complex glomerulonephritis (IC- 
GN) is tightly linked to the human leukocyte antigen genes that encode for MHC-
II15,117,118. This implicates an essential role of MHC-II-mediated priming of adaptive 
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Figure 7. Schematic representation of normal B-cell ontogeny in the GC. Naïve B-cells encounter 
antigen and undergo proliferation, clonal expansion, somatic hypermutation and class-switch 
recombination in the GC microenvironment. The resulting B-cell clones with high affinity 
antibodies are positively selected to differentiate into plasma cells and secrete large quantities of 
specific antibodies or become memory B-cells that recognize and respond to repeat antigen 
exposure. The remaining B-cell clones are eliminated by apoptosis. (Adapted and modified from 
ASH Education Program Book 2007119) 
 
immunity in the development of IC-GN. The presentation of foreign or self-antigenic 
peptides within MHC-II in the context of TLR-dependent costimulation activates antigen-
specific CD4+T helper cells for their clonal expansion and polarization into the various 
CD4+ T cell subsets. These cells then activate antigen-specific B cells undergo clonal 
expansion inside the GC of the lymphoid follicles (Figure 7). The GC environment is also 
needed for driving the somatic hypermutation of activated B cells, which involves affinity 
maturation and Ig class switch from immunoregulatory IgM-producing B cells into high 
affinity and complement-binding IgG antibody producing plasma cells120. Since formation 
and maintenance of GCs is T cell-dependent, altered T cell activation may be due to either 
Cat S-mediated disruption of antigen presentation or the unavailability of proper DC due to 
Cat S-mediated DC migration defects.  
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This process contributes to antigen-induced adaptive immunity as demonstrated by 
vaccinating mice with myelin oligodendrocyte glycoprotein 35e55 peptide112, bovine type 
II collagen112 or ovalbumin121, even though Cat S was not required for thyroid stimulating 
hormone receptor-induced autoimmune thyroiditis122. As, in addition, Cat S degrades 
autoantigenic peptides favoring autoreactive CD4+ T cells to escape thymic selection123, 
there is a strong rationale for Cat S being a mediator of autoimmune IC-GN. To address 
this concept we first characterized Cat S expression in female MRL-(Fas)lpr mice with 
spontaneous lupus-like systemic autoimmunity and IC-GN. To study the functional 
contribution of Cat S and its suitability as a therapeutic target, we developed a specific, 
orally available, Cat S inhibitor that dose-dependently suppresses the proteolytic activity 
of murine and human Cat S in vitro and in vivo. By treating diseased female MRL-(Fas)lpr 
mice with this compound we not only demonstrate a non-redundant role of Cat S in IgG 
autoantibody production and glomerulonephritis but also identify Cat S as a novel 
therapeutic target for IC-GN.  
 
1.4 MRL-Fas(lpr) mice - mouse model of SLE 
 
MRL-Fas(lpr) mice develop an autoimmune disease that reflects pathologies of 
human SLE, including lymph node enlargement, increased IgG levels, antinuclear 
antibody production, proteinuria, and kidney failure. Female MRL-Fas(lpr) mice die at an 
average age of 17 weeks and male mice at 22 weeks. This accelerated phenotype was 
attributed to a recessive autosomal mutation termed lymphoproliferation (lpr). The lpr 
mutation, located on chromosome 19, alters transcription of the Fas receptor124. MRL-
Fas(lpr) mice lack functional expression of the apoptosis-inducing receptor Fas, thereby 
accelerating the manifestation of the autoimmune disease, which also develops in wild-
type MRL mice, albeit, with a slower kinetic. Studies on B-cells and T-cells from MRL-
Fas(lpr), which both express Fas, confirmed a defect in apoptosis due to the lack of 
functional Fas receptor. 
 
MRL-Fas(lpr) mice spontaneously develop lupus-like disease beginning at twelve 
weeks of age and often succumb to death from glomerulonephritis125. MRL-Fas(lpr) mice 
develop immune complex glomerulonephritis, associated with mononuclear cell 
infiltration, endothelial and mesangial cell proliferation, and crescent formation. MRL-
Introduction 
 
 
Page | 40  
 
Fas(lpr) mice show systemic autoimmunity, massive lymphadenopathy associated with 
proliferation of aberrant CD3+B220+CD4-CD8- T cells and immune complex-derived 
glomerulonephritis. Starting at approximately 3 months of age, levels of circulating 
immune complexes, such as those from spontaneously generated anti-dsDNA antibodies, 
rise dramatically in MRL-Fas(lpr) but not in wild-type MRL controls. The spleen weight 
of MRL- Fas(lpr) mice is sevenfold larger than that of controls. The lymph node weight of 
MRL-Fas(lpr) increases approximately 75-fold over controls and renal pathology occurs 
extensively in MRL-Fas(lpr) at approximately 4 months of age and die usually before 6 
months of age.  
 
Serologically, MRL-Fas(lpr) mice have fivefold increase in gamma-region 
proteins. Twofold increases in IgA, IgM, and IgG2b and six fold increases in IgG1 and 
IgG2a have been identified by radial immunodiffusion. Sera of MRL-Fas(lpr) mice are 
uniformly positive for antinuclear autoantibodies by 12 weeks of age. The presence of 
anti-single stranded DNA (anti-ssDNA), anti-dsDNA and anti-Smith (anti-Sm) 
autoantibodies is characteristic. Retroviral gp70 immune complexes and IgM and IgG 
rheumatoid factors are found in significant concentrations in MRL-Fas(lpr) mice126. 
 
The lungs of MRL-Fas(lpr) mice show extensive perivascular and peribronchial 
lymphocytic infiltration with only occasional atelectasis and exudates. Joints of MRL-
Fas(lpr) mice show arthritic changes resembling those of rheumatoid arthritis126. Coronary 
artery disease and myocardial infarction can be a contributing cause of death. Near the end 
of their lifespan, MRL-Fas(lpr) mice develop erythematous skin lesions, necrosis of the 
ears, swollen feet, and, frequently, generalized edema. MRL-Fas(lpr) mice spontaneously 
develop lacrimal gland inflammatory lesions and are a model of human Sjogren’s 
syndrome.  
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2. Research objectives  
 
Current treatment for SLE including nonsteroidal anti-inflammatory drugs, 
corticosteroids, antimalarials and immunosuppressive drugs has significant side effects. 
Recent clinical trials for SLE using novel biological drugs have failed to achieve desired 
results. There is an unmet medical need for new drugs for SLE with a better safety profile. 
Considering all these findings we evaluated the role of two proteases namely aPC (serine 
protease) and Cat S (cysteine protease) as a novel therapeutic targets in the pathogenesis of 
SLE. 
 
1.       Our first objective was to study the effect of exogenous administration of aPC on 
systemic inflammation in MRL-Fas(lpr) mouse lupus model. Systemic lupus 
erythematosus (SLE) is a chronic autoimmune disease leading to inflammatory tissue 
damage in multiple organs. The role of aPC in inflammatory conditions is well known. 
aPC is a natural anticoagulant, in addition it has cytoprotective activities like anti-
inflammatory, anti-apoptotic, profibrinolytic and protects endothelial barrier. Recombinant 
aPC was recently shown to suppress a number of hyperinflammatory and autoimmune 
states; hence, we had hypothesized that recombinant aPC may also suppress SLE and 
lupus nephritis.  
 
2.       Our second objective was to study the effect of cathepsin S inhibitor R05461111 on 
the pathogenesis of lupus in MRL-Fas(lpr) mouse model. SLE is characterized by loss of 
self-tolerance and abnormally activated B cells, T cells and antigen presenting cells. Cat S 
is a lysosomal cysteine protease and is responsible for the final proteolysis of MHC-II 
associated chaperone invariant chain (Ii) in antigen-presenting cells, thus plays an 
important role in antigen presentation. Cat S has emerged as an attractive target and 
inhibitors of Cat S block the presentation of autoantigens. Since abnormal antigen 
presentation leads to autoimmunity, we hypothesized that Cat S inhibitor would suppress 
SLE and lupus nephritis.  
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3. Materials and Methods 
3.1 Materials  
 
Equipments  
 
Balances:  
Analytic Balance, BP 110 S                  Sartorius, Göttingen, Germany  
Mettler PJ 3000                                   Mettler-Toledo, Greifensee, Switzerland  
 
Cell Incubators:  
Type B5060 EC-CO 2                        Heraeus Sepatech, München, Germany  
 
Centrifuges:  
Heraeus Minifuge T                             VWR International, Darmstadt, Germany  
Heraeus Biofuge primo                         Kendro Laboratory Products GmbH,  
                                                               Hanau, Germany  
Heraeus Sepatech Biofuge A                    Heraeus Sepatech, München, Germany  
Eppendorf centrifuge 5417 R                  Eppendorf AG, Hamburg, Germany 
 
ELISA-Reader:  
Tecan, GENios Plus                                 Tecan, Crailsheim, Germany  
 
Fluorescence Microsocopes  
Leica DC 300F                                       Leica Microsystems, Cambridge, UK   
Olympus BX50                                       Olympus Microscopy, Hamburg, Germany 
                                                                           
Spectrophotometer:  
Beckman DU ® 530                                Beckman Coulter, Fullerton, CA, USA  
Nanodrop                                                Thermoscientific, Wilmington, DE, USA 
 
Real time PCR:                                                   
LightCycler480                                      Roche diagnostics, Mannheim, Germany  
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Other Equipments: 
 
Cryostat RM2155                                    Leica Microsystems, Bensheim, Germany 
Cryostat CM 3000                                   Leica Microsystems, Bensheim, Germany 
Homogenizer ULTRA-TURRAX   
T25                                                        IKA GmbH, Staufen, Germany    
Microtome HM 340E                   Microm, Heidelberg, Germany  
pH meter WTW                                WTW GmbH, Weilheim, Germany  
Thermomixer 5436                               Eppendorf, Hamburg, Germany  
Vortex Genie 2™                                        Bender&Hobein AG, Zurich, Switzerland 
Water bath HI 1210                                     Leica Microsystems, Bensheim, Germany  
 
Chemicals and materials  
Chemicals for molecular biology techniques  
RNeasy Mini Kit                                         Qiagen GmbH, Hilden, Germany  
qPCR primers                                             Metabion, Germany  
  
Cell culture   
RPMI-1640 medium                                    GIBCO/Invitrogen, Paisley, Scotland, UK  
FSC                                                          Biochrom KG, Berlin, Germany  
Dulbecco’s PBS (1×)                                   PAA Laboratories, Cölbe, Germany     
Penicillin/Streptomycin (100×)                     PAA Laboratories, Cölbe, Germany     
 
Antibodies   
anti-Mac-2                                                 Cederlane, Ontario, Canada  
anti-CD3                                                  BD Pharmingen, Heidelberg, Germany  
anti-CD4                                                    BD Pharmingen, Heidelberg, Germany  
anti-CD8                                                    BD Pharmingen, Heidelberg, Germany  
anti-CD25                                                     BD Pharmingen, Heidelberg, Germany  
anti-CD11c                                                   BD Pharmingen, Heidelberg, Germany  
anti-F4/80                                                     AbD Serotec, Düsseldorf, Germany 
anti-MHC-II                                                  BD Pharmingen, Heidelberg, Germany  
anti-B220  BD Pharmingen, Heidelberg, Germany  
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Miscellaneous  
Needles BD Drogheda, Ireland  
Pipette’s tip 1-1000µl Eppendorf, Hamburg, Germany  
Plastic histosettes NeoLab, Heidelberg, Germany  
Pre-separation filters Miltenyi Biotec, Bergish Gladbach, 
Germany  
SuperFrost® Plus  Microscope slides Menzel-Gläser, Braunschweig, Germany  
Silver Impregnation Kit                               Bio-Optica, Milano, Italy  
Syringes Becton Dickinson GmbH, Germany  
  
Chemicals:   
Acetone                                                        Merck, Darmstadt, Germany   
Bovine Serum Albumin                               Roche, Mannheim, Germany  
DEPC                                                           Fluka, Buchs, Switzerland  
DMSO                                                          Merck, Darmstadt, Germany  
EDTA                                                          Calbiochem, SanDiego, USA  
Ethanol                                                         Merck, Darmstadt, Germany  
Formalin                                                       Merck, Darmstadt, Germany   
HCl (5N)                                                       Merck, Darmstadt, Germany  
Isopropanol                                                   Merck, Darmstadt, Germany  
Potassium chloride                                     Merck, Darmstadt, Germany   
Potassium dihydrogenphosphate                Merck, Darmstadt, Germany  
Potassium hydroxide                                 Merck, Darmstadt, Germany  
MACS-Buffer                                               Miltenyi Biotec, Bergisch Gladbach,  
                                                                    Germany 
Mercaptoethanol                                         Roth, Karlsruhe, Germany  
Sodium acetate                                            Merck, Darmstadt, Germany   
Sodium chloride                                            Merck, Darmstadt, Germany  
Sodium citrate                                               Merck, Darmstadt, Germany  
Penicillin                                                      Sigma, Deisenhofen, Germany  
SSC (Saline-sodium citrate Buffer)            Sigma, Deisenhofen, Germany  
Tissue Freezing Medium                                Leica, Nussloch, Germany  
Trypan Blue                                                  Sigma, Deisenhofen, Germany  
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3.2 Methods 
 
3.2.1 Animal experiments 
 
Eight-week-old female MRL-Fas(lpr) mice were obtained from Harlan 
Winkelmann (Borchen, Germany) and kept under pathogen-free and normal housing 
conditions in a 12-h light and dark cycle. All experiments were performed according to 
German animal protection laws and had been approved by the local government 
authorities. 
 
Experimental protocol - I 
At the age of 14 wk, groups of 15 mice each started to receive either 5 mg/kg body 
weight mouse recombinant human aPC (Xigris™; Lilly Deutschland) or vehicle PBS (50 
mM Tris, 150 mM NaCl, pH 7.6) only by i.p. injection on alternate days. Water and 
standard chow (Ssniff, Soest, Germany) were available ad libitum. All mice were 
sacrificed by cervical dislocation at the end of week 18 of age. Wild-type (wt) MRL mice 
were used as healthy controls. Blood and urine samples were collected from each mouse at 
the end of the study period.  
 
 
 
Experimental protocol – II 
At the age of 11 wk, proteinuria was assessed and only proteinuric mice were 
randomized to receive from week 12 either a medicated diet formulated by mixing the Cat 
S inhibitor (R05461111, 262.5mg/kg chow) or standard diet (vehicle). The mice consumed 
approximately 5 g food per day (1.31 mg drug per day) with no difference in food intake 
or body weight between the two groups. All mice were sacrificed by cervical dislocation at 
20 weeks of age. Blood and urine samples were collected from each mouse during the 4th 
week of the study and at the end of the study period (8th week). For sheep IgG 
immunization study 8 week old male C57BL/6 mice were immunized on day 0 
Sacrifice 
Activated protein C – 5 weeks treatment 
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subcutaneously (s.c) in the both hind foot pads with 10µg of sheep IgG (Jackson 
immunoresearch laboratories, New market, Suffolk, UK) in an emulsion containing 50% 
(v/v) sterile PBS and 50% (v/v) Complete Freund’s Adjuvant (sigma). On day 7, mice 
were re-challenged with 10µg of sheep IgG using retro-orbital injection. Ten days after 
immunization, the mice were sacrificed by cervical dislocation to collect blood and spleen 
tissue.  
 
 
 
        
 
 
3.2.2 Quantification of activated protein C levels 
 
The endogenous levels of aPC were estimated in plasma samples using an ELISA 
kit for aPC from Uscn Life Science (Wuhan, China). In this experiment pre-coated 
microplate plate has been used. The microplate used in this experiment has been pre-
coated with an antibody specific to aPC. Standards or samples were added to the 
appropriate wells and incubated for 2h at 37ºC. Next, 100ul detection reagent A (Biotin-
conjugated antibody specific for aPC) was added to the each well and incubated for 1h at 
37ºC. After washing 3 times, 100ul detection reagent B (Avidin conjugated to Horseradish 
Peroxidase (HRP)) was added to the each well and incubated for 30 min at 37ºC. After 
washing 5 times, 90ul of the TMB substrate solution was added to each well and incubated 
for 15 min resulting in the development of a blue color. The color development was 
stopped using 50ul of stop solution. Then, using microplate reader absorbance was 
measured at 450nm. The concentration of aPC in the samples was then determined by 
comparing the O.D. of the samples to the standard curve. 
 
 
3.2.3 Cathepsin S Inhibitor RO5461111 
 
RO5461111 (CAS 1252637-46-9) is a competitive inhibitor of the active site of Cat 
S. The nitril function of RO5461111 allows covalent reversible inhibition of Cat S. It was 
provided by F. Hoffmann-La Roche, Ltd., Basel, Switzerland. The synthesis and drug 
development of RO5461111 has been described in WO 2010121918.  
R05461111 – 8 weeks treatment 
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Recombinant cathepsins were produced in house or purchased from commercial 
vendors and enzymatic assay performed using the fluorogenic substrate (Z-Val-Val-Arg-
AMC for human and mouse Cat S, human Cat L & Cat B, Z-Leu-Arg-AMC for human Cat 
K and Cat V). The generation of fluorescence over 10 min was measured using 10 µM of 
substrate and 1 nM of enzyme in the presence of increasing concentrations of RO5461111 
to determine IC50 values. The cellular activity of RO5461111 was tested on B-cell lines of 
human (RAJI) or mouse (A20) origin. Increasing concentrations of RO5461111 was 
incubated overnight and then protein extracts prepared for detection of p10 upregulation 
by Cat S inhibition on western blots.  
 
For the determination of in vivo enzyme inhibition activity of Cat S by RO5461111 
we used normal BALB/c mice. After oral dosing of 0.1 mg/kg to 100 mg/kg of 
RO5461111 mice were sacrificed after 7 hours and spleens harvested. Protein extracts 
were separated by SDS-gel electrophoresis for the determination of p10 upregulation by 
Cat S inhibition as described below. 
 
3.2.4 Morphological evaluation 
 
Kidneys, spleens and lungs from all mice were fixed in 10% buffered formalin, 
processed and embedded in paraffin. Two-micrometer paraffin sections for periodic acid-
Schiff (PAS) stains were prepared from spleen, lung and kidney tissue samples following 
routine protocols as described127. The severity of the renal lesions was graded using the 
indices for activity and chronicity as described for human lupus nephritis128. Cat S, IgG, 
C3c and Mac-2 immunostaining staining was performed using the following primary Abs: 
anti-cathepsin S antibody (Abcam, Cambridge, UK), anti-mouse IgG (Caltag Laboratories, 
Burlingame, CA), anti-mouse C3c (Nordic Immunological Laboratories, Tilburg, 
Netherlands) and anti-mouse Mac-2 (Cedarlane Laboratories, Toronto, Ontario, Canada). 
IgD immunostaining was performed on spleen tissue sections using rat anti-mouse IgG 
antibody (BD) to detect mantle B cells. Spleen tissue sections were also stained with the 
lectin peanut agglutinin (PNA) (Vector labs) as described107, which binds to immature, 
proliferating B cells within the GC. The severity of the peribronchial inflammation was 
graded semi quantitatively from 0–4 as described129. 
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3.2.5 In situ hybridization 
 
In situ hybridization was performed using Quantigene ViewRNA ISH Tissue 
Assay Kit (Affymetrix / Panomics Solutions). The assay uses proprietary chemistry for the 
target specific probe sets and branched-DNA signal amplification for detection of a 
specific signal. Specific probe sets for mouse CTSS and EMR1 mRNAs were designed by 
Affymetrix based on the following sequences: NM_001267695 and NM_021281 for 
CTSS, NM_010130 for EMR1. Tissue sections of 4 µm prepared from Formalin Fixed 
Paraffin Embedded (FFPE) mouse kidney and spleen tissues, were mounted onto micro 
slides (X-traTM Adhesive, Leica) and processed according to manufacturer’s instructions. 
Briefly, slides were baked for 1h at 60oC (Thermobrite, Abbott Molecular) and fixed in 
10% formaldehyde for 1h at RT. Deparaffinization was achieved using Histo-Clear reagent 
(National Diagnostics). Pre-hybridization conditions were found to be optimal with 10 
minutes of boiling at 95oC and 10 minutes incubation at 40oC with Protease QF diluted 
1/100x. Target probe set hybridization (Type-6 or Type-1 probe sets for blue or red 
staining respectively) was carried out for 2h at 40oC. Hybridized probes were amplified 
using PreAmplifier Mix QT and Amplifier Mix QT oligonucleotides incubating slides at 
40oC for 25 and 15 minutes respectively. Slides were then exposed to Label Probe 
conjugated with alkaline phosphatase (Label Probe 6-AP or 1-AP for blue or red staining 
respectively) for 15 minutes at 40oC and to Fast Blue or Fast Red Substrates at RT for 15 
min or at 40oC for 30 minutes respectively. When 2-Plex assays were carried-out, 
incubations with Label Probe 6-AP and Fast Blue Substrate were carried –out before 
incubations with Label Probe 1-AP and Fast Red Substrate. Slides were counterstained 
with Gill’s Hematoxylin stain for 5-10 seconds at RT. Between each incubation, slides 
were washed 2-3 times in washing solution, PBS or water according to the manufacturer’s 
instructions. Imaging was performed under brightfield with a Zeiss microscope equipped 
with an Axiocam MRC camera.  
 
3.2.6 Plasma cytokines 
 
The plasma levels of IL-6, IL-10, IL-12p40 and CCL2/MCP-1 were measured 
using commercial kits from BD (BD Biosciences, San Diego, CA) according to the 
manufacturer’s instructions. Plasma levels of IL-2, IFN-γ and TNF-α were measured using 
Methods 
 
Page | 49  
 
commercial kits from BioLegend (Fell, Germany). Absorbance was determined using a 
Tecan Microplate Reader (Biotek, Winooski, VT).  
 
 
3.2.7 Serological analysis  
 
For the detection of IgG and its isotypes, plates were precoated with anti-mouse 
IgG, IgG1, IgG2a, IgG2b, IgG2c and IgG3 (Bethyl Laboratories, Montgomery, TX), and 
sera were applied at dilutions of 1:10,000 to 1:50,000. For the detection of IgM, plates 
were precoated with anti-mouse IgM (Bethyl Laboratories), and sera were applied at 
dilutions of 1:5000. The assay was developed with HRP-labeled goat anti-mouse IgG, 
IgG1, IgG2a, IgG2b, IgG2c, IgG3 and IgM Abs. The plates were developed by adding 
TMB substrate to the wells and incubating for 15 min. The reaction was stopped by adding 
2N H2SO4 and absorbance was measured at 450 nm. A standard curve was derived with 
purified mouse IgG, IgG1, IgG2a, IgG2b, IgG2c, IgG3 and IgM Abs.  
 
Analysis of serum anti-dsDNA autoantibodies by ELISA  
Serum dsDNA autoantibodies were determined by using commercial ELISA kits 
using the following antibodies: anti-mouse IgG, IgM, IgG1, IgG2a, IgG2b, IgG2c and 
IgG3 following the manufacturer’s protocols. First, the NUNC maxisorp 96 well flat 
bottom ELISA plate was coated with 100 µl of poly-L-Lysine (Trevigen, Gaithersburg, 
MD, USA) and incubated for 1 hour at room temperature. After incubation, the plate was 
washed 5 times with PBS. After washing I added 100 µl of dsDNA (1 µg/ml) which was 
diluted in SSC buffer (1X) to the wells and incubated for overnight at 4ºC. For standards, 
the wells were coated with the capture antibody in coating buffer. After washing the plate 
5 times with wash buffer, blocking solution was added to the wells and incubated for one 
hour. After incubation, diluted standards and samples were added in respective wells and 
incubated for 2 hours. After washing the plate the wells were incubated for 1 hour with 
secondary antibody. The plate was developed by adding TMB substrate to the wells and 
incubated for 15 min. The reaction was stopped by adding 2N H2SO4 and absorbance was 
measured at 450 nm. 
 
Anti-Sm and anti Sm-RNP antibodies  
NUNC maxisorp ELISA plates were coated with 1:250 diluted Smith (Sm) antigen 
(Immunovision, Springdale, AR, USA). An anti-Sm IgG (Y12) antibody was used as 
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standard. A horseradish peroxidase-conjugated goat anti-mouse IgG (2 mg/ml) was used as 
secondary antibody at a dilution of 1 µl in 50 ml in PBS (pH 7). After that TMB substrate 
was added to develop color and kept for 20 min in the dark. Later on the reaction was 
stopped by using 2N H2SO4. Absorbance was measured at 450 nm using a microplate 
reader (Tecan). The same procedure was followed for anti-SmRNP ELISA. Here the 
ELISA plates were captured with Sm-RNP complex (1000 units/ml) (Immunovision) at a 
dilution of 1:250 instead of Sm antigen. 
 
Rheumatoid factor  
 NUNC maxisorp ELISA plates were coated with rabbit IgG at a concentration of 
10µg/ml (Jackson Immunoresearch, West Grove, PA, USA) overnight at 4ºC. Serum 
samples were diluted 1:100 in PBS (pH 7), 10 weeks old C57BL/6 mouse serum was used 
as negative control. HRP conjugated goat anti-mouse IgG (2 mg/ml, Rockland 
Immunochemicals Research, Gilbertsville, PA, USA) was used as secondary antibody at a 
dilution of 1 µl in 50 ml of PBS (pH 7). TMB Substrate was used to develop the color and 
reaction was stopped by using 2N H2SO4. The absorbance was measured at 450 nm by 
using a microplate reader (Tecan). 
 
3.2.8 Antinuclear antibody and Crithidia staining   
 
Antinuclear antibody (ANA) is a general term used to describe autoantibodies 
against various cell nuclear proteins. ANA staining uses the indirect fluorescent antibody 
technique first described by Weller and Coons. Patient samples are incubated with antigen 
substrate to allow specific binding of autoantibodies to cell nuclei. If ANA’s are present, a 
stable antigen-antibody complex is formed. After washing to remove non-specifically 
bound antibodies, the substrate is incubated with an anti-human antibody conjugated to 
fluorescein. When the results are positive, there is the formation of a stable three-part 
complex consisting of fluorescent antibody bound to a human antinuclear antibody, which 
binds to nuclear antigen. This complex can be visualized with the aid of a fluorescent 
microscope. In positive samples, the cell nuclei will show an apple-green fluorescence 
with a staining pattern characteristic of the particular nuclear antigen distribution within 
the cells. If the sample is negative for ANA, the nucleus will not show a clearly discernible 
pattern of nuclear fluorescence. 
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Serum samples were diluted to 1:50, 1:100 and 1:200 with PBS. Kallestad HEp-2 
slide (ANA staining) or Kallestad Crithidia luciliae (Crithidia staining) slide was removed 
from the pouch and serum samples (20-25 µl) were added to the wells. The slide was 
incubated 30 minutes at room temperature in a moist covered chamber (a petri dish with 
moistened paper toweling will be adequate). The slide was removed from incubator tray 
and rinsed briefly with PBS using a squirt bottle. The slide was washed 10 minutes with 
PBS in a Coplin jar. The PBS wash solution was discarded after use. The slide was 
removed from PBS and dipped 3-5 times in distilled water. The slide was tapped on its 
side against bibulous paper or paper toweling to remove excess water. The slide was 
returned to the incubation chamber and covered the wells completely using fluorescent 
antibody reagent (Goat anti-mouse IgG-FITC, Invitrogen). The slide was incubated 30 
minutes at room temperature in a moist chamber. During incubation, incubation chamber 
was covered with a paper towel to prevent exposure to light. The slide was removed from 
incubator tray and rinsed briefly with PBS. The slide was washed 10 minutes with PBS in 
a Coplin jar. The slide was removed from PBS and dipped 3-5 times in distilled water. The 
slide was tapped on its side against bibulous paper or paper toweling to remove excess 
water. 4-5 drops of mounting medium with DAPI was added along midline of each slide. 
The coverslip was placed on the slide carefully, avoiding air pockets, by gently lowering 
the coverslip from one end of the slide to the other. The slide was observed under 
fluorescent microscope. 
 
3.2.9 Western blotting  
 
Invariant chain p10 accumulation was detected in spleen tissue by western blotting. 
Spleen tissues from the vehicle and treated animals were homogenized in RIPA buffer 
with protease inhibitors. Lysates were electrophoresed and proteins were transferred to 
PVDF membrane. Following transfer, I blocked membrane with 5% nonfat dry milk for 30 
min at room temperature. The membrane was incubated with CD74 primary antibody (BD 
Pharmingen, Heildelberg, Germany) at 4ºC overnight. After washing 3 times with TBST, 
the membrane was incubated with anti-rabbit HRP secondary antibody. After washing 5 
times with TBST, the membrane was developed with ECL (GE Healthcare, 
Buckinghamshire, UK). The chemiluminescent signal was detected and recorded by 
exposure of the membrane to a light-sensitive X-ray film. 
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3.2.10 Renal function analysis  
 
Urinary albumin to creatinine ratio, plasma creatinine and plasma BUN  
Urinary albumin levels were determined using an albumin Elisa kit from Bethyl 
laboratories following manufacturer’s instructions. Generally albumin levels in urine 
samples from MRL-Fas(lpr) mice were quite high, so urine samples were diluted to 2000 
times with water before estimation. In short, capture antibody (Anti-mouse albumin, 1:100 
dilution) was coated on polyethylene flat bottom 96 well plates (Nunc plates) using 
carbonate-bicarbonate (pH 9.6) coating buffer. After overnight incubation of the capture 
antibody at 4ºC, the plate was washed 3 times with wash buffer (50mM Tris, 0.14M NaCl, 
0.05% Tween 20, pH 8) and blocked with blocking solution (50mM Tris, 0.14M NaCl, 1% 
BSA, pH 8) at room temperature for 1 hour. After blocking, the plate was washed 5 times 
with wash buffer and then diluted samples/standards were added to the respective wells 
and further incubated for 1 hour. After incubation, the plate was washed 5 times with wash 
buffer and diluted HRP-conjugated detection antibody (using the suggested dilution) was 
added and the plate was incubated in dark for 1 hour. After incubation, the plate was 
washed 5 times with wash buffer and TMB reagent (freshly prepared by mixing equal 
volumes of two substrate reagents) was added and incubated in the dark till color reaction 
was completed followed by addition of stop solution (2N H2SO4). The absorbance was 
read at 450 nm. The albumin content in each sample was determined using the equation of 
regression line generated by plotting absorbance of different standards against their known 
concentrations.  
  
Urinary creatinine and plasma creatinine levels were measured using Jaffe´s 
enzymatic reaction using a Creatinine FS kit (DiaSys Diagnostic Systems GmbH, 
Holzheim, Germany). Urine samples were diluted 10 times with distilled water whereas 
plasma samples were used undiluted. Different dilutions of standard were prepared using 
the stock provided with the kit. Working monoreagent was prepared by mixing 4 parts of 
reagent 1 (R1) and 1 part of reagent 2 (R2) provided with the kit. Then, 10 µl of each of 
the diluted samples and standards were added to a 96 well plate with flat bottom (Nunc 
maxisorb plate). The monoreagent (200 µl) was added to each well and the reaction 
mixture was incubated for one minute before measuring the absorbance at 492 nm 
immediately after and 1 (A1) and 2 (A2) min of addition using an ELISA plate reader. The 
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change in absorbance (∆A) was calculated as ∆A = [(A2 – A1) sample or standard] – [(A2 
– A1) blank]. The creatinine content of the samples was calculated as:  
 
Creatinine (mg/dL) = ∆A sample /∆A standard * Concentration of standard (mg/dL) 
 
Plasma BUN levels were measured using an enzymatic reaction using a Urea FS kit 
(DiaSys Diagnostic Systems GmbH, Holzheim, Germany). Different dilutions of standard 
were prepared using the stock provided with the kit. Working monoreagent was prepared 
by mixing 4 parts of reagent 1 (R1) and 1 part of reagent 2 (R2) provided with the kit. 
Then, 2 µl of each of the sample and standards were added to a 96 well plate with flat 
bottom (Nunc maxisorb plate). The monoreagent (200µl) was added to each well and the 
reaction mixture was incubated for one minute before measuring the absorbance at 360 nm 
immediately after and 1 (A1) and 2 (A2) min of addition using an ELISA plate reader. The 
change in absorbance (∆A) was calculated as ∆A = [(A1 – A2) sample or standard] – [(A1 
– A2) blank]. The BUN content of the samples was calculated as:  
 
BUN (mg/dL) = ∆A sample /∆A standard * Concentration of standard (mg/dL)*0.467 
 
Urinary albumin to creatinine ratio was calculated after converting values for 
albumin and creatinine to similar units (mg/dL). The albumin content for each sample 
calculated (mg/dL) was divided by creatinine content (mg/dL) for the same sample. 
 
Glomerular filtration rate (GFR) 
Mice were anesthetized using Isoflurane, which for approximately 20 seconds. 5% 
FITC-inulin was dissolved in two ml of 0.9% NaCl - facilitated by heating the solution in 
boiling water. 5% FITC-inulin (3.74µl /g body weight) was injected retroorbitally under 
anesthesia within 10 seconds. Under general anaesthesia, blood was drawn from the retro 
orbital plexus at 5, 10, 15, 20, 35, 60 and 90 minutes post administration. Since pH 
significantly affects FITC fluorescence value, each plasma sample was buffered to pH 7.4, 
by mixing 10 µl of plasma with 40 µl of 500 mM HEPES (pH 7.4). The titrated samples 
were then loaded onto a 96-well plate, 50µl sample/well. Fluorescence was determined 
with 485 nm excitation, and read at 538 nm emission. 
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A two - compartment clearance model may be employed for the calculation of 
GFR. In the two-compartment model used, depicted in Figure 8, the initial, rapid decay 
phase represents redistribution of the tracer from the intravascular compartment to the 
extracellular fluid. Systemic elimination also occurs, but the distribution process is 
relatively dominant during this initial phase. During the later, slower decay in 
concentration of the tracer systemic clearance of the tracer from the plasma predominates. 
At any given time (tx), the plasma concentration of the tracer (Y) equals to  
 
Ae -αtx + Be -βtx +Plateau 
 
The parameters of above equation could be calculated using a non-linear regression 
curve-fitting program (GraphPad Prism, GraphPad Software, Inc., San Diego, CA). GFR 
was calculated using the equation: 
 
GFR= I/(A/α + B/β), 
 
 
 
 
Figure 8: Representation two phase regression curve 
 
where I is the amount of FITC-inulin delivered by the bolus injection; A (Span1) and B 
(Span2) are the y-intercept values of the two decay rates, and α and β are the decay 
constants for the distribution and elimination phases, respectively. 
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3.2.11 Flow cytometry 
 
Spleen and kidney cells were obtained from mice of all groups at the end of the 
study for FACS analysis. 
 
Isolation and preparation of murine spleen cells  
Spleen was isolated under sterile conditions from the MRL-Fas(lpr) mice. Spleen 
was placed in a sterile petri plate containing 2-3 ml of ice-cold media (RPMI + 10% FCS + 
1% PS) on ice. Then it was mashed using forceps in the petri plate itself and broken into 
fine pieces of tissues. Then the cell suspension was passed through 70 µm cell strainer (BD 
Biosciences). This single cell suspension was collected into a 15 ml Falcon tube and 
centrifuged at 1500 rpm at 4°C for 5 min. The supernatant was decanted and the pellet was 
resuspended in 3 ml of sterile 0.3M NH4Cl (RBC lysis buffer) and incubated at room 
temperature 5 min. Then it was centrifuged at 1500 rpm at 4°C for 5 min. Supernatant was 
decanted and the pellet was resuspended in ice cold PBS and passed through 30 µm cell 
strainer (BD Biosciences). The flow through was centrifuged at 1500 rpm at 4°C for 5 
min. Supernatant was decanted and the pellet was resuspended in ice-cold FACS buffer 
(PBS, 0.2% BSA, 0.1% sodium azide). 
 
Isolation and preparation of murine kidney cells  
Kidneys were isolated under sterile conditions from MRL-Fas(lpr) mice. The 
capsule was removed from the kidneys and placed in a petri dish containing 3ml of 
digestion buffer (collagenase + DNAse I). Inject digestion buffer into the kidneys several 
times and incubate at 37°C for 30 min. After incubation the kidneys were mashed with the 
help of a plunger and incubated again for 15 min. Single cell suspension was then prepared 
by repeatedly passing it through (5 times) 20G, 25G and 26G needles. The cell suspension 
was filtered through a 70 µm cell strainer and transferred into a 15ml falcon tube and the 
volume was adjusted to 10 ml with PBS and centrifuged at 1500 rpm for 5 min at 4°C. 
After centrifugation supernatant was discarded and the pellet was resuspended in PBS and 
filtered through a 30 µm cell strainer. The flow through was centrifuged again at 1500 rpm 
for 5 min at 4°C. After centrifugation supernatant was discarded and the pellet was 
resuspended in FACS buffer. 
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Staining of spleen and kidney cells for FACS  
Cell suspensions were stained with the following Abs from BD Pharmingen 
(Heidelberg, Germany): anti-mouse CD4-allophycocyanin, CD8-PerCP, CD3-FITC, 
CD25-PerCP, CD45R-allophycocyanin, CD11c-FITC, B220-Alexa Fluor 647, IgD-FITC, 
IgM-PE, CD23-PE, CD21-FITC, CD40-FITC, and κ light Chain-PE (intracellular). The 
following Abs were procured from Serotec (Oxford, U.K.): F4/80-allophycocyanin, CD19-
FITC, and MHC-II-FITC. Siglec-H is from eBioscience (San Diego, CA). Intracellular 
IFN-γ and IL-17A staining was performed as described elsewhere130. Briefly, splenocytes 
were isolated by standard protocols and incubated with PMA (5 ng/ml; Sigma-Aldrich) 
and ionomycin (1 mg/ml; Calbiochem) for 5 h. After 30 min, brefeldin A (10 mg/ml; 
Sigma-Aldrich) was added. After washing, cells were stained for CD3 and CD4. After 
permeabilization of the cells with Cytofix/Cytoperm (BD Biosciences), cells were stained 
with IFN-γ –PE (eBioscience) and IL-17A–Alexa Fluor 647 (BD Biosciences). To analyze 
the effect of aPC on short-lived and long-lived plasma cells, we injected BrdU (FITC-
BrdU, BD Biosciences) in mice 5 days before sacrifice, which allowed us to differentiate 
short- from long-lived plasma cells.  
 
3.2.12 RNA isolation, cDNA synthesis and Real-time PCR 
 
RNA isolation 
Mice were sacrificed on termination of the study, tissue samples from each mouse 
were preserved in RNA-later at -20°C until processed for RNA isolation. Total RNA was 
isolated from spleen and kidney tissue using PureLink RNA Mini Kit (Invitrogen, 
Carlsbad, CA). In short, tissues (30 mg) preserved in RNA-later were homogenized using 
blade homogenizer for 30 seconds at 14500 rpm in lysis buffer (600 µl) containing β-
mercaptoethanol (10 µl/ml). The homogenate was centrifuged at 14000 rpm for 3 min and 
500 µl of supernatant was transferred to fresh DEPC-treated tube and to this tube equal 
amount (500 µl) of 70 % ethanol was added. The solution was mixed thoroughly by 
vortexing to disperse any visible precipitate that form after adding ethanol. 700 µl of whole 
mixture was transferred to the spin catridge (with the collection tube) and centrifuged at 
12,000 x g for 15 seconds at room temperature. Flow-through was discarded and reinserted 
the spin cartridge into the same collection tube. Repeated the above step until the entire 
sample has been processed. Next, 350 µl of wash buffer I was added to the spin cartridge 
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containing the bound RNA and centrifuged at 12,000 x g for 15 seconds at room 
temperature. Flow-through and the collection tube were discarded. The spin cartridge was 
inserted into a new collection tube. 80 µl PureLink® DNase mixture (10 µl DNase + 70 µl 
reaction buffer) was added directly onto the surface of the spin cartridge membrane and 
incubated at room temperature for 15 minutes. After incubation, 350 µl wash buffer I was 
added to the spin cartridge and centrifuged at 12,000 x g for 15 seconds at room 
temperature. Flow-through and the collection tube were discarded and inserted the spin 
cartridge into a new collection tube. Next, 500 µl wash buffer II with ethanol was added to 
the spin cartridge and centrifuged at 12,000 x g for 15 seconds at room temperature. Flow-
through was discarded and reinserted the spin cartridge into the same collection tube. 
Again 500 µl wash buffer II with ethanol was added to the spin cartridge and centrifuged at 
12,000 x g for 15 seconds at room temperature. Flow-through was discarded and reinserted 
the spin cartridge into the same collection tube. The spin cartridge was centrifuged at 
12,000 x g for 1–2 minutes to dry the membrane with bound RNA. Collection tube was 
discarded and inserted the spin cartridge into a recovery tube. 30-50µl RNase-free water 
was added to the center of the spin cartridge. Spin catridge was incubated at room 
temperature for 2 minutes. After the incubation, the spin cartridges were centrifuged for 2 
minutes at 8000 x g at room temperature to elute the RNA from the membrane into the 
recovery tube. Isolated RNA was stored at -80°C until further used.  
 
For quantification isolated RNA samples, 1µl of RNA sample was added on to the 
nanodrop and absorbance was measured at two wavelengths as 260 nm and 280 nm. The 
ratio of optical densities at 260 nm and 280 nm is an indicator of RNA purity (indicative of 
protein contamination in the RNA samples). Only samples with a ratio of 1.8 or more were 
considered to be of acceptable quality.  
 
A further quality check was performed using a denaturing RNA gel. In short 2 % 
Agarose gel with Ethidium-bromide was cast, RNA samples were mixed with RNA 
loading buffer (4:1 ratio) (Sigma) and were loaded on the gel. Electrophoresis was carried 
out at constant volt (70-100 V) using MOBS running buffer for 1 hour and the gel was 
read on a gel documentation apparatus under a UV lamp. RNA samples showing a single 
bright band were considered to be of good quality. Loss of RNA integrity could be 
detected as smear formation in the agarose gel. 
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cDNA synthesis 
cDNA was synthesized from 1 µg total RNA by using random hexamers and 
SuperScript II Reverse Transcriptase (Invitrogen). The enzyme is used to synthesize first-
strand cDNA and it can generate cDNA up to 12.3 kb. Random Hexamers are short 
oligodeoxyribonucleotides of random sequence. Random hexamer primers bind throughout 
the entire length of RNA, ensuring reverse transcription of all RNA sequences due to their 
random structure. Each reaction tube contained 4 µl of 5X First strand buffer, 0.5 µl of 
SuperScript II Reverse Transcriptase, 0.5 µl of RNase, 2µl of 0.1M DTT, 0.5 µl of dNTP, 
0.5µl of random hexamers, 1µg of total RNA and made up the volume to 20 µl with sterile 
milli-Q water. After mixing the contents of the tube gently, tubes were incubated at 25°C 
for 10 min. The cDNA synthesis reaction took place at 42°C for 1 hr and then the reaction 
was inactivated by incubating at 70°C for 10 min. This cDNA was used as a template for 
amplification in real time PCR. 
 
Real time PCR using SYBR Green I 
SYBR Green I Dye detection system was used for quantitative PCR (qPCR) on 
LightCycler® 480 (Roche Diagnostics, Mannheim, Germany). The sequences of the gene-
specific primers (Metabion, Martinsried, Germany) used are listed in Table 5. The 
conditions for real-time PCR were as follows: 95˚C for 3 min (1 cycle), 94˚C for 20 sec, 
60˚C for 20 sec, and 72˚C for 40 sec (45 cycles), followed by melting curve program. Each 
reaction consisted of 10 µl of 2X SYBR Green I mix, 0.5 µl of 10 mM forward primer, 0.5 
µl of 10 mM reverse primer, 0.2 µl (1 unit) of Taq DNA polymerase, 4 µl of cDNA and 
made up the volume to 20 µl with milli-Q water. 96 well PCR reaction plate was 
centrifuged briefly to spin down the contents and to eliminate air bubbles before starting 
the reaction. Real time PCR analysis was done using LightCycler®480 software. All 
reactions were performed in triplicate, and negative controls contained no template DNA. 
We used 18S rRNA as an endogenous control for normalization. To verify that the used 
primer pair produced only a single specific product, a dissociation protocol was added 
after thermocycling, to determine the dissociation of the PCR products from 60˚C to 95˚C. 
Data were analyzed using the comparative threshold cycle (∆∆Ct) method. 
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Table 5. Primer sequences used for Real Time - PCR 
Gene Accession number Primer Sequence 
   CCL2/MCP-1 NM_011333 F : 5’- CCTGCTGTTCACAGTTGCC -3’ 
R : 5’- ATTGGGATCATCTTGCTGGT -3’ 
IL-6 NM_031168 F : 5’- TGATGCACTTGCAGAAAACA -3’ 
R : 5’- ACCAGAGGAAATTTTCAATAGGC -3’ 
IL-12p40 NM_008352 F : 5’- AGCAGTAGCAGTTCCCCTGA -3’ 
R : 5’- AGTCCCTTTGGTCCAGTGTG -3’ 
18S rRNA NR_003278 F : 5’- GCAATTATTCCCCATGAACG -3’ 
R : 5’- AGGGCCTCACTAAACCATCC -3’ 
CXCL10 NM_021274 
 
F : 5’- GGCTGGTCACCTTTCAGAAG -3’ 
R : 5’- ATGGATGGACAGCAGAGAGC -3’ 
TNF NM_013693.2 F : 5’- CCACCACGCTCTTCTGTCTAC -3’ 
R : 5’- AGGGTCTGGGCCATAGAACT -3’ 
IL-12p35 NM_001159424.1 F : 5’- CTAGACAAGGGCATGCTGGT -3’ 
R : 5’- GCTTCTCCCACAGGAGGTTT-3’ 
IL-10 NM_021274 
 
F : 5’- TGTCAAATTCATTCATGGCCT -3’ 
R : 5’- ATCGATTTCTCCCCTGTGAA -3’ 
IL-1β NM_008361 F : 5’- TTCCTTGTGCAAGTGTCTGAAG -3’ 
R : 5’- CACTGTCAAAAGGTGGCATTT -3’ 
IL-23p19 NM_031252.2 F : 5’- AATAATGTGCCCCGTATCCAGT -3’ 
R : 5’- GCTCCCCTTTGAAGATGTCAG -3’ 
TGF-β1 NM_011577.1 F : 5’- CAACCCAGGTCCTTCCTAAA -3’ 
R : 5’-GGAGAGCCCTGGATACCAAC -3’ 
CXCL12 NM_001012477.2 F : 5’- GCGCTCTGCATCAGTGAC -3’ 
R : 5’- TTTCAGATGCTTGACGTTGG -3’ 
IFN-γ NM_008337.3 F : 5’- ACAGCAAGGCGAAAAAGGAT -3’ 
R : 5’- TGAGCTCATTGAATGCTTGG-3’ 
April NM_001159505.1 F : 5’- GTTGCTCTTTGGTTGAGTTGGG -3’ 
R : 5’- GTTGGATCAGTAGTGCGACAGC -3’ 
BAFF NM_033622.1 F : 5’- CCACCGTGCCTCTGTTTTTGC -3’ 
R : 5’- AGCCAACTGGTACAAGGACATCG -3’ 
Taci NM_021349.1 F : 5’- GGTCCAGGATTGAGGCTAAGTA -3’ 
R : 5’- GGAGAGTTTGCTTGTGACCCA -3’ 
Rorc NM_011281.2 F : 5’- GGTGATAACCCCGTAGTGGA -3’ 
R : 5’- ACAGAGACACCACCGGACAT -3’ 
Gata3 NM_008091.3 F : 5’- CTCGGCCATTCGTACATGGAA -3’ 
R : 5’- GGATACCTCTGCACCGTAGC-3’ 
Foxp3 NM_001199347.1 F : 5’- CCCATCCCCAGGAGTCTTG -3’ 
R : 5’- ACCATGACTAGGGGCACTGTA -3’ 
T-bet NM_019507.2 F : 5’- CACTAAGCAAGGACGGCGAATGT -3’ 
R : 5’- CTGGGTGGACATATAAGCGGTTC-3’ 
CCL5 NM_013653.3 F : 5’- CCACTTCTTCTCTGGGTTGG -3’ 
R : 5’- GTGCCCACGTCAAGGAGTAT -3’ 
Cathepsin S NM_001267695.1 F : 5’- AAGCGGTGTCTATGACGACCC -3’ 
R : 5’- GAGTCCCATAGCCAACCACAAG -3’ 
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Cathepsin L NM_009984.3 F : 5’- GTGGACTGTTCTCACGCTCA -3’ 
R : 5’- TATCCACGAACCCTGTGTCA-3’ 
Cathepsin B NM_007798.3 F : 5’- GCAGGCTGGACGCAACTTCTAC -3’ 
R : 5’- GGTCTCTAATCTGTCCAATGGTCG -3’ 
Cathepsin C NM_009982.4 F : 5’- GAAGTTGGATACTGCCTACGACGAG -3’ 
R : 5’- CACATCATGGACCCACCCAGTC -3’ 
Cathepsin D NM_009983.2 F : 5’- CGCCTAAGACCACGGAGCCA -3’ 
R : 5’- ACTTATGGTGGACCCAGCAGGC -3’ 
Cathepsin H NM_007801.2 F : 5’- GCTGACCGTGAACGCCATAGA -3’ 
R : 5’- GCTGTACGTCTTTTGATGCTGTTTCA -3’ 
 
3.2.13 Statistical analysis 
 
Data are expressed as means ± SD. The statistical differences between two groups 
were performed using a Student t test, and comparison of three groups was performed 
using one-way ANOVA. A p value < 0.05 was considered statistically significant. All 
statistical calculations were performed using commercially available statistical software 
GraphPad Prism (version 5.0; GraphPad, San Diego, CA). GraphPad Prism combines 
scientific graphing, comprehensive curve fitting (nonlinear regression), understandable 
statistics, and data organization. 
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4. Results 
 
4.1 Part I – Activated protein C in SLE 
 
4.1.1 Recombinant aPC suppresses renal pathology in MRL-Fas(lpr) mice. 
 
We addressed our hypothesis by observing MRL-Fas(lpr) mice until the first signs 
of lupus nephritis occurred (i.e., albuminuria of >3 µg/dL, which was evident in almost all 
animals at 14 wk of age). Note that serum levels of aPC in MRL-Fas (lpr) mice were 
significantly lower compared with MRL wt mice at 14 wk of age (Figure 9). Albuminuric 
MRL-Fas(lpr) mice were randomized to two treatment regimens with i.p. injections given 
on alternate days for 5 weeks. One group was treated with recombinant aPC at a dose of 5 
mg/kg in PBS, whereas the other group received PBS (vehicle) injections only. At 18 wk 
of age, vehicle-treated MRL-Fas(lpr) mice developed diffuse proliferative glomerulo-
nephritis, which was associated with diffuse mesangial matrix expansion, profound 
mesangial cell proliferation, and focal segmental glomerulosclerosis. Cellular crescents 
and global glomerulosclerosis were often seen (Figure 10A). Most animals revealed 
profound tubulointerstitial inflammation as characterized by periglomerular and diffuse 
interstitial leukocyte infiltrates, tubular atrophy, and intraluminal cast formation. On 
immunostaining, diffuse proliferative glomerulonephritis was associated with extensive 
glomerular IgG and complement factor C3c deposits presenting in mesangial and capillary 
staining patterns altogether, indicating diffuse proliferative lupus nephritis as the renal 
manifestation of SLE in MRL-Fas(lpr) mice (Figure 10A, 10B).  
 
Treatment with recombinant aPC suppressed lupus nephritis as documented by a 
significant reduction of the lupus nephritis activity index that encompasses glomerular cell 
proliferation, matrix deposition, leukocyte infiltration, focal necrosis, crescent formation, 
and tubulointerstitial inflammation (Figure 10B). There was no significant difference in the 
chronicity index that encompasses glomerular sclerosis, fibrous crescents, tubular fibrosis 
and interstitial fibrosis (Figure 10B). Glomerular crescents and globally sclerotic glomeruli 
were no longer observed (Figure 10A). This improvement of renal structure was associated 
with a significant reduction in plasma BUN levels and a trend towards less proteinuria. 
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Serum creatinine levels in our model were low and not significantly reduced in aPC-treated 
mice (Figure 11). Together, recombinant aPC attenuates lupus-like renal pathology in 
MRL-Fas(lpr) mice. 
 
4.1.2 Recombinant aPC reduces renal immune complex disease in MRL-
Fas(lpr) mice 
 
In SLE, renal damage and dysfunction result from immune complex 
glomerulonephritis, in which glomerular deposits of immune complexes activate the 
components of the classical complement pathway, which finally leads to the assembly of 
the C5b-9 multimer membrane attack complex131. The favorable effects of recombinant 
aPC treatment on markers of active lupus nephritis were associated with a significant 
reduction of glomerular IgG deposits as well as the deposition of complement factor C3c, a 
marker of intraglomerular complement activation (Figure 10A, 10B). Together, we 
conclude that aPC treatment reduces SLE-associated immune complex glomerulonephritis 
and glomerular complement activation. 
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Figure 9. Plasma levels of aPC was quantified by ELISA in the wild type MRL and MRL-Fas(lpr) 
mice. **p<0.01. (Wild type MRL n=5, MRL-Fas(lpr) n=15).  
 
 
 
Results 
 
Page | 63  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 10. Recombinant aPC suppresses renal pathology in MRL-Fas(lpr) mice. (A) Renal 
sections of 18-wk-old MRL-Fas(lpr) mice were stained with PAS. Representative PAS staining 
kidney sections showed glomerular damage in vehicle-injected mice when compared with aPC-
injected mice. MRL control mice showed no glomerular abnormalities. Renal sections of 18-wk-
old MRL-Fas(lpr) mice were stained with Abs for IgG and complement C3c as indicated. Note that 
aPC-injected mice show less glomerular IgG and C3c deposits. Images are representative for 15 
mice in each treatment group and 5 MRL wt mice. Original magnification x400 (PAS and IgG) or 
x200 (C3c). (B) Quantitative measures of lupus nephritis in MRL-Fas(lpr) mice. The lupus 
nephritis disease activity index (score ranging from 0–24) and the lupus nephritis chronicity index 
(score ranging from 0–12) were determined as markers of kidney damage in lupus nephritis. 
Glomerular IgG and complement C3c deposition was compared between vehicle- and aPC-treated 
groups (score ranging from 0–3). Data are expressed as means ± SEM. *p<0.05, **p<0.01 versus 
vehicle group (vehicle n=15; aPC n=15). 
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Figure 11. Proteinuria, blood urea nitrogen (BUN) and serum creatinine levels in MRL-Fas(lpr) 
mice. (A) Proteinuria was determined at 18 weeks of age. Urinary albumin/creatinine ratio is a 
functional marker of damage to the glomerular filtration barrier. The albumin/creatinine ratio was 
reduced substantially in aPC-injected mice when compared to vehicle-injected mice. (B) BUN 
levels at 18 weeks of age were significantly reduced in aPC-treated mice. (C) Serum creatinine 
levels were low in MRL-Fas(lpr) mice. There was no significant reduction in aPC treated mice. 
Data are expressed as means ± SEM. *p<0.05 versus vehicle group (Vehicle n=15, aPC n=15).  
 
4.1.3 Recombinant aPC reduces intrarenal inflammation in MRL-Fas(lpr) 
mice 
 
Local complement activation has the potential to activate (and eventually kill) renal 
cells; therefore, we next evaluated the intrarenal expression of pro-inflammatory 
mediators. Recombinant aPC treatment reduced mRNA expression levels of the 
proinflammatory cytokines IL-6 and IL-12p40 and of the chemokine CCL2/MCP-1 
(Figure 12A), which correlated with a significant reduction of Mac-2 positive glomerular 
macrophages (Figure 12B). Together, we conclude that aPC treatment reduces intrarenal 
inflammation. 
 
4.1.4 Recombinant aPC improves cutaneous lupus in MRL-Fas(lpr) mice 
 
Is the therapeutic effect of recombinant aPC limited to renal manifestations of 
SLE? To address this question, we carefully monitored the skin of MRL-Fas(lpr) mice 
throughout the duration of the study. Skin disease is the most common organ manifestation 
in SLE affecting up to 85% SLE patients3. Skin disease includes three major subtypes: 
chronic lupus erythematosus, subacute lupus erythematous and acute lupus erythematosus.  
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Figure 12. Kidney qPCR and glomerular macrophages. (A) Renal mRNA expression levels of IL-
12p40, IL-6 and CCL2/MCP-1 in MRL-Fas(lpr) mice were determined by qPCR. Data are 
expressed as a mean ratio to the respective 18S rRNA mRNA expression level ± SEM. (B) Renal 
sections of 18-wk-old MRL-Fas(lpr) mice were stained with an anti–Mac-2 antibody. 
Representative images show Mac-2 positive glomerular macrophages and quantification of Mac-2 
positive glomerular macrophages. Images are representative for 15 mice in each treatment group 
and 5 mice in MRL wt group. Data are expressed as means ± SEM. Original magnification x100. 
*p<0.05, **p<0.01 versus vehicle group (wt MRL n=5; Vehicle n=15; aPC n=15). 
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Treatment with recombinant aPC significantly delayed the onset of facial dermatitis 
as well as of neck skin ulcerations as compared with vehicle-treated MRL-Fas(lpr) mice 
(Figure 13A). During that period, all vehicle-treated MRL-Fas(lpr) mice developed a skin 
disease characterized by typical lesions in the facial area (Figure 13B). In contrast, among 
aPC-treated MRL-Fas(lpr) mice, 20% developed skin lesions. Thus, recombinant aPC 
protects MRL-Fas(lpr) mice not only from lupus nephritis but also from cutaneous lupus. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 13. Recombinant aPC improves cutaneous lupus in MRL-Fas(lpr) mice. (A) The plot 
shows the percentage of mice developing skin lesions during the treatment period. Mice of both 
groups were regularly checked for cutaneous lupus manifestations, which typically occur in the 
facial or neck/back area and were less common in aPC-injected mice. (B) The image shows 
representative mice from both groups at 18 wk of age. 
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4.1.5 Recombinant aPC improves lung disease in MRL-Fas(lpr) mice 
 
The autoimmune lung disease is another manifestation of SLE132. More than 50% 
of people with lupus have an autoimmune lung disease. Inflammation of the lining of the 
lung (pleurisy) is the most common problem. The lungs of MRL-Fas(lpr) mice show 
extensive perivascular and peribronchial lymphocytic infiltration with occasional 
atelectasis and exudates. We carefully analyzed the lungs of MRL-Fas(lpr) mice upon 
sacrifice. Vehicle-treated MRL-Fas(lpr) mice displayed focal areas of peribronchial and 
perivascular lymphocyte infiltrates. Such infiltrates were significantly decreased in 18-wk- 
old aPC-treated MRL-Fas(lpr) mice. This was evaluated by a semiquantitative lung injury 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 14. Recombinant aPC improves lung disease in MRL-Fas(lpr) mice. Lung sections of 18-
wk-old MRL-Fas(lpr) mice of all groups were stained with PAS. Treatment with aPC reduced 
peribronchial inflammation in MRL-Fas(lpr) mice. Images are representative for 15 mice in each 
treatment group and 5 MRL/wt mice. Original magnification x100. Morphometry was used to 
quantify the peribronchiolar and perivascular inflammation by using a score ranging from 0–3 and 
scored semiquantitatively as described in Materials and Methods section. The data represent mean 
scores ± SEM. **p <0.01 versus vehicle group. 
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score ranging from 0–3 (Figure 14). Thus, recombinant aPC protects MRL-Fas(lpr) mice 
not only from lupus nephritis but also from autoimmune lung disease. 
 
4.1.6 Recombinant aPC suppresses the abnormal humoral immunity in 
MRL-Fas(lpr) mice 
 
As treatment with recombinant aPC reduced glomerular immune complex 
deposition, the question arises whether aPC modulates systemic autoimmunity and lupus 
autoantibody production in MRL-Fas(lpr) mice. At the age of 18 wk, MRL-Fas(lpr) mice 
displayed significant hypergammaglobulinemia, which was significantly reduced by aPC 
treatment (Figure 15A). This effect related especially to IgG of the IgG2a and IgG3 
isotype, which are known to activate complement in murine lupus nephritis (Table 6). 
Plasma IgM levels were affected the same way (Figure 15B). Furthermore, aPC reduced 
the amount of circulating lupus autoantibodies as evidenced by a marked reduction in 
diffuse ANA staining intensity on Hep2 cells as well as quantitative plasma anti-dsDNA 
IgG and rheumatoid factor (anti-IgG) measured by ELISA (Figure 15C–E). Serum IgG as 
well as autoantibodies derive from Ig-producing plasma cells. Therefore, we performed 
flow cytometry for CD138 and kappa light chain-positive plasma cells in spleen of both 
treatment groups. aPC treatment significantly reduced the absolute numbers of total plasma 
cells (Figure 16A). To analyze the effect of aPC on short-lived and long lived plasma cells, 
we injected Bromodeoxyuridine (BrdU) in mice 5 days before sacrifice, which allowed us 
to differentiate short- from long-lived plasma cells. BrdU is a thymidine analog that is used 
in cell proliferation studies. BrdU is incorporated into newly synthesized DNA by cells 
entering and progressing through the DNA synthesis phase of the cell cycle. aPC treatment 
also significantly reduced the short- and long-lived spleen plasma cells (Figure 16B). 
Similarly, follicular B cell (CD23high CD21low), marginal zone B cells (CD23low CD21high), 
and mature B cells (IgM+ IgD+) were reduced by aPC treatment (Figure 16C), whereas 
other major spleen T cell populations (i.e., CD4+ T cells, CD8+ T cells, and CD4/CD8 
double-negative T cells) remained unaffected (Table 6). Interestingly, aPC treatment 
reduced the Th1 and Th17 polarization of T cells (Table 6). Together, treatment with 
recombinant aPC specifically reduces B cells and plasma cells as well as Th1 and Th17 
polarization of T cells, which decreases overproduction of IgGs and lupus autoantibodies 
causing lupus nephritis in MRL-Fas(lpr) mice. 
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Figure 15. Recombinant aPC reduces autoantibodies in MRL-Fas(lpr) mice. Plasma levels of total 
IgG (A) and total IgM (B) were determined by ELISA. (C) ANA staining patterns on Hep-2 human 
epithelial cells for serum, derived from MRL wt, vehicle-treated and aPC treated MRL-Fas(lpr) 
mice at 1:200 dilution. Original magnification x1000. Plasma levels of total IgG against dsDNA 
(D) or rheumatoid factor (E) were determined by ELISA. Data are expressed as means ± SEM 
(n=15 each treatment group; n=5 MRL/wt). *p<0.05, **p<0.01 versus vehicle group. 
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Figure 16. Recombinant aPC affects plasma cells and B cells in MRL-Fas(lpr) mice. (A) FACS 
analysis of the absolute number of total spleen plasma cells. (B) FACS analysis of the absolute 
number of short- and long-lived spleen plasma cells. (C) FACS analysis of the absolute number of 
the follicular B cells, marginal zone B cells and mature B cells from spleen. Data are expressed as 
means ± SEM. (n=10 each treatment group). *p<0.05, **p<0.01, ***p<0.001 versus vehicle group. 
 
 
Table 6. Phenotype of SLE in MRL-Fas(lpr) mice 
       Vehicle              aPC  p value by t-test 
FACS (cells/spleen (millions)) 
CD3+CD4+ 53.39 ± 5.24 45.17 ± 7.09 0.3873 
CD3+CD8+ 14.75 ± 2.36 17.18 ± 3.69 0.5875 
CD3+CD4-CD8- 27.57 ± 5.02         24.14 ± 3.72 0.6073 
CD3+CD4+CD25+   8.44 ± 0.44   6.715 ± 0.768 0.0680 
Th1 cells   14.40 ± 1.994   9.428 ± 0.785 0.0488 
Th17 cells   0.122 ± 0.037   0.034 ± 0.007 0.0478 
Serum IgG isotypes 
IgG1   591.1 ± 180.0 344.3 ± 94.98 0.2382 
IgG2a   142.1 ± 3.866 130.1 ± 2.795 0.0194 
IgG2b   20.95 ± 3.824 14.70 ± 1.564 0.1443 
IgG2c   0.828 ± 0.067 0.806 ± 0.079 0.8328 
IgG3   0.313 ± 0.010 0.279 ± 0.006 0.0124 
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4.1.7 Recombinant aPC treatment suppresses the activation of antigen 
presenting cells in MRL-Fas(lpr) mice 
 
The activation of antigen presenting cells is a major stimulus for B cell 
proliferation and autoantibody production in SLE43,133. Therefore, we analyzed the 
activation of spleen DCs by flow cytometry in MRL-Fas(lpr) mice of both treatment 
groups. aPC treatment significantly reduced the total numbers of CD11c+ cells including 
CD4+CD11c+ and CD8+CD11c+ cells (Figure 17A). aPC treatment also reduced dendritic 
cell activation as demonstrated by a significant reduction in CD11c-positive cells that were 
also positive for the activation markers CD40 or MHC-II (Figure 17B).  
 
In addition, aPC decreased activation marker CD40 in CD11c+CD4+and 
CD11c+CD8+ cells (Figure 17C). Consequently, the spleens of aPC-treated MRL-Fas(lpr) 
mice expressed much lower mRNA levels of proinflammatory cytokines (IL-6 and IL-
12p40) and chemokines (CXCL10 and CCL2/MCP-1) (Figure 18), using primers listed in 
Table 5. Spleen mRNA levels of TNF remained unaffected by aPC treatment (Figure 18). 
Thus, treatment with recombinant aPC reduced the activation of splenic DCs in MRL-
Fas(lpr) mice. 
 
4.1.8 Recombinant aPC treatment suppresses systemic inflammation in 
MRL-Fas(lpr) mice 
 
Systemic lupus erythematosus is a systemic inflammatory autoimmune disease 
which can affect multiple organs of the human body. We measured systemic inflammation 
by estimating protein levels of proinflammatory cytokines in the plasma. aPC significantly 
reduced plasma protein levels of IL-6, IL-12p40 and CCL2/MCP-1. Plasma protein levels 
of TNF remained unaffected by aPC treatment (Figure 19). Thus, treatment with 
recombinant aPC suppressed systemic inflammation in MRL-Fas(lpr) mice. 
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Figure 17.  Recombinant aPC suppresses dendritic cell activation in MRL-Fas(lpr) mice. Spleen 
cell suspensions were prepared for flow cytometry by using specific antibodies that identify subsets 
of DCs. (A) FACS analysis of the absolute numbers of CD11c, CD11c+CD4+, and CD11c+ CD8+ 
cells. (B) FACS analysis of total numbers of CD11c-positive cells that were also positive for the 
activation markers CD40 or MHC-II. (C) FACS analysis of total numbers of CD11c+CD4+ or 
CD11c+CD8+ positive cells that were also positive for the activation marker CD40. Data are 
expressed as means ± SEM (n=10 each treatment group). *p<0.05, **p<0.01, ***p<0.001 versus 
vehicle group. 
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Figure 18. The spleen mRNA expression levels were determined for the IL-12p40, IL-6, CXCL10, 
CCL2 and TNF by qPCR. Data are expressed as mean of the ratio versus the respective 18S rRNA 
level ± SEM (MRL/wt n=5; vehicle n=15; aPC n=15). *p<0.05, **p<0.01 versus vehicle group. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 19. Plasma protein levels of IL-12p40, IL-6, MCP-1 and TNF-α were estimated by ELISA. 
Data are expressed as means ± SEM (MRL/wt n=5; vehicle n=15; aPC n=15). *p<0.05, **p<0.01, 
***p<0.001 versus vehicle group. ND, not detectable. 
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4.2 Part – II Cathepsin S in SLE 
 
4.2.1 Cathepsins expression in MRL-Fas(lpr) mice 
 
First we quantified the mRNA expression levels of Cat-B, -C, -D, -H, -L, and -S in 
kidneys and spleens of 6, 10, and 14 week old female MRL-Fas(lpr) mice with SLE by 
real-time PCR. Age- and sex-matched MRL wild-type mice served as controls. In the 
kidney, among all the cathepsins only Cat S, -B, and -C were induced only at 14 weeks of 
age (Figure 20A). By contrast, all cathepsins were induced in spleen starting from 10 
weeks of age (Figure 20B). In-situ hybridization localized Cat S mRNA expression to 
F4/80+ myeloid antigen-presenting cells but not to CD20+ B cells or CD247+ T cells in 
spleen, lung, and kidney of female MRL-Fas(lpr) mice (Figure 21A). Cat S 
immunostaining was consistent with that cell type-specific expression pattern in spleen and 
lung, while in kidney, epithelial cells of proximal tubuli stained positive, implying that Cat 
S protein gets reabsorbed from the glomerular filtrate (Figure 21B). In the kidney, Cat S 
positivity was also seen in the DCs of the tertiary lymphoid tissue formed in the 
perivascular area of larger arteries (Figure 22). Together, Cat S is expressed exclusively in 
myeloid antigen-presenting cells inside and outside the lymphoid tissue.  
 
 
 
0
4
8
12
* **
C
a
t 
S
R
el
a
ti
v
e 
ex
p
re
ss
io
n
0
2
4
6
wt MRL
MRL/lpr
**
C
a
t 
S
R
el
a
ti
v
e 
ex
p
re
ss
io
nA B 
 Figure continued... 
0
2
4
6
8
*
C
a
t 
B
R
el
a
ti
v
e 
ex
p
re
ss
io
n
0
5
10
15
*
***
C
a
t 
B
R
el
a
ti
v
e 
ex
p
re
ss
io
n
Results 
 
Page | 75  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 20. Cathepsin S, B, C, D, H and L mRNA expression levels in the kidney (A) and spleen 
(B) were quantified in wildtype MRL and in MRL-Fas(lpr) mice by real time PCR. Data are 
expressed as a mean ratio to the respective 18S rRNA mRNA expression level ± SEM. *p<0.05, 
**p<0.01. ***p<0.001 (wildtype MRL n=3, MRL-Fas(lpr) n=3). 
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Figure 21. Cat S in-situ hybridization and immunohistochemistry. Spleen, lung, and kidney 
sections were prepared for in-situ hybridization (A) and Cat S immunostaining (B) as described in 
methods. Cat S mRNA expression is indicated by red colour. Co-staining by either F4/80 (myeloid 
DCs), CD20 (B cells), or CD247 (T cells) is shown in blue colour, respectively. Representative 
images are shown here for all organs at original magnifications of 100x, 200x or 400x (insert).  
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Figure 22. Cat S immunostaining. Kidney sections were stained for Cat S as described in methods. 
Representative image of intrarenal tertiary lymphoid tissue and is shown at an original 
magnification of 200x. 
 
4.2.2 Pharmacodynamics and pharmacokinetics of RO5461111 in mice 
 
To test the functional contribution of Cat S in systemic autoimmunity we used the Roche 
Cat S Inhibitor RO5461111 (Figure 23A). RO5461111 is a potent and selective Cat S 
inhibitor. In enzymatic assays it inhibits human Cat S with an IC50 of 0.4 nM. The mouse 
Cat S activity is comparable to the human activity with an IC50 of 0.5 nM. No submicro-
molar inhibition of any other cathepsin (Cat B, Cat K, Cat L and Cat V) tested was 
detected (Table 7). In addition, RO5461111 has been tested in the diversity panel of 
CEREP consisting of nearly 100 receptor binding and enzymatic assays at 10 µM 
concentration. Here, RO5461111 showed ≤ 30% inhibition for all assays tested. The 
capability of RO5461111 to inhibit Cat S in cells was tested with the Iip10 accumulation 
assay in a human and mouse B-cell line and a potent induction of Iip10 was determined 
with EC50 of 17 nM and 8 nM respectively was determined (data not shown). The acute  
 
 
Table 7. In vitro enzyme inhibition assay 
Cathepsin IC50 
Human cathepsin S 0.4 nM 
Mouse cathepsin S 0.5 nM 
Human cathepsin K >25 µM 
Human cathepsin L 49 µM 
Human cathepsin B 44 µM 
Human cathepsin V 1.3 µM 
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Figure 23. Pharmacokinetics of Cat S inhibitor R05461111 in MRL-Fas(lpr).(A) Chemical 
structure of R05461111. (B) For the determination of in-vivo Cat S activity inhibition by 
RO5461111, we used BALB/c mice. After oral dosing of 0.1 mg/kg to 100 mg/kg of RO5461111 
mice were sacrificed after 7 hours and spleens were harvested. Protein extracts were separated by 
SDS-gel electrophoresis for the determination of p10 upregulation by Cat S inhibition. (C) 
Concomitant pharmacokinetic studies were performed for R05461111 in female MRL Fas(lpr) 
mice during the course of treatment from 12 to 20 wk of age. Plasma sampling was carried every 
two weeks and R05461111 plasma levels were determined by modification of a sandwich 
hybridization procedure. (R05461111 n=5). (D) Invariant chain p10 levels were estimated from 
spleen tissue using western blotting.  
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pharmacodynamics effect of RO5461111 was tested after oral gavage at doses from 0.1-
100 mg/kg. Splenic induction of p10 was used as measured of enzyme inhibition and a 
strong p10 upregulation was measured with maximal induction at low doses as 1 mg/kg 
(Figure 23B). Oral administration of RO5461111 by food admix (262 mg/kg) to female 
MRL-(Fas)lpr mice results in a dose of 30 mg/kg and stable plasma levels of RO5461111 
at 400-600 ng/ml over a period of 8 weeks and resulted in robust p10 accumulation in the 
spleen (Figures 23C and 23D). Furthermore, oral treatment of C57BL/6 mice with 
RO5461111 suppressed T cell priming upon vaccination with sheep IgG and also 
treatment with R05461111 significantly reduced anti-sheep IgG antibodies (Figure 24A 
and 24B). Together, RO5461111 is a specific small molecule Cat S antagonist with 
favorable pharmacodynamic and pharmacokinetic profiles to efficiently block Cat S over 
prolonged periods of time in mice, which has the potential to suppress antigen-induced B 
and T cell priming. 
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Figure 24. (A) Spleen FACS analysis of the percentage of total CD3+CD69+ T cells, 
CD3+CD4+CD69+ T cells and CD3+CD8+CD69+ T cells. (B) Anti-sheep IgG antibodies were 
estimated by ELISA. Data are expressed as means ± SEM. *p<0.05, versus vehicle group. (Vehicle 
n=6, R05461111 n=6). 
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4.2.3 Cat S blockade with RO5461111 reduces plasma levels of IL-10 and  
TNF in MRL-(Fas)lpr mice 
 
To test the effects of therapeutic Cat S inhibition in autoimmune IC-GN, 12 week 
old albuminuric female MRL-Fas(lpr) mice were randomized to two groups that received 
either normal chow (vehicle) or a food admix with RO5461111. Food intake and weight 
gain were identical during the following 8 weeks until all mice were sacrificed (data not  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 25. Plasma protein levels of IL-10, IL-12p40, TNF-α, IL-2 and IFN-γ were estimated by 
ELISA. Data are expressed as means ± SEM (n=15 each treatment group). *p<0.05, **p<0.01, 
versus vehicle group.  
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     Table 8. Spleen and lymph node weight in MRL-Fas(lpr) mice 
 Vehicle R05461111 P value by t-test 
Spleen 1.777 ± 0.1152  1.505 ± 0.1111  0,1026 
Lymph node 2.369 ± 0.2555 1.913 ± 0.1509  0,1364 
 
 
shown). The same applied to spleen and lymph node weights (table 8). Plasma samples 
were obtained at baseline (12 weeks of age), at 4 and 8 weeks of treatment (16 and 20 
weeks of age). We first measured IL-10 and IL-12p40 as major dendritic cell-derived 
cytokines that promote B and T cell activation and proliferation. IL-10 is a potent growth 
and differentiation factor for activated B cells. The Cat S blockade had significantly 
reduced IL-10 (not IL-12p40) levels but only after 8 weeks of treatment (Figure 25). 
Therefore, additional cytokines were measured at 8 weeks only. Cat S blockade 
significantly reduced TNF-α levels, while IL-2 and IFN-γ levels remained unaffected. IL-2 
is a cytokine primarily produced by T cells and is necessary for T cell activation and 
proliferation. It has been reported that production of IL-2 is decreased in patients with 
systemic lupus erythematosus. High IFN-γ serum levels have been reported in SLE. IFN-γ 
receptor knockout lupus prone mouse strain has suggested that IFN-γ is essential for the 
development of nephritis in mice134. Thus, Cat S promotes the systemic expression of IL-
10 and TNF-α in MRL-(Fas)lpr mice. 
 
4.2.4 Cat S blockade with RO5461111 reduces the activation and expansion 
of spleen DCs in MRL-(Fas)lpr mice 
 
Autoimmune IC-GN involves overactivation of adaptive immunity. Inappropriately 
stimulated monocytic antigen-presenting cells are a source for systemic cytokine release as 
well as immune dysregulation43,133. As immunostaining had localized Cat S positivity 
predominantly to antigen-presenting cells we performed splenocyte flow cytometry on 
MRL-(Fas)lpr mice. RO5461111 treatment reduced the percentages of CD11c+MHC-II+ 
and CD11c+CD40+ activated DCs in MRL-(Fas)lpr mice (Figure 26A). This was 
associated with lower spleen mRNA expression levels for IL-1β, IL-10, IL-23p19, and 
CXCL12, while the levels of IL-6, IL-12p35, IFN-γ, TGF-β, CCL2, and CCL5 were not 
reduced (Figure 26B and 26C). 
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Figure 26. FACS analysis of splenic DCs. Spleen cell suspensions were prepared for flow 
cytometry by using specific antibodies that identify subsets of DCs. (A) FACS analysis of total 
numbers of CD11c positive cells that were also positive for the activation markers MHC-II or 
CD40. Data are expressed as mean percentages of all splenocytes ± SEM. (B) Splenic mRNA 
expression levels of IL-1β, IL-10, IL-23p19 and CXCL12 were determined by qPCR. (C) Splenic 
mRNA expression levels of IL-6, IL-12p35, IFN-γ, TGF-β, CCL2 and CCL5 were determined by 
qPCR. Data are expressed as mean of the ratio versus the respective 18S rRNA level ± SEM. 
(n=15 each treatment group). *p<0.05, **P<0.01 versus vehicle group. 
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4.2.5 Cat S blockade with RO5461111 reduces the activation and expansion 
of CD4 and autoreactive T cells in MRL-(Fas)lpr mice 
 
 Less spleen dendritic cell activation and cytokine expression may affect T cell 
priming. RO5461111 significantly reduced the amount of spleen CD3 cells as well as of 
activated (CD69+) CD3 cells (Figure 27A). Treatment with inhibitor specifically 
significantly reduced CD4+ cells and CD4/CD8 double negative ‘autoreactive’ T cells as 
well as activated (CD69+) CD4+ T cells and CD4/CD8 double negative T cells (Figure 
27A). CD4+ cell polarization is driven by distinct transcription factors, e.g. T-bet (Th1), 
Gata3 (Th2), Rorc (Th17) and Foxp3 (Treg). Cat S inhibition significantly specifically 
reduced spleen mRNA levels of Gata3 and Rorc (Figure 28). In contrast to RO5461111`s 
effect on CD4+ cells, it did not affect the amount and the activation stage of CD8+ T cells 
(Figure 27B). Together, Cat S promotes the activation and expansion of spleen DCs, CD4+ 
T cells and autoreactive T cells in MRL-(Fas)lpr mice, a process that can be blocked with 
RO5461111. 
 
 
 
 
Figure 27. FACS analysis of splenic T cells. (A) FACS analysis of the percentage of total CD3+, 
CD3+CD69+ T cells, double negative T cells and CD69+ double negative T cells. (B) Percentage of 
total CD4+, CD4+CD69+ T cells, CD8+ and CD8+CD69+ T cells. Data are expressed as mean 
percentages of all splenocytes ± SEM. *p<0.05, **P<0.01 versus vehicle group. 
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Figure 28. Splenic mRNA expression levels of T cell transcription factors like T-bet, Gata-3, Rorc 
and Foxp3 were determined by real time PCR. (n=15 each treatment group). *p<0.05, ***P<0.001 
versus vehicle group. 
 
4.2.6 Cat S blockade with RO5461111 reduces B cells and plasma cells in 
MRL-(Fas)lpr mice 
 
 DCs and activated T helper cells both regulate antigen-specific B cell and plasma 
cell responses. The inhibitor significantly reduced B220+, B220+CD69+ cells but not the 
percentages of mature (B220+IgM+IgD+), marginal zone (B220+CD21+CD23-), and 
follicular B cells (B220+CD21-CD23+), while total plasma cells were significantly reduced 
(Figures 29A; 29D). Beyond the cytokines mentioned above, RO5461111 did not affect 
the expression of April, BAFF and Taci (Figure 29C). However, RO5461111 treatment 
significantly reduced the numbers of CD138+ k Light chain+ plasma cells (Figure 29B). 
Together, Cat S promotes the activation and expansion of splenic B cells and plasma cells 
in MRL-(Fas)lpr mice, a process that can be blocked with RO5461111. 
 
4.2.7 Cat S blockade with RO5461111 disrupts germinal centers in MRL-
(Fas)lpr mice 
 
Systemic autoimmunity depends on the complex interaction of myeloid cells and 
lymphocytes to promote the clonal selection of autoreactive lymphocytes as well as Ig 
class switch and affinity maturation of autoantibodies120,4,3. These processes involve 
peanut agglutinin (PNA)+ follicular B cells and takes place in the GC of the lymphoid 
tissue107. Vice versa, disruption of GC formation counteracts autoimmunity120. PNA 
immunostaining revealed that Cat S inhibition altered the distribution of follicular B cells 
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Figure 29. FACS analysis of splenic B cells and plasma cells. Spleen cell suspensions were 
prepared for flow cytometry by using specific antibodies that identify subsets of B cells and plasma 
cells. (A) FACS analysis of the percentage of total splenic B220+ and B220+CD69+ cells. (B) 
FACS analysis of the percentage of total spleen plasma cells. (C) Splenic mRNA expression levels 
of April, BAFF and Taci were determined by qPCR. Data are expressed as a mean ratio to the 
respective 18S rRNA mRNA expression level ± SEM. (D) FACS analysis of the percentage of 
total mature B cells (B220+IgM+IgD+), marginal zone B cells (B220+CD21+CD23-) and follicular B 
cells (B220+CD21-CD23+) from spleen tissue. Data are expressed as mean percentages of all 
splenocytes ± SEM (n=15 each treatment group). *p<0.05, **P<0.01 versus vehicle group.  
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away from lymphoid follicles to the perifollicular area in spleens of MRL-(Fas)lpr mice 
(Figure 30), implying that Cat S inhibition disrupted the spatial organization of GC. IgD 
immunostaining revealed naïve B cells, these cells are present in the light zone of GC. 
These findings were consistent with a RO5461111-related significant reduction of spleen 
CXCL12 mRNA expression that is required for GC formation (Figure 30). Cat S inhibition 
by R05461111 completely eliminated IgD+ B cells from GC (Figure 31). Together, Cat S 
is required for GC formation in MRL-(Fas)lpr mice, which can be suppressed by 
RO5461111. 
 
 
 
 
Figure 30. PNA immunostaining was performed in the spleens of both groups to identify follicular 
B cells in the GC of lymph follicles. (A) Vehicle (B) R05461111. Note that Cat S inhibition led to 
a redistribution of PNA+ cells to the perifollicular area. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 31. IgD immunostaining was performed in spleens of both groups to identify mantle B cells 
of the lymph follicles. (A) Vehicle (B) R05461111. Note that Cat S inhibition led to absence of 
IgD+ B cells from the light zone of GC. 
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4.2.8 Cathepsin S blockade with RO5461111 reduces hypergammaglobuli-
nemia in MRL-(Fas)lpr mice 
 
B cell maturation and plasma cell expansion account for hypergammaglobulinemia 
and the production of high affinity IgG autoantibodies in autoimmunity. In vehicle-treated 
MRL-(Fas)lpr mice total IgG plasma levels increased from week 12 to 20 of age, which 
mostly related to IgG1 and IgG2a (Figure 32A). RO5461111 treatment significantly 
reduced total IgG, IgG1, IgG2a, IgG2b, and IgG2c levels already after 4 weeks of 
treatment but there was a progressive decline of especially IgG1 and IgG2a below baseline 
along treatment (Figure 32A). In contrast, IgG3 and IgM levels remained unaffected 
(Figures 32A and 32B). Thus, Cat S drives hypergammaglobulinemia in MRL-(Fas)lpr 
mice, a process that can be reversed by RO5461111. 
 
4.2.9 Cat S blockade with RO5461111 reduces autoantibody production in 
MRL-(Fas)lpr mice 
 
B cell maturation and plasma cell expansion account for the production of high 
affinity IgG autoantibodies in autoimmunity. 20 week old MRL-(Fas)lpr mice displayed 
strong positivity for antinuclear antibodies in a diffuse nuclear staining pattern consistent 
with the presence of anti-DNA antibodies (Figure 33A). This was validated by kinetoplast 
staining of the monocellular organism Critidiae luciliae that contains pure dsDNA (Figure 
33B). Cat S blockade with RO5461111 drastically reduced ANA as well as Critidiae 
luciliae kinetoplast positivity (Figures 33A, 33B). Quantitative assessment of anti-dsDNA 
IgG and IgM during the treatment period confirmed that RO5461111 treatment reduced 
anti-dsDNA IgG but not IgM plasma levels (Figure 33C). This effect on Ig class switch 
related to all subclasses of IgG except for IgG2c (Figure 34A). It is of note that Cat S 
blockade lead to a progressive decline below baseline levels during the treatment period 
(Figure 34A) suggesting that Cat S is needed to maintain autoantibody production in 
existing clones of autoreactive plasma cells. RO5461111 treatment also significantly 
reduced the plasma levels of anti-nucleosome IgG, anti-smRNP IgG, and rheumatic factor 
in MRL-(Fas)lpr mice, while the respective IgM autoantibodies remains unaffected (Figure 
34B, 35). Thus, Cat S drives the production of antinuclear IgG autoantibody production in 
MRL-(Fas)lpr mice, a process that can be reversed by RO5461111. 
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Figure 32. R05461111 reduces IgG antibodies in MRL-Fas(lpr) mice. (A) Plasma levels of total 
IgG and its isotypes IgG1, IgG2a, IgG2b, IgG2c and IgG3were determined by ELISA. (B) Plasma 
levels of IgM antibodies were determined by ELISA. Data are expressed as means ± SEM (n=15 
each treatment group,). *p<0.05, **p<0.01, ***p<0.001 versus vehicle group.  
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Figure 33. R05461111 reduces autoantibodies in MRL-Fas(lpr) mice. (A) ANA staining patterns 
on Hep2 human epithelial cells for plasma, derived from vehicle-treated and R05461111 treated 
MRL-Fas(lpr) mice at 1:200 dilution. (B) Crithidia luciliae slides were incubated with 1:50 diluted 
plasma of 20 weeks old mice from both treatment groups, and autoantibody binding to the 
flagellate’s kinetoplast was detected using an FITC-labeled goat anti-mouse IgG. Images on the 
left show anti-dsDNA IgG in green, and staining the kinetoplast DNA itself with DAPI is in blue 
was shown in the middle. The merged pictures are shown on the right side demonstrating that 
FITC positivity matches with the kinetoplast at the flagella pole of C. luciliae. (C) Plasma levels of 
anti-dsDNA IgG and IgM antibodies were determined by ELISA. Data are expressed as means ± 
SEM (n=15 each treatment group). *p<0.05, **p<0.01 versus vehicle group. 
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Figure 34. (A) Plasma levels of IgG isotypes such as IgG1, IgG2a, IgG2b, IgG2c and IgG3 against 
ds-DNA were determined by ELISA. (B) Plasma levels of anti-RNP/Sm, anti-nucleosome 
antibodies and rheumatoid factor were determined by ELISA. Data are expressed as means ± SEM 
(n=15 each treatment group). *p<0.05, **p<0.01, ***p<0.001 versus vehicle group.  
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Figure 35. R05461111 does not affect IgM autoantibodies in MRL-Fas(lpr) mice. Plasma levels of 
IgM autoantibodies (smith antigen, anti-nucleosome, Rheumatoid factor) were determined by 
ELISA. Data are expressed as means ± SEM (n=15 each treatment group).  
 
4.2.10 Cat S blockade with RO5461111 improves lupus nephritis in MRL-
(Fas)lpr mice 
 
Autoimmune IC-GN develops from intrarenal immune complex deposition and 
local complement activation135. Vehicle-treated 20 week old female MRL-Fas(lpr) mice 
displayed strong intraglomerular IgG and complement C3c deposits, which was associated 
with diffuse mesangial matrix expansion, profound mesangial cell proliferation, and focal 
segmental glomerulosclerosis (Figure 36A). Cellular crescents and global 
glomerulosclerosis were often seen. Most animals revealed profound tubulointerstitial 
inflammation as characterized by periglomerular and diffuse interstitial leukocyte 
infiltrates, tubular atrophy and intraluminal cast formation. Cat S blockade with 
RO5461111 significantly reduced glomerular IgG and C3c deposits (Figure 36B) and the 
glomerular as well as the tubulointerstitial immunopathology as quantified by the lupus 
nephritis activity index that encompasses glomerular cell proliferation, matrix deposition, 
leukocyte infiltration, focal necrosis, crescent formation, and tubulointerstitial inflamm- 
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Figure 36. Cat S inhibitor R05461111 suppresses renal pathology in MRL-Fas(lpr) mice. (A) 
Renal sections of 20 week old MRL-Fas(lpr) mice were stained with antibodies for IgG and 
complement C3c as indicated. Note that inhibitor treated mice showed less glomerular IgG and 
C3c deposits. Renal sections of 20 week old MRL-Fas(lpr) mice were stained with periodic acid-
Schiff (PAS). Representative PAS staining kidney sections showed glomerular damage in vehicle-
treated mice when compared with inhibitor treated mice. Images are representative for 15 mice in 
each treatment group. Magnification, ×400 or ×200. (B) Glomerular IgG and complement C3c 
deposition was compared between vehicle- and inhibitor-treated groups (score ranging from 0 to 
3). *p<0.05, **p<0.01, versus vehicle group. (Vehicle n=15, R05461111 n=15). 
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Figure 37. The lupus nephritis disease activity index (score ranging from 0 to 24), and the lupus 
nephritis chronicity index score ranging from 0 to 12) were determined as markers of kidney 
damage in lupus nephritis. Data are expressed as means ± SEM. *p<0.05, **p<0.01, versus vehicle 
group. (Vehicle n=15, R05461111 n=15). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 38. Renal functional parameters like Proteinuria (A), plasma creatinine (B) and glomerular 
filtration rate (C) were determined from 15 mice in the each treatment group at 20 weeks of age. 
Data are expressed as means ± SEM. *p<0.05 versus vehicle group. (Vehicle n=15, R05461111 
n=15).  
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tion. Treatment with RO5461111 suppressed IC-GN as documented by a significant 
reduction of the nephritis chronicity index that encompasses glomerular sclerosis, fibrous 
crescents, tubular fibrosis and interstitial fibrosis (Figure 37). This improvement of renal 
structure was associated with a significant reduction of proteinuria and serum creatinine 
levels after 8 weeks of treatment (Figures 38A and 38B). Glomerular filtration rate, as 
assessed by FITC-inulin clearance kinetics at the end of the study, was severely impaired 
in vehicle-treated MRL-Fas(lpr) mice but significantly increased upon RO5461111 
treatment (Figure 38C). These effects were associated with significantly reduced mRNA 
expression levels of IL-1β, IL-6, IL-10 and IL-12p35, while IFN-γ and TGF-β1 remained 
unaffected (Figure 39A). RO5461111 significantly reduced the number of glomerular 
Mac-2+ macrophages (Figure 39B and 39C). FACS analysis of kidney has shown 
significantly reduced the number of activated DCs (Figure 39D). FACS analysis of F4/80+ 
macrophages has shown a trend towards less macrophages in the kidneys of R05461111 
treated mice (Figure 39E). Thus, Cat S contributes to the progression of IC-GN in MRL-
Fas(lpr) mice, a process that can be prevented by RO5461111. 
 
4.2.11 Cat S blockade with RO5461111 reduces lung inflammation in 
MRL-(Fas)lpr mice 
 
The lung is another organ frequently affected by systemic autoimmunity in MRL-
Fas(lpr) mice. Vehicle-treated MRL-Fas(lpr) mice developed prominent peribronchial 
immune cell infiltrates that compressed and destroyed lung tissue (Figure 40A; 40B). Such 
infiltrates were significantly decreased in 20-wk-old RO5461111-treated MRL-Fas(lpr) 
mice together with less mRNA expression levels of IL-6, IL-12p40 and CCL2 (Figure 
40C), and lower numbers of Mac-2+ macrophages (Figure 40D). Thus, Cat S also 
promotes pulmonary inflammation and damage in MRL-Fas(lpr) mice. Obviously, late 
onset of RO5461111 therapy has beneficial effects on immune deregulation, autoantibody 
production as well as IC-GN and lung disease in MRL-Fas(lpr) mice with systemic 
autoimmunity. 
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Figure 39. (A) Renal mRNA expression of IL-1β, IL-6, IL-10, IL-12p35, IFN-γ and TGF-β were 
determined by real time PCR. Data are expressed as a mean ratio to the respective 18S rRNA 
mRNA expression level ± SEM. (B) Renal sections of 20 weeks old MRL-Fas(lpr) mice were 
stained with an anti-Mac-2 antibody. (C) Quantification of Mac-2 positive glomerular 
macrophages. (D) FACS analysis of renal DCs and activated DCs. (E) FACS analysis of renal 
macrophages and activated macrophages. Data are expressed as means ± SEM. *p<0.05 versus 
vehicle group. Original magnification, ×100. (Vehicle n=15, RO5461111 n=15).  
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Figure 40. Cat S inhibitor R05461111 improves lung disease in MRL-Fas(lpr) mice. (A) Lung 
sections of 20 week old MRL-Fas(lpr) mice of both groups were stained with Periodic acid Schiff. 
Note the peribronchial and perivascular lymphocyte infiltrates were less in RO5461111 mice when 
compared with vehicle mice. Images are representative for 15 mice in each treatment group. 
Original magnification, ×100. (B) Morphometry was used to quantify the peribronchiolar and 
perivascular inflammation by using a score ranging from 0 to 3 and scored semiquantitatively as 
described in the methods section. (C) Lung mRNA expression levels of IL-6, IL-12p40 and CCL2 
in MRL-Fas(lpr) mice of both groups were determined by qPCR. (D) Quantification of lung 
macrophages. The data represent mean scores ± SEM. *p<0.05, **p<0.01 versus vehicle group. 
(Vehicle n=15, RO5461111 n=15).  
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5. Discussion 
 
5.1 Part I - Activated protein C in SLE 
 
Recombinant aPC was recently shown to suppress a number of hyperinflammatory 
and autoimmune states; hence, we had hypothesized that recombinant aPC may also 
suppress SLE and lupus nephritis. Our experiments using autoimmune and nephritic MRL-
Fas(lpr) mice now document that recombinant human aPC can suppress lupus nephritis as 
well as other organ manifestations of SLE such as cutaneous lupus and lung disease. Lupus 
nephritis is triggered by glomerular immune complex deposits that activate complement, 
increased intrarenal expression of proinflammatory cytokines and chemokines, and 
subsequent recruitment of macrophages and other immune cells that contribute to renal 
inflammation and damage. Therefore, active lupus nephritis in humans and MRL-Fas(lpr) 
mice is characterized by diffuse mesangioproliferative glomerulonephritis and often 
associated with fibrinoid tuft necrosis, focal adhesions and crescent formation.  
 
In this study, we used Drotrecogin alfa activated (Xigris®; Lilly Deutschland 
GmbH), a human recombinant aPC that was shown to be effective in mice. Xigris® had a 
neuroprotective effect in murine neuronal and brain endothelial cell injury models136. 
Extracellular histones are cytotoxic toward endothelium in-vitro and are lethal in mice. 
aPC cleaves histones and reduces their cytotoxicity. Administration of aPC prevented 
septic-like reactions after injection of histones into mice137. Lethal toxin (LT) is a major 
virulence factor of Bacillus anthracis that plays a vital role in pathogenesis and the 
suppression of the host immune response. Sprague Dawley rats manifested pronounced 
lung edema and shock after LT treatments, resulting in high mortality. The activation of 
the coagulation cascade is involved in LT-mediated pathogenesis in rats. The anticoagulant 
aPC significantly reduced mortality in LT-treated rats138. Tissue plasminogen activator 
(tPA) is the only approved therapy for acute ischemic stroke. However, tPA has a brief 
therapeutic window. Its side effects include intracerebral bleeding and neurotoxicity. The 
tPA and 3K3A-APC (aPC variant with reduced anticoagulant activity) combination 
therapy reduced the infarct volume and improved behavior in models of ischemic stroke in 
rodents139. Thus, aPC and its variants have protective role. 
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In sepsis, it was initially thought that aPC has antithrombotic and profibrinolytic 
functions. Other agents with more potent anticoagulation functions were not effective in 
treating severe sepsis140,141. Recently, it has been postulated that cytoprotective effects of 
aPC are responsible for reduced mortality. Treatment with aPC variants with diminished 
anticoagulant activity could still have cytoprotective effects in a mouse model of sepsis142. 
This suggests that the effects of aPC in MRL-Fas(lpr) mice are due to cytoprotective 
signaling properties. aPC variants with reduced bleeding risk may permit therapies using 
higher aPC doses for shorter times. Higher doses of aPC may stabilize stressed cells at risk 
for excessive inflammation or apoptosis and prevent organ failure.  
 
In addition, we could detect lower serum aPC levels in MLR-Fas(lpr) mice 
compared with MRL wt mice, indicating a suppression of the protein C pathway during 
SLE. In septic patients, reduced aPC levels have been associated with an increased risk of 
death143,144. The brain is one of the first organs affected clinically in sepsis. 
Microcirculatory alterations are suggested to be a critical component in the 
pathophysiology of sepsis. aPC treatment significantly improved  pial microcirculation by 
reducing leukocyte adhesion and increasing functional capillary density in experimental 
endotoxemia in Lewis rats145. A pathogenic role for high-mobility group box 1 (HMGB1) 
protein has been postulated in severe sepsis. aPC not only inhibited HMGB1 release but 
also down-regulated the cell surface expression of all three HMGB1 receptors in 
endothelial cells. Thus, anti-inflammatory activities of aPC play important role in the 
suppression of severe sepsis. The protective effects of aPC were mediated through EPCR 
and PAR-1146. 
 
Aberrations of the monocyte/macrophage phenotype and function are increasingly 
recognized in SLE and animal models of the disease. Cao et al.147. showed that the anti-
inflammatory activity of aPC on macrophages is dependent on integrin CD11b/CD18, but 
not on EPCR. They showed that CD11b/CD18-bound aPC, facilitated cleavage and 
activation of PAR-1, leading to enhanced production of sphingosine-1-phosphate and 
suppression of the proinflammatory response of activated macrophages147. aPC decreases 
the release of the MIP-1 a from the monocytic cell line THP-1 and from human monocytes 
of septic patients148. aPC also inhibits LPS-induced nuclear translocation of NF-kB, TNF-
α, IL-1β, IL-6, and IL-8 production in the THP-1 cells149,150. Thus, treatment with aPC 
inhibits proinflammatory effects of monocytes/macrophages. 
Discussion 
 
Page | 99  
 
Treatment with recombinant aPC over a period of 5 weeks suppressed all of the 
aforementioned histopathological abnormalities of lupus nephritis. Renal function 
parameter serum BUN was significantly reduced by aPC treatment. Other renal function 
parameters like proteinuria and serum creatinine showed non-significant trends toward 
improvement of secretory and barrier functions, indicating that recombinant aPC is not as 
potent as pulse dosing with cyclophosphamide, which we previously reported to almost 
completely abrogate kidney disease in this model151. What are the mechanisms by which 
aPC treatment suppresses kidney disease in MRL-Fas(lpr) mice? aPC can elicit direct 
cytoprotective effects on glomerular endothelial cells and podocytes by inhibiting the 
intrinsic mitochondrial apoptosis pathways in mice with diabetic nephropathy105. aPC 
preserves endothelial cells via a PAR-1 and EPCR-dependent mechanism. Conversely, in 
podocytes, aPC inhibits apoptosis through proteolytic activation of PAR-3 independent of 
EPCR. PAR-3 is not signaling competent itself as it requires aPC-induced 
heterodimerization with PAR-2 (human podocytes) or PAR-1 (mouse podocytes)152. aPC 
also has anti-oxidant effects. Recently, Bock et al. have shown that aPC inhibits the 
expression of the redox-regulating protein p66Shc, which is primarily associated with 
mitochondrial ROS generation and apoptosis. p66Shc deficient mice are protected against 
diabetic nephropathy. Treatment with aPC ameliorated diabetic nephropathy by inhibiting 
mitochondrial dysfunction in podocytes153. These studies identify mechanisms underlying 
the cytoprotective effects of aPC. These effects could contribute to the protective effects 
on glomerular damage in MRL-Fas(lpr) mice. 
 
Recombinant aPC has been reported to prevent microvascular inflammation in 
autoimmune bowel disease106. Microvascular inflammation is a central element of 
infectious as well as autoimmune tissue damage and mediated by the activation of 
endothelial cells. A recent report first described that extracellular histones, which are 
released from dying cells, elicit a direct killing effect on endothelial cells followed by 
microvascular inflammation, a process that is inhibited by recombinant aPC, because the 
proteolytic activity of aPC degrades histones to immunologically inactive peptides137. The 
immunostimulatory effect and cytopathic effects of extracellular histones likely contribute 
also to lupus nephritis, at least in areas of focal necrosis, because histones are an essential 
element of neutrophil extracellular traps that were recently shown to mediate glomerular 
inflammation in anti-neutrophil cytoplasmic autoantibody-associated renal vasculitis154. 
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Thus, aPC has protects endothelium by cleaving histones and thereby reducing their 
cytotoxicity.   
 
aPC is a serine protease derived from its inactive zymogen protein C, and the fact 
that kidney, skin, and lung disease were all improved similarly suggests that recombinant 
aPC might suppress systemic disease mechanisms of SLE. In fact, our analysis revealed 
that aPC treatment affected many elements of autoimmunity. For example, lupus nephritis 
and most other tissue pathologies in SLE develop secondary to immune complex disease 
involving a polyclonal expansion of autoreactive B cells, plasma cells, and anti-nuclear 
autoantibody production4. aPC significantly reduced all of these elements of humoral 
autoimmunity as well as subsequent glomerular IgG deposits, indicating that protection 
from severe lupus nephritis is due to a systemic suppression of immune complex disease. 
The proliferation of autoreactive B cells in lupus depends on autoantigen-presentation and 
costimulatory signals from DCs133. Therefore, it is of note that recombinant aPC 
suppressed the activation of spleen DCs, which is an important determinant of SLE disease 
activity133,40. The activation of DCs also contributes to systemic inflammation; hence, we 
attribute the aPC-mediated suppression of plasma cytokine levels to its capacity to 
suppress DCs. Pretreatment with aPC in isolated macrophages activated in vitro with LPS 
showed less release of IL-6, whereas aPC-pretreated T cells activated with CD3/CD28 
showed inhibition of NF-kB signaling155. Therefore, we conclude that, treatment with aPC 
suppressed the activation splenic DCs, leading to the reduction in B cells and consequently 
resulting in less plasma cells.  
 
The signaling effects of aPC on B cells are still unknown. In mouse endotoxemia 
and sepsis models, mortality reduction requires the cell signaling function of aPC, 
mediated through PAR1 and EPCR. A recent study discovered that the expression of 
EPCR was limited to the CD8+ subset of spleen conventional DCs and is sufficient to 
suppress immune responses during sepsis. In addition, aPC (5A-aPC) inhibited the 
inflammatory response of conventional DCs independent of EPCR and suppressed IFN-γ 
production by natural killer-like DCs156. Our own data are in line with these observations, 
as recombinant aPC reduced the activation of CD4+ and CD8+ spleen dendritic cell subsets 
in MRL-Fas(lpr) mice. As such, we assume that aPC did not have direct effects on T and B 
cells, but rather that these are secondary to aPC-mediated suppression of dendritic cell 
activation. Interestingly, recombinant aPC did not have an effect on spleen T cell counts, 
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and its suppressive effect was limited to Th1 and Th17 T cells, two effector T cell 
subpopulations that play a dominant role in the cellular component of autoimmunity in 
human SLE as well as in SLE of MRL-Fas(lpr) mice130. Also, in a mouse model of 
multiple sclerosis, the amelioration of disease after aPC treatment was accompanied by 
inhibition of Th1 and Th17 cytokines155. Recently Kulkarni et al. have shown that 
cyclophosphamide or Mycophenolate mofetil cause broad T cell ablation in MRL-Fas(lpr) 
mice, like in humans, which should be a causative factor for the infectious complications 
that are associated with such therapies142,157. In this regard, recombinant aPC may have a 
better toxicity profile as T cell ablation was not observed. The most frequent toxicity that 
occurred in the recombinant aPC sepsis trials was bleeding101,158, notifying aPC’s 
biological function as a natural anticoagulant. It is of note that bleeding or hemorrhages 
were not observed in aPC-treated MRL-Fas(lpr) mice, macroscopically or on 
histopathological assessment of the lungs, skin, and kidneys. 
 
In summary, recombinant aPC improves lupus nephritis and lupus-related skin and 
lung disease mainly by suppressing the abnormal autoimmunity of SLE. 
 
5.2 Part II - Cathepsin S in SLE 
 
The central role of MHC-II-mediated adaptive immunity for the several forms of 
IC-GN and the non-redundant role of Cat S in peptide loading and MHC-II assembly 
prompted us to speculate that Cat S would be an essential mediator and potential 
therapeutic target for IC-GN. During the primary immune response low affinity antibodies 
of the IgM subclass are produced. Subsequently, driven by antigen stimulation through the 
B-cell antigen receptor and CD40, naïve B-cells enter the GC microenvironment, where 
they begin to proliferate and undergo clonal expansion. Germinal centers are specialized 
structures in which B lymphocytes undergo clonal expansion, class switch recombination, 
somatic hypermutation, and affinity maturation. Autoimmune IC disease develops from 
the presentation of autoantigens in the context of costimulation, followed by an expansion 
of autoreactive lymphocytes and the clonal selection of high affinity IgG autoantibody-
producing plasma cells, a process that takes place in the GC of lymphoid follicles120. 
Somatic hypermutation and class switch recombination occur at the centroblast stage of B-
cell maturation and together are responsible for generating high-affinity antibodies of 
Discussion 
 
Page | 102  
 
different subclasses that are capable of mediating specific immune responses. Our data 
confirm previously published reports that Cat S inhibition interferes with all of these 
processes upon vaccination with foreign or self-antigens159,123,112,107, most likely by 
limiting Ii-dependent peptide loading onto MHC-II.  
 
The novel aspects of our study are three-fold. First, here we first report a novel Cat 
S antagonist (R05461111) that is potentially suitable for therapy in humans. Second, we 
first document the contribution of Cat S in autoimmune IC-GN involving lupus-like 
spontaneous systemic autoimmunity and antinuclear antibody production. This process 
specifically involves priming of CD4+ T cell subsets (but not CD8+ T cells) and affinity 
maturation towards IgG autoantibody-producing plasma cells within the GC. Third, Cat S 
blockade initiated as late as upon ‘clinically’ detectable signs of IC-GN, such as 
proteinuria and/or elevated serum creatinine, was effective in suppressing 
hypergammaglobulinemia and autoantibody production below baseline and in preventing 
IC disease progression.  
 
The possibility of using a Cat S inhibitor to regulate overactive autoimmune 
responses was confirmed, with the use of Cat S inhibitor CLIK-60 in a murine model for 
Sjoegren’s syndrome. Intraperitoneal administration of CLIK-60 showed elimination of 
the autoimmune manifestations by preventing the presentation of organ specific antigen α-
fodrin by MHC-II. The remission of lesions in salivary and lachrymal glands was not 
observed with a cathepsin B or L inhibitor114. A highly selective Cat S inhibitor, CSI-75, 
was tested in a murine model of multiple sclerosis and in a murine model of rheumatoid 
arthritis. When given orally, CSI-75 caused a significant reduction in disease score in both 
disease models. These studies have revealed that Cat S inhibitor, CSI-75 caused a selective 
suppression of the Th1 and Th17 cytokines112. Thus, indicating a promising role for Cat S 
inhibitors in the treatment of autoimmune diseases. 
 
Cat S inhibitors or Cat S knockout mice have shown protection in some animal 
models of disease other than autoimmune diseases. Deschamps et al. have used genetic 
and pharmacological approaches to illustrate that Cat S is critically required for antigen-
induced lung inflammation. Oral administration of Cat S inhibitor compound 7 has been 
found to block the rise in immunoglobulin E titers and eosinophil infiltration in the lungs, 
in a mouse model of ovalbumin-induced pulmonary inflammation. Cat S knockout mice 
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did not develop ovalbumin-induced pulmonary inflammation, consistent with a role for Cat 
S in the development of the allergic response. This suggests that Cat S is involved in 
asthma121. Zheng et al. have used selective Cat S inhibitor 05141 in IFN-γ-induced 
alveolar remodeling and emphysema. Cat S-dependent epithelial cell apoptosis is a critical 
event in the pathogenesis of IFN-γ-induced alveolar remodeling and emphysema. Selective 
Cat S inhibition with oral administration of 015141 or a null mutation of Cat S decreased 
IFN-γ-induced apoptosis, emphysema and inflammation. In conclusion, these studies 
demonstrated that Cat S-dependent epithelial cell apoptosis is a critical event in the 
pathogenesis of IFN-γ-induced alveolar remodeling and emphysema160. Thus, Cat S 
inhibition has therapeutic potential in the treatment of emphysema.  
 
Human atherosclerotic lesions overexpress the lysosomal cysteine protease Cat S. 
Compared with LDLR–/– mice, double-knockout mice (CatS–/–LDLR–/–) developed 
significantly less atherosclerosis, as indicated by plaque size. These findings establish a 
pivotal role for Cat S in atherogenesis and Cat S deficient mice developed significantly 
less atherosclerosis116. Samokhin et al.161 have investigated the effect of a specific Cat S 
inhibitor on atherosclerotic plaque progression in the brachiocephalic artery. Male and 
female Apoe-/- mice on a cholate-containing high-fat diet containing or lacking a specific 
Cat S inhibitor were evaluated for the remodeling of atherosclerotic lesions. The size of 
atherosclerotic plaques in inhibitor-treated mice was reduced by 36% in male and 68% in 
female mice. In conclusion, the inhibition of Cat S showed a strong atheroprotective 
activity. Thus, Cat S inhibition through specific inhibitors or genetic elimination of the 
gene has therapeutic potential. 
 
Cat S inhibition with the novel, orally available, and highly selective Cat S 
inhibitor RO5461111 was effective in-vivo and had profound effects on the SLE-like 
systemic autoimmunity that spontaneously develops in MRL-Fas(lpr) mice. The most 
striking therapeutic effect was the suppression of IgG but not IgM (auto-) antibody 
production, which was consistent for all ANA specificities tested. This effect on Ig class 
switch implies that Cat S contributes to the affinity maturation of the respective antibody-
producing cells, which was consistent with a significant suppression of spleen plasma cells 
upon Cat S inhibition. Affinity maturation takes place in the GC of lymphoid follicles and 
requires an orchestrated interaction of antigen-presenting cells and lymphocytes such as 
follicular DCs, follicular B cells, and antigen-specific CD4+ T helper cells120. Cat S 
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inhibition disrupted the typical spatial organization of the GC in MRL-Fas(lpr) mice, as it 
was reported by previous vaccination studies using Cat S-deficient mice or Cat S 
antagonists107. Obviously, compromising appropriate MHC-II assembly is sufficient to 
impair GC formation, e.g. by suppressing CXCL12 expression, a factor needed for the 
spatial organization of follicular B cells to the dark zone of GC and their and the 
maturation towards plasma cells that produce high affinity IgG autoantibodies162,163.  
 
By contrast, Cat S is not involved in peptide loading to MHC-I, hence, Cat S 
inhibition did not affect CD8+ T cells in MRL-Fas(lpr) mice. This implies that therapeutic 
Cat S inhibition should spare MHC-I and CD8+ T cell-mediated immunity, which should 
reduce the risks of therapy-associated infections as compared to global 
immunosuppressants such as steroids, cyclophosphamide or mycophenolate mofetil. Of 
note, we did not observe any infectious complications in the mice studied with the Cat S 
inhibitor. 
 
We designed our study also to test the therapeutic potential of Cat S inhibition; 
hence, treatment was initiated not before ‘clinically’ detectable signs of autoimmune tissue 
injury, such as proteinuria and/or elevated serum creatinine, became evident. It is of note 
that Cat S inhibition suppressed hypergammaglobulinemia and autoantibody production 
below the baseline levels, consistent with a reversal of the underlying systemic 
autoimmune process. However, at the tissue level Cat S inhibition was effective only in 
terms of preventing a further increase in serum creatinine, which implies a stabilization of 
renal function and not a reversal of tissue remodeling. Even when admitting that the 
reversal of tissue remodeling may take more time than we studied here, our data would 
favor to initiate Cat S blockade at an early stage of IC-GN disease to normalize aberrant 
immunity and to prevent disease progression.  
 
 In summary, Cat S is a non-redundant mediator of autoimmune IC-GN. Cat S 
inhibition with RO5461111 protects from progressive IC-GN.  
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There are some limitations to the conclusions drawn from the present two studies. 
1. Both studies are performed in a murine model of SLE, therefore they lack supporting 
evidence from human experiments. 2. Only a fixed dose of aPC (5 mg/kg) or Cat S 
inhibitor R05461111 (30 mg/kg) was used throughout the study. But it might be possible 
that higher doses are even more effective. 3. We have treated mice for 5 weeks in aPC-
SLE study and 8 weeks in Cat S inhibitor-SLE study. But it might be possible that 
different treatment durations are even more effective. 4. The mouse models of SLE are 
highly homogeneous in terms of disease development and progression, whereas in humans, 
it is highly variable from person to person. 5. The conclusions were drawn from studying 
only one animal model of SLE. To mimic the genetic and pathological heterogeneity in 
humans, it is crucial to use various mouse models in therapeutic studies. It has been shown 
that same treatment can have variable effects on different mouse models. Thus, multiple 
models should be used to ensure the applicability of drugs on the more complicated human 
genetic background. It might be possible that exogenous administration of aPC or blockade 
of cat S lead to different results in other disease models. 6. There is no mouse model that 
can mimic the complexity of human lupus. Thus, drugs validated in MRL-Fas(lpr) mouse 
model may only be effective for a subset of symptoms or patients. 7. Recombinant aPC 
used in the present study is a human specific protein. 8. Cat S inhibition-related 
immunosuppression may impair host defense, which was not addressed here. However, 
there is currently little data available on infection risk in the Cat S KO or in animals treated 
with Cat S inhibitors. 9. In the present studies we compared the treatment to placebo rather 
than the standard of care. 10. We did not evaluate survival benefit in both studies, which 
would have required an additional set of experiments with drug exposure until death. Such 
studies were not permitted by the ethical committee. 
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6. Summary and Conclusion 
 
Systemic lupus erythematosus (SLE) is a chronic autoimmune disease leading to 
inflammatory tissue damage in multiple organs (e.g., lupus nephritis). Current treatments 
including steroids, antimalarials, and immunosuppressive drugs have significant side 
effects. There is an unmet medical need for new drugs with less side effects. We evaluated 
the role of two proteases, namely activated protein C (aPC) and cathepsin S (Cat S), in the 
pathogenesis of SLE in MRL-Fas(lpr) mice.  
 
aPC is a serine protease and acts as a natural anticoagulant. In addition to its 
anticoagulation functions, aPC also has cytoprotective activities such as anti-inflammatory, 
anti-apoptotic, pro-fibrinolytic and endothelial barrier protection. The immunosuppressive 
and cytoprotective effects of aPC have now emerged as a potential treatment for a number 
of autoimmune and inflammatory diseases that are associated with excessive immune 
responses such as acute respiratory distress syndrome, multiple sclerosis, rheumatoid 
arthritis, brain injury, lung injury, spinal cord injury, asthma, stroke, ischemia/reperfusion-
induced renal injury, diabetic nephropathy and chronic wounds.  
 
Based on immunosuppressive and cytoprotective effects of aPC, we hypothesized 
that recombinant aPC would suppress SLE and lupus nephritis. To test this concept, 
autoimmune female MRL-Fas(lpr) mice were injected with either vehicle (PBS) or 
recombinant human aPC for a period of 5 weeks, from 14-18 weeks of age. Treatment with 
Recombinant aPC improves lupus nephritis and lupus-related skin and lung disease mainly 
by suppressing the abnormal autoimmunity of SLE. aPC treatment significantly suppressed 
lupus nephritis as evidenced by a decrease in activity index, glomerular IgG and 
complement C3 deposits, macrophage counts, as well as intrarenal IL-12 expression. In 
addition, aPC attenuated cutaneous lupus and lung disease as compared with vehicle-
treated MRL-Fas(lpr) mice. In addition, parameters of systemic autoimmunity, such as 
plasma cytokine levels of IL-12p40, IL-6, and CCL2/MCP-1, and numbers of B cells and 
plasma cells in the spleen were suppressed by aPC. The latter was associated with lower 
total plasma IgM and IgG levels as well as lower titers of anti-dsDNA IgG and rheumatoid 
factor. Our analysis supports previous findings that aPC acts as a suppressor of activated 
CD4+ or CD8+ DCs without causing T cell ablation. In conclusion, recombinant aPC 
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appears to be suitable to block the abnormal immune activation of SLE and thereby 
prevent lupus nephritis and other lupus manifestations.  
  
 Cat S is a lysosomal cysteine protease, which plays an important role in antigen 
presentation and extracellular matrix degradation. It is mainly expressed in antigen 
presenting cells (APCs) such as B cells, DCs and macrophages. Cat S has been implicated 
in the pathophysiology of a number of auto-immune and allergic conditions where CD4+ 
T-cells are believed to play a role, namely rheumatoid arthritis, multiple sclerosis, psoriasis 
and bronchial asthma. In addition, Cat S in its secreted form is implicated in the 
degradation of the extracellular matrix, which may contribute towards initiation and 
propagation of a number of diseases, including atherosclerosis and chronic obstructive 
pulmonary disease.  
 
 Genetic studies consistently suggest the most common forms of immune complex 
glomerulonephritis (IC-GN) develop from polymorphisms in HLA genes, implying a role 
for MHC class II-mediated priming of (auto-) antibody production. Cat S degrades the 
invariant peptide chain during MHCII assembly with antigenic peptide in APCs, therefore, 
we hypothesized that Cat S inhibition would be therapeutic in IC-GN. We developed a 
highly specific small molecule, orally available, Cat S antagonist, RO5461111, with 
suitable pharmacodynamic and pharmacokinetic properties that efficiently suppressed 
antigen-specific T cell and B cell priming in-vitro and in-vivo. We treated MRL-Fas(lpr) 
mice with Cat S inhibitor R05461111, for a period of 8 weeks, from 12-20 weeks of age. 
RO5461111 significantly reduced the activation of spleen DCs and the subsequent 
expansion and activation of CD4+ T cells and CD4/CD8 double negative ‘autoreactive’ T 
cells. Cat S inhibition impaired the spatial organization of germinal centers, suppressed 
follicular B cell maturation to plasma cells, and Ig class switch and subsequent production 
of high affinity IgG autoantibodies. This reversed hyergammaglobulinemia and 
significantly suppressed the plasma levels of numerous IgG (but not IgM) autoantibodies 
below baseline, including anti-dsDNA. This effect was associated with less glomerular 
IgG deposits, which protected kidneys from IC-GN. In conclusion, Cat S promotes IC-GN 
by driving MHCII-mediated T and B cell priming, germinal center formation, and B cell 
maturation towards plasma cells. These afferent immune pathways can be specifically 
reversed with the Cat S antagonist RO5461111, which prevents IC-GN progression even 
when given after disease onset. This novel therapeutic strategy could correct a common 
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pathomechanism of several IC-GNs. This very specific therapeutic intervention, e.g. 
sparing CD8+ T cell-mediated adaptive immunity, holds the potential to avoid the 
unfavorable side effects of unselective immunosuppressive drugs currently used for the 
treatment of IC-GN. 
 
 Based on our investigation of the therapeutic potential of aPC and Cat S in a mouse 
model of SLE, we propose that aPC and Cat S could be novel therapeutic targets for SLE. 
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7. Zusammenfassung und Fazit 
 
 Der Systemische Lupus Erythematodes (SLE) ist eine chronische 
Autoimmunerkrankung, die mit entzündungsvermittelten Organschäden einhergeht (z.B. 
Lupusnephritis). Die derzeitigen Therapieregime beinhalten Steroide, Antimalarika und 
immunsuppressive Medikamente. Sie alle haben beachtliche Nebenwirkungen. Benötigt 
werden daher neue, nebenwirkungsärmere Substanzen. Wir haben die Rolle der Proteasen 
Protein C (aPC) und Cathepsin S (Cat S) bei der Pathogenese des SLE in MRL-Fas(lpr) 
Mäusen untersucht. aPC ist eine Serinprotesase und fungiert als endogenes Antikoagulanz. 
Außerdem hat aPC anti-entzündliche, anti-apoptotische und pro-fibrinolytische 
zytoprotektive Funktionen und schützt Endothelbarrieren. Die immunsuppressiven und 
zytoprotektiven Effekte des aPC liefern möglicherweise einen neuen Behandlungsansatz 
für eine Reihe von autoimmunen und entzündlichen Erkrankungen, die mit exzessiven 
Immunantworten einhergehen, wie ARDS, MS, RA, Gehirnschäden, Lungenverletzung, 
Rückenmarksverletzung, Asthma, Schlaganfall, Ischämie/Reperfusion induzierte 
Nierenschädigung, diabetische Nephropathie und chronische Wunden. 
  
 Basierend auf dem immunsuppressiven und zytoprotektiven Effekt von aPC 
vermuteten wir, dass rekombinantes aPC die Klinik des SLE und der Lupusnephritis 
verbessern würde. Um dies zu überprüfen, verabreichten wir MRL-Fas(lpr) Mäusen 
entweder PBS oder rekombinantes humanes aPC über einen Zeitraum von 5 Wochen 
(Woche 14-18). Die Behandlung mit aPC verbessert die Lupusnephritis und Lupus 
bedingte Haut- und Lungenläsionen. Dieser Effekt beruht hauptsächlich auf einer 
Unterdrückung der abnormen Autoimmunität beim SLE. Die aPC Behandlung reduzierte 
signifikant den Schweregrad der Lupusnephritis, was in einem reduzierten Aktivitätsindex, 
weniger glomerulären IgG und C3 Ablagerungen, reduzierter Makrophagenanzahl und 
intrarenaler IL-12 Expression Ausdruck fand. Außerdem senkte aPC kutane und 
pulmonale Manifestationen in MRL-Fas(lpr) Mäusen und es fanden sich eine Reduktion 
der Plasma IL-12p40, IL-6, MCP-1/CCL2 Spiegel und eine verminderte Anzahl an 
milzresidenten B- und Plasma Zellen in aPC behandelten Tieren - Parameter, die mit 
systemischer Autoimmunität korrelieren. In der Folge der zellulären Befunde fanden sich 
daher erniedrigte IgM, IgG, Rheumafaktor, und anti-dsDNA IgG Plasmaspiegel. Unsere 
Studie stützt vorherige experimentelle Befunde, dass aPC als ein Suppressor-aktivierter 
CD4+ oder CD8+ DCs fungiert, ohne dabei T-Zell Depletion zu bewirken. Daher scheint 
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rekombinantes aPC ein nützliches Therapeutikum, um abnorme Immunzellaktivierung 
beim SLE zu blockieren und dadurch Lupusnephritis und andere Organmanifestationen 
vorzubeugen.  
 
 Cat S ist eine lysosomale Cysteinprotease, die eine wesentliche Rolle bei der 
Antigenpräsentation und beim Abbau extrazellulärer Matrix spielt. Hauptsächlich wird sie 
in Antigen - präsentierenden Zellen (APCs), wie B Zellen, dendritischen Zellen und 
Makrophagen exprimiert. Cat S hat pathophysiologisch relevante Rollen unter zahlreichen 
autoimmunen und allergischen Zuständen, bei denen CD4+ T Zellen beteiligt zu sein 
scheinen, z.B.: RA, MS, Psoriasis und Asthma bronchiale. Zudem ist die sezernierte Form 
von Cat S am Abbau extrazellulärer Matrixkomponenten beteiligt, die möglicherweise zur 
Initiation und Aufrechterhaltung von zahlreichen Erkrankungen, wie z.B. Atherosklerose 
oder COPD beitragen.  
 
 Genetische Analysen deuten darauf hin, dass sich die häufigsten Formen der 
Immunkomplex-Glomerulonephritiden (IC-GN) auf dem Boden von Polymorphismen in 
den HLA-Genen entwickeln. Dies suggeriert eine Rolle für MHCII vermitteltes Priming 
der (Auto-) Antikörper Produktion bei der Pathogenese dieser Erkrankungen. Cat S spaltet 
in APC die invariante Peptidkette des MHCII Moleküls während dessen Bindung an ein 
Antigen. Daher vermuteten wir, dass Cat S Inhibition in IC-GN therapeutisch nützlich sein 
würde. Wir entwickelten / benutzten einen hochspezifischen, oral verfügbaren Cat S 
Antagonisten, RO5461111, mit adäquaten pharmakokinetischen und -dynamischen 
Eigenschaften, der effektiv antigenspezifisches Priming von T und B Zellen in-vitro und 
in-vivo supprimierte. Über 8 Wochen (Woche 12-20) behandelten wir MRL-Fas(lpr) 
Mäuse mit dem Cat S Inhibitor RO5461111. Die Aktivität von DCs in der Milz und die 
Anzahl sowie die Aktivierung von CD4+ T- und CD4/CD8 doppelnegativen 
‘autoreaktiven’ T Zellen fand sich signifikant erniedrigt. Cat S Inhibition beeinträchtigte 
die räumliche Organisation der Keimzentren, unterdrückte die Reifung von B Zellen zu 
Plasmazellen und hemmte den Ig Klassenwechsel und die Affinitätsreifung. Die Folge 
waren ein Rückgang der Hypergammaglobulinämie und eine signifikante Reduktion der 
IgG - aber nicht IgM - Autoantikörper unter die Ausgangswerte, wie z.B. Anti-ds DNA. 
Assoziiert damit waren eine Reduktion der glomerulären IgG Ablagerungen, was die Niere 
vor IC-GN schützte. Zusammenfassend aggraviert Cat S durch seinen fördernden Beitrag 
zur MHCII abhängigen T und B Zell Aktivierung, Keimzentrumsbildung und 
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Plasmazellreifung den Verlauf der IC-GN. Diese immunologischen Signalwege können 
spezifisch mit dem Cat S Antagonist RO5461111 inhibiert werden, was den Verlauf der 
IC-GN bessert, auch wenn erst nach Erkrankungsbeginn therapiert wird. Dieser neue 
therapeutische Ansatz könnte einen, verschieden IC-GN gemeinsamen, 
pathomechanistischen Defekt adressieren und korrigieren. Diese sehr selektive 
therapeutische Intervention könnte damit, z.B. durch reduzierte CD8 vermittelte adaptive 
Immunität, im Vergleich zu bisherigen unselektiven Therapieregimen weniger 
unerwünschte Nebenwirkungen aufweisen. 
  
 Aus unseren Untersuchungen des therapeutischen Potentials von aPC und Cat S im 
Mausmodell des SLE folgern wir, dass aPC und Cat S neue therapeutische Angriffspunkte 
für die Behandlung von SLE darstellen könnten. 
 
 
 
 
 
References 
 
Page | 112  
 
8. References 
 
1. Hall RC, S.S. Medical and psychiatric features of systemic lupus erythematosus. 
Psychiatr Med. Sep;1(3):, 287-301. (1983). 
2. Smyth, A., et al. A Systematic Review and Meta-Analysis of Pregnancy Outcomes 
in Patients with Systemic Lupus Erythematosus and Lupus Nephritis. Clinical 
Journal of the American Society of Nephrology 5, 2060-2068 (2010). 
3. Rahman, A. & Isenberg, D.A. Systemic Lupus Erythematosus. New England 
Journal of Medicine 358, 929-939 (2008). 
4. Goodnow, C.C. Multistep Pathogenesis of Autoimmune Disease. Cell 130, 25-35 
(2007). 
5. Lateef, A. & Petri, M. Unmet medical needs in systemic lupus erythematosus. 
Arthritis Research & Therapy 14, S4 (2012). 
6. Martínez Valle, F., Balada, E., Ordi-Ros, J. & Vilardell-Tarres, M. DNase 1 and 
systemic lupus erythematosus. Autoimmunity Reviews 7, 359-363 (2008). 
7. Vedove, C., Giglio, M., Schena, D. & Girolomoni, G. Drug-induced lupus 
erythematosus. Arch Dermatol Res 301, 99-105 (2009). 
8. Appel, G.B., et al. Mycophenolate Mofetil versus Cyclophosphamide for Induction 
Treatment of Lupus Nephritis. Journal of the American Society of Nephrology 20, 
1103-1112 (2009). 
9. Tumlin, J.A. Lupus nephritis - Histology, diagnosis and treatment. Bulletin of the 
NYU hospital for joint diseases 66, 188-194 (2008). 
10. Weening, J.J., et al. The Classification of Glomerulonephritis in Systemic Lupus 
Erythematosus Revisited. Journal of the American Society of Nephrology 15, 241-
250 (2004). 
11. Ye, D., et al. Polymorphisms in the promoter region of RANTES in Han Chinese 
and their relationship with systemic lupus erythematosus. Arch Dermatol Res 297, 
108-113 (2005). 
12. Gorman, C.L., et al. Polymorphisms in the CD3Z Gene Influence TCRζ Expression 
in Systemic Lupus Erythematosus Patients and Healthy Controls. The Journal of 
Immunology 180, 1060-1070 (2008). 
13. Tan, W., et al. Association of PPP2CA polymorphisms with systemic lupus 
erythematosus susceptibility in multiple ethnic groups. Arthritis & Rheumatism 63, 
2755-2763 (2011). 
14. Graham, R.R., et al. Specific combinations of HLA-DR2 and DR3 class II 
haplotypes contribute graded risk for disease susceptibility and autoantibodies in 
human SLE. Eur J Hum Genet 15, 823-830 (2007). 
15. Hom, G., et al. Association of Systemic Lupus Erythematosus with C8orf13–BLK 
and ITGAM–ITGAX. New England Journal of Medicine 358, 900-909 (2008). 
16. Prokunina, L., et al. A regulatory polymorphism in PDCD1 is associated with 
susceptibility to systemic lupus erythematosus in humans. Nat Genet 32, 666-669 
(2002). 
17. Manolio, T.A., et al. Finding the missing heritability of complex diseases. Nature 
461, 747-753 (2009). 
18. Niederer, H.A., Clatworthy, M.R., Willcocks, L.C. & Smith, K.G.C. FcγRIIB, 
FcγRIIIB, and systemic lupus erythematosus. Annals of the New York Academy of 
Sciences 1183, 69-88 (2010). 
References 
 
Page | 113  
 
19. Gross, A.J., Hochberg, D., Rand, W.M. & Thorley-Lawson, D.A. EBV and 
Systemic Lupus Erythematosus: A New Perspective. The Journal of Immunology 
174, 6599-6607 (2005). 
20. Mok, C.C. & Lau, C.S. Pathogenesis of systemic lupus erythematosus. Journal of 
Clinical Pathology 56, 481-490 (2003). 
21. Sanchez-Guerrero, J., et al. Past use of oral contraceptives and the risk of 
developing systemic lupus erythematosus. Arthritis & Rheumatism 40, 804-808 
(1997). 
22. Bynoe, M.S., Grimaldi, C.M. & Diamond, B. Estrogen up-regulates Bcl-2 and 
blocks tolerance induction of naïve B cells. Proceedings of the National Academy 
of Sciences 97, 2703-2708 (2000). 
23. Grimaldi, C.M., Jeganathan, V. & Diamond, B. Hormonal Regulation of B Cell 
Development: 17β-Estradiol Impairs Negative Selection of High-Affinity DNA-
Reactive B Cells at More Than One Developmental Checkpoint. The Journal of 
Immunology 176, 2703-2710 (2006). 
24. Rider, V., Jones, S.R., Evans, M. & Abdou, N.I. Molecular Mechanisms Involved 
in the Estrogen-Dependent Regulation of Calcineurin in Systemic Lupus 
Erythematosus T Cells. Clinical Immunology 95, 124-134 (2000). 
25. Hughes, G.C. & Clark, E.A. Regulation of dendritic cells by female sex steroids: 
Relevance to immunity and autoimmunity*. Autoimmunity 40, 470-481 (2007). 
26. Grimaldi, C.M. Sex and systemic lupus erythematosus: the role of the sex 
hormones estrogen and prolactin on the regulation of autoreactive B cells. Current 
Opinion in Rheumatology 18, 456-461 (2006). 
27. Smith-Bouvier, D.L., et al. A role for sex chromosome complement in the female 
bias in autoimmune disease. The Journal of Experimental Medicine 205, 1099-
1108 (2008). 
28. Jacob, C.O., et al. Identification of IRAK1 as a risk gene with critical role in the 
pathogenesis of systemic lupus erythematosus. Proceedings of the National 
Academy of Sciences 106, 6256-6261 (2009). 
29. Chang, D.-M., Lan, J.-L., Lin, H.-Y. & Luo, S.-F. Dehydroepiandrosterone 
treatment of women with mild-to-moderate systemic lupus erythematosus: A 
multicenter randomized, double-blind, placebo-controlled trial. Arthritis & 
Rheumatism 46, 2924-2927 (2002). 
30. Licht, R., Dieker, J.W.C., Jacobs, C.W.M., Tax, W.J.M. & Berden, J.H.M. 
Decreased phagocytosis of apoptotic cells in diseased SLE mice. Journal of 
Autoimmunity 22, 139-145 (2004). 
31. Herrmann, M., et al. Impaired phagocytosis of apoptotic cell material by 
monocyte-derived macrophages from patients with systemic lupus erythematosus. 
Arthritis & Rheumatism 41, 1241-1250 (1998). 
32. Rovere, P., Fazzini, F., Sabbadini, M. & Manfredi, A. Apoptosis and systemic 
autoimmunity: the dendritic cell connection, (2009). 
33. Kamradt, T. & Mitchison, N.A. Tolerance and Autoimmunity. New England 
Journal of Medicine 344, 655-664 (2001). 
34. Nagata, S. & Golstein, P. The Fas death factor. Science 267, 1449-1456 (1995). 
35. Goodnow, C.C., Sprent, J., de St Groth, B.F. & Vinuesa, C.G. Cellular and genetic 
mechanisms of self tolerance and autoimmunity. Nature 435, 590-597 (2005). 
36. Erbacher, A.I.M., Rönnefarth, V.M. & Decker, P. Circulating nucleosomes due to a 
defective clearance of dying cells: Consequences for systemic lupus erythematosus. 
Autoimmunity 40, 311-314 (2007). 
References 
 
Page | 114  
 
37. Seery, J.P., Cattell, V. & Watt, F.M. Cutting Edge: Amelioration of Kidney 
Disease in a Transgenic Mouse Model of Lupus Nephritis by Administration of the 
Caspase Inhibitor Carbobenzoxy-Valyl-Alanyl-Aspartyl-(β-o-methyl)-
Fluoromethylketone. The Journal of Immunology 167, 2452-2455 (2001). 
38. Green, D.R., Ferguson, T., Zitvogel, L. & Kroemer, G. Immunogenic and 
tolerogenic cell death. Nat Rev Immunol 9, 353-363 (2009). 
39. Voll RE, U.V., Herrmann M, Kalden JR. High mobility group box 1 in the 
pathogenesis of inflammatory and autoimmune diseases. The Israel Medical 
Association Journal 10, 26-28 (Jan 2008). 
40. Guiducci, C., et al. TLR recognition of self nucleic acids hampers glucocorticoid 
activity in lupus. Nature 465, 937-941 (2010). 
41. Jego, G., et al. Plasmacytoid Dendritic Cells Induce Plasma Cell Differentiation 
through Type I Interferon and Interleukin 6. Immunity 19, 225-234 (2003). 
42. Mellman, I. & Steinman, R.M. Dendritic Cells: Specialized and Regulated Antigen 
Processing Machines. Cell 106, 255-258 (2001). 
43. Ohnmacht, C., et al. Constitutive ablation of dendritic cells breaks self-tolerance of 
CD4 T cells and results in spontaneous fatal autoimmunity. The Journal of 
Experimental Medicine 206, 549-559 (2009). 
44. Datta, S.K., Patel, H. & Berry, D. Induction of a cationic shift in IgG anti-DNA 
autoantibodies. Role of T helper cells with classical and novel phenotypes in three 
murine models of lupus nephritis. The Journal of Experimental Medicine 165, 
1252-1268 (1987). 
45. Wofsy, D. & Seaman, W.E. Reversal of advanced murine lupus in NZB/NZW F1 
mice by treatment with monoclonal antibody to L3T4. The Journal of Immunology 
138, 3247-3253 (1987). 
46. Finck BK, L.P., Wofsy D. Treatment of murine lupus with CTLA4Ig. Science Aug 
26;265(5176), 1225-1227 (1994). 
47. Cunnane, G., et al. Prevention of renal damage in murine lupus nephritis by CTLA-
4Ig and cyclophosphamide. Arthritis & Rheumatism 50, 1539-1548 (2004). 
48. Isenberg, D. & Rahman, A. Systemic lupus erythematosus[mdash]2005 annus 
mirabilis? Nat Clin Pract Rheum 2, 145-152 (2006). 
49. O'Shea, J.J. & Paul, W.E. Mechanisms Underlying Lineage Commitment and 
Plasticity of Helper CD4+ T Cells Science 327, 1098-1102 (2010). 
50. Wang, A., et al. Dysregulated expression of CXCR4/CXCL12 in subsets of 
patients with systemic lupus erythematosus. Arthritis & Rheumatism 62, 3436-
3446 (2010). 
51. Wither, J. & Vukusic, B. Autoimmunity Develops in Lupus-Prone NZB Mice 
Despite Normal T Cell Tolerance. The Journal of Immunology 161, 4555-4562 
(1998). 
52. Fatenejad, S., Peng, S.L., Disorbo, O. & Craft, J. Central T Cell Tolerance in 
Lupus-Prone Mice: Influence of Autoimmune Background and the lpr Mutation. 
The Journal of Immunology 161, 6427-6432 (1998). 
53. Dawisha, S.M., Gmelig-Meyling, F. & Steinberg, A.D. Assessment of Clinical 
Parameters Associated with Increased Frequency of Mutant T Cells in Patients with 
Systemic Lupus Erythematosus. Arthritis & Rheumatism 37, 270-277 (1994). 
54. Vassilopoulos, D., Kovacs, B. & Tsokos, G.C. TCR/CD3 complex-mediated signal 
transduction pathway in T cells and T cell lines from patients with systemic lupus 
erythematosus. The Journal of Immunology 155, 2269-2281 (1995). 
References 
 
Page | 115  
 
55. Mishra, N., Reilly, C.M., Brown, D.R., Ruiz, P. & Gilkeson, G.S. Histone 
deacetylase inhibitors modulate renal disease in the MRL-lpr/lpr mouse. The 
Journal of Clinical Investigation 111, 539-552 (2003). 
56. Barrat, F.J., Meeker, T., Chan, J.H., Guiducci, C. & Coffman, R.L. Treatment of 
lupus-prone mice with a dual inhibitor of TLR7 and TLR9 leads to reduction of 
autoantibody production and amelioration of disease symptoms. European Journal 
of Immunology 37, 3582-3586 (2007). 
57. Chan, O.T.M., Hannum, L.G., Haberman, A.M., Madaio, M.P. & Shlomchik, M.J. 
A Novel Mouse with B Cells but Lacking Serum Antibody Reveals an Antibody-
independent Role for B Cells in Murine Lupus. The Journal of Experimental 
Medicine 189, 1639-1648 (1999). 
58. Shlomchik, M.J., Madaio, M.P., Ni, D., Trounstein, M. & Huszar, D. The role of B 
cells in lpr/lpr-induced autoimmunity. The Journal of Experimental Medicine 180, 
1295-1306 (1994). 
59. O’Neill, S.K., et al. Antigen-Specific B Cells Are Required as APCs and 
Autoantibody-Producing Cells for Induction of Severe Autoimmune Arthritis. The 
Journal of Immunology 174, 3781-3788 (2005). 
60. Martin, F. & Chan, A.C. B CELL IMMUNOBIOLOGY IN DISEASE: Evolving 
Concepts from the Clinic. Annual Review of Immunology 24, 467-496 (2006). 
61. Cartron, G., Watier, H., Golay, J. & Solal-Celigny, P. From the bench to the 
bedside: ways to improve rituximab efficacy. Blood 104, 2635-2642 (2004). 
62. Traczewski, P. & Rudnicka, L. Treatment of systemic lupus erythematosus with 
epratuzumab. British Journal of Clinical Pharmacology 71, 175-182 (2011). 
63. Cancro, M.P., D’Cruz, D.P. & Khamashta, M.A. The role of B lymphocyte 
stimulator (BLyS) in systemic lupus erythematosus. The Journal of Clinical 
Investigation 119, 1066-1073 (2009). 
64. Sanz, I. & Lee, F.E.-H. B cells as therapeutic targets in SLE. Nat Rev Rheumatol 6, 
326-337 (2010). 
65. Holborow EJ, W.D., Johnson GD. A serum factor in lupus erythematosus with 
affinity for tissue nuclei. British Medical Journal. 2, 732-734 (1957). 
66. Hahn, B.H. Antibodies to DNA. New England Journal of Medicine 338, 1359-1368 
(1998). 
67. Chan, T.M. & Cheng, I.K.P. Identification of Endothelial Cell Membrane Proteins 
that Bind Anti-DNA Antibodies from Patients with Systemic Lupus Erythematosus 
by Direct or Indirect Mechanisms. Journal of Autoimmunity 10, 433-439 (1997). 
68. Chan, T.-M., Leung, J.K.-H., Ho, S.K.-N. & Yung, S. Mesangial Cell-Binding 
Anti-DNA Antibodies in Patients with Systemic Lupus Erythematosus. Journal of 
the American Society of Nephrology 13, 1219-1229 (2002). 
69. Madaio, M.P. & Yanase, K. Cellular Penetration and Nuclear Localization of Anti-
DNA Antibodies: Mechanisms, Consequences, Implications and Applications. 
Journal of Autoimmunity 11, 535-538 (1998). 
70. Hsieh, S.C., et al. Monoclonal anti‐double stranded DNA antibody is a 
leucocyte‐binding protein to up‐regulate interleukin‐8 gene expression and elicit 
apoptosis of normal human polymorphonuclear neutrophils. Rheumatology 40, 
851-858 (2001). 
71. Madaio, M.P., Fabbi, M., Tiso, M., Daga, A. & Puccetti, A. Spontaneously 
produced anti-DNA/DNase I autoantibodies modulate nuclear apoptosis in living 
cells. European Journal of Immunology 26, 3035-3041 (1996). 
References 
 
Page | 116  
 
72. Casciola-Rosen, L. & Rosen, A. Ultraviolet light-induced keratinocyte apoptosis: A 
potential mechanism for the induction of skin lesions and autoantibody production 
in LE. Lupus 6, 175-180 (1997). 
73. Mevorach, D., Zhou, J.L., Song, X. & Elkon, K.B. Systemic Exposure to Irradiated 
Apoptotic Cells Induces Autoantibody Production. The Journal of Experimental 
Medicine 188, 387-392 (1998). 
74. Kalaaji, M., Mortensen, E., Jørgensen, L., Olsen, R. & Rekvig, O.P. Nephritogenic 
Lupus Antibodies Recognize Glomerular Basement Membrane-Associated 
Chromatin Fragments Released from Apoptotic Intraglomerular Cells. The 
American Journal of Pathology 168, 1779-1792 (2006). 
75. Kalaaji, M., et al. Glomerular apoptotic nucleosomes are central target structures 
for nephritogenic antibodies in human SLE nephritis. Kidney Int 71, 664-672 
(2007). 
76. Kowal, C., et al. Human lupus autoantibodies against NMDA receptors mediate 
cognitive impairment. Proceedings of the National Academy of Sciences 103, 
19854-19859 (2006). 
77. Wang, Y., et al. Amelioration of lupus-like autoimmune disease in NZB/WF1 mice 
after treatment with a blocking monoclonal antibody specific for complement 
component C5. Proceedings of the National Academy of Sciences 93, 8563-8568 
(1996). 
78. Walport, M.J. Complement. New England Journal of Medicine 344, 1140-1144 
(2001). 
79. Robson, M.G., et al. Accelerated Nephrotoxic Nephritis Is Exacerbated in C1q-
Deficient Mice. The Journal of Immunology 166, 6820-6828 (2001). 
80. Einav, S., Pozdnyakova, O.O., Ma, M. & Carroll, M.C. Complement C4 Is 
Protective for Lupus Disease Independent of C3. The Journal of Immunology 168, 
1036-1041 (2002). 
81. Sekine, H., et al. Complement Component C3 Is Not Required for Full Expression 
of Immune Complex Glomerulonephritis in MRL/lpr Mice. The Journal of 
Immunology 166, 6444-6451 (2001). 
82. Ronnblom, L. & Alm, G. Systemic lupus erythematosus and the type I interferon 
system. Arthritis Res Ther 5, 68 - 75 (2003). 
83. Baechler, E.C., et al. Interferon-inducible gene expression signature in peripheral 
blood cells of patients with severe lupus. Proceedings of the National Academy of 
Sciences 100, 2610-2615 (2003). 
84. Mathian, A., Weinberg, A., Gallegos, M., Banchereau, J. & Koutouzov, S. IFN-α 
Induces Early Lethal Lupus in Preautoimmune (New Zealand Black × New 
Zealand White)F1 but Not in BALB/c Mice. The Journal of Immunology 174, 
2499-2506 (2005). 
85. Kishimoto, T. INTERLEUKIN-6: From Basic Science to Medicine—40 Years in 
Immunology. Annual Review of Immunology 23, 1-21 (2005). 
86. Kishimoto, T. The biology of interleukin-6. Blood 74, 1-10 (1989). 
87. Houssiau, F., et al. Serum interleukin 10 titers in systemic lupus erythematosus 
reflect disease activity. Lupus 4, 393-395 (1995). 
88. Llorente, L., et al. Clinical and biologic effects of anti–interleukin-10 monoclonal 
antibody administration in systemic lupus erythematosus. Arthritis & Rheumatism 
43, 1790-1800 (2000). 
89. Jacob, C.O. & McDevitt, H.O. Tumour necrosis factor-[alpha] in murine 
autoimmune 'lupus' nephritis. Nature 331, 356-358 (1988). 
References 
 
Page | 117  
 
90. Charles, P.J., Smeenk, R.J.T., De Jong, J., Feldmann, M. & Maini, R.N. 
Assessment of antibodies to double-stranded DNA induced in rheumatoid arthritis 
patients following treatment with infliximab, a monoclonal antibody to tumor 
necrosis factor α: Findings in open-label and randomized placebo-controlled trials. 
Arthritis & Rheumatism 43, 2383-2390 (2000). 
91. Mohan, A.K., Edwards, E.T., Coté, T.R., Siegel, J.N. & Braun, M.M. Drug-
induced systemic lupus erythematosus and TNF-α blockers. The Lancet 360, 646 
(2002). 
92. Yamamoto, T., et al. Expression of transforming growth factor-[beta] isoforms in 
human glomerular diseases. Kidney Int 49, 461-469 (1996). 
93. Raz, E., et al. Modulation of disease activity in murine systemic lupus 
erythematosus by cytokine gene delivery. Lupus 4, 286-292 (1995). 
94. Ouyang, W., Kolls, J.K. & Zheng, Y. The Biological Functions of T Helper 17 Cell 
Effector Cytokines in Inflammation. Immunity 28, 454-467 (2008). 
95. Tesch, G.H., Maifert, S., Schwarting, A., Rollins, B.J. & Kelley, V.R. Monocyte 
Chemoattractant Protein 1–Dependent Leukocytic Infiltrates Are Responsible for 
Autoimmune Disease in Mrl-Faslpr Mice. The Journal of Experimental Medicine 
190, 1813-1824 (1999). 
96. Kulkarni, O., et al. Spiegelmer Inhibition of CCL2/MCP-1 Ameliorates Lupus 
Nephritis in MRL-(Fas)lpr Mice. Journal of the American Society of Nephrology 
18, 2350-2358 (2007). 
97. Anders, H.-J., et al. CC Chemokine Ligand 5/RANTES Chemokine Antagonists 
Aggravate Glomerulonephritis Despite Reduction of Glomerular Leukocyte 
Infiltration. The Journal of Immunology 170, 5658-5666 (2003). 
98. Chong, B.F. & Mohan, C. Targeting the CXCR4/CXCL12 axis in systemic lupus 
erythematosus. Expert Opinion on Therapeutic Targets 13, 1147-1153 (2009). 
99. Lee, S.-J., Silverman, E. & Bargman, J.M. The role of antimalarial agents in the 
treatment of SLE and lupus nephritis. Nat Rev Nephrol 7, 718-729 (2011). 
100. Jackson, C.J. & Xue, M. Activated protein C—An anticoagulant that does more 
than stop clots. The International Journal of Biochemistry & Cell Biology 40, 
2692-2697 (2008). 
101. Bernard, G.R., et al. Efficacy and Safety of Recombinant Human Activated Protein 
C for Severe Sepsis. New England Journal of Medicine 344, 699-709 (2001). 
102. Kerschen, E.J., et al. Endotoxemia and sepsis mortality reduction by non-
anticoagulant–activated protein C. The Journal of Experimental Medicine 204, 
2439-2448 (2007). 
103. Guo, H., et al. Neuroprotective activities of activated protein C mutant with 
reduced anticoagulant activity. European Journal of Neuroscience 29, 1119-1130 
(2009). 
104. Jackson, C., et al. New therapeutic applications for the anticoagulant, activated 
protein C. Expert Opinion on Biological Therapy 8, 1109-1122 (2008). 
105. Isermann, B., et al. Activated protein C protects against diabetic nephropathy by 
inhibiting endothelial and podocyte apoptosis. Nat Med 13, 1349-1358 (2007). 
106. Scaldaferri, F., et al. Crucial role of the protein C pathway in governing 
microvascular inflammation in inflammatory bowel disease. The Journal of 
Clinical Investigation 117, 1951-1960 (2007). 
107. Shi, G.-P., et al. Cathepsin S Required for Normal MHC Class II Peptide Loading 
and Germinal Center Development. Immunity 10, 197-206 (1999). 
References 
 
Page | 118  
 
108. Gupta, S., Singh, R.K., Dastidar, S. & Ray, A. Cysteine cathepsin S as an 
immunomodulatory target: present and future trends. Expert Opinion on 
Therapeutic Targets 12, 291-299 (2008). 
109. Nakagawa, T.Y. & Rudensky, A.Y. The role of lysosomal proteinases in MHC 
class Il-mediated antigen processing and presentation. Immunological Reviews 172, 
121-129 (1999). 
110. Villadangos, J.A., et al. Proteases involved in MHC dass II antigen presentation. 
Immunological Reviews 172, 109-120 (1999). 
111. Riese, R.J., et al. Cathepsin S activity regulates antigen presentation and immunity. 
The Journal of Clinical Investigation 101, 2351-2363 (1998). 
112. Baugh, M., et al. Therapeutic dosing of an orally active, selective cathepsin S 
inhibitor suppresses disease in models of autoimmunity. Journal of Autoimmunity 
36, 201-209 (2011). 
113. Nakagawa, T.Y., et al. Impaired Invariant Chain Degradation and Antigen 
Presentation and Diminished Collagen-Induced Arthritis in Cathepsin S Null Mice. 
Immunity 10, 207-217 (1999). 
114. Saegusa, K., et al. Cathepsin S inhibitor prevents autoantigen presentation and 
autoimmunity. The Journal of Clinical Investigation 110, 361-369 (2002). 
115. Anna K. Clark, F.M., Marta D’ Auria, Meirion Davies, John Grist, Marzia 
Malcangio and Stephen B. McMahon. Cathepsin S Inhibition Attenuates 
Neuropathic Pain and Microglial Response Associated with Spinal Cord Injury. 
The Open Pain Journal 3, 117-122 (2010). 
116. Sukhova, G.K., et al. Deficiency of cathepsin S reduces atherosclerosis in LDL 
receptor–deficient mice. The Journal of Clinical Investigation 111, 897-906 
(2003). 
117. Feehally, J., et al. HLA Has Strongest Association with IgA Nephropathy in 
Genome-Wide Analysis. Journal of the American Society of Nephrology 21, 1791-
1797 (2010). 
118. Stanescu, H.C., et al. Risk HLA-DQA1 and PLA2R1 Alleles in Idiopathic 
Membranous Nephropathy. New England Journal of Medicine 364, 616-626 
(2011). 
119. Appendix: Color Figures. ASH Education Program Book 2007, 509-520 (2007). 
120. Victora, G.D. & Nussenzweig, M.C. Germinal Centers. Annual Review of 
Immunology 30, 429-457 (2012). 
121. Deschamps, K., et al. Genetic and Pharmacological Evaluation of Cathepsin S in a 
Mouse Model of Asthma. American Journal of Respiratory Cell and Molecular 
Biology 45, 81-87 (2011). 
122. Kala, M., et al. Cathepsin S is not crucial to TSHR processing and presentation in a 
murine model of Graves' disease. Immunology 116, 532-540 (2005). 
123. Stoeckle, C., et al. Cathepsin S dominates autoantigen processing in human thymic 
dendritic cells. Journal of Autoimmunity 38, 332-343 (2012). 
124. Perry, D., Sang, A., Yin, Y., Zheng, Y.-Y. & Morel, L. Murine Models of Systemic 
Lupus Erythematosus. Journal of Biomedicine and Biotechnology 2011(2011). 
125. Tsokos, L.A.L.a.G.C. The IL-2 Defect in Systemic Lupus Erythematosus Disease 
Has an Expansive Effect on Host Immunity. Journal of Biomedicine and 
Biotechnology 2010(2010). 
126. Andrews, B.S., et al. Spontaneous murine lupus-like syndromes. Clinical and 
immunopathological manifestations in several strains. The Journal of Experimental 
Medicine 148, 1198-1215 (1978). 
References 
 
Page | 119  
 
127. Patole, P.S., et al. Coactivation of Toll-like receptor-3 and -7 in immune complex 
glomerulonephritis. Journal of Autoimmunity 29, 52-59 (2007). 
128. Austin, H.A., III, Muenz, L.R., Joyce, K.M., Antonovych, T.T. & Balow, J.E. 
Diffuse proliferative lupus nephritis: Identification of specific pathologic features 
affecting renal outcome. Kidney Int 25, 689-695 (1984). 
129. Allam, R., et al. Viral 5′-triphosphate RNA and non-CpG DNA aggravate 
autoimmunity and lupus nephritis via distinct TLR-independent immune responses. 
European Journal of Immunology 38, 3487-3498 (2008). 
130. Steinmetz, O.M., et al. CXCR3 Mediates Renal Th1 and Th17 Immune Response 
in Murine Lupus Nephritis. The Journal of Immunology 183, 4693-4704 (2009). 
131. Biesecker, G., Katz, S. & Koffler, D. Renal localization of the membrane attack 
complex in systemic lupus erythematosus nephritis. The Journal of Experimental 
Medicine 154, 1779-1794 (1981). 
132. Pego-Reigosa, J.M., Medeiros, D.A. & Isenberg, D.A. Respiratory manifestations 
of systemic lupus erythematosus: old and new concepts. Best practice & research. 
Clinical rheumatology 23, 469-480 (2009). 
133. Teichmann, L.L., et al. Dendritic Cells in Lupus Are Not Required for Activation 
of T and B Cells but Promote Their Expansion, Resulting in Tissue Damage. 
Immunity 33, 967-978 (2010). 
134. Haas, C., Ryffel, B. & Le Hir, M. IFN-γ Receptor Deletion Prevents Autoantibody 
Production and Glomerulonephritis in Lupus-Prone (NZB × NZW)F1 Mice. The 
Journal of Immunology 160, 3713-3718 (1998). 
135. Kulkarni, O.P. & Anders, H.-J. Lupus nephritis. How latest insights into its 
pathogenesis promote novel therapies. Current Opinion in Rheumatology 24, 457-
465 (2012). 
136. Wang, Y., et al. Differential Neuroprotection and Risk for Bleeding From 
Activated Protein C With Varying Degrees of Anticoagulant Activity. Stroke 40, 
1864-1869 (2009). 
137. Xu, J., et al. Extracellular histones are major mediators of death in sepsis. Nat Med 
15, 1318-1321 (2009). 
138. Kau, J.-H., et al. Activated protein C ameliorates Bacillus anthracis lethal toxin-
induced lethal pathogenesis in rats. Journal of Biomedical Science 19, 98 (2012). 
139. Wang, Y., et al. An Activated Protein C Analog With Reduced Anticoagulant 
Activity Extends the Therapeutic Window of Tissue Plasminogen Activator for 
Ischemic Stroke in Rodents. Stroke 43, 2444-2449 (2012). 
140. Abraham E, R.K.O.S. & et al. Efficacy and safety of tifacogin (recombinant tissue 
factor pathway inhibitor) in severe sepsis: A randomized controlled trial. JAMA 
290, 238-247 (2003). 
141. Warren Bl, E.A.S.P. & et al. High-dose antithrombin iii in severe sepsis: A 
randomized controlled trial. JAMA 286, 1869-1878 (2001). 
142. Griffin, J.H., FernÁNdez, J.A., Gale, A.J. & Mosnier, L.O. Activated protein C. 
Journal of Thrombosis and Haemostasis 5, 73-80 (2007). 
143. Yan, S.B., Helterbrand, J.D., Hartman, D.L., Wright, T.J. & Bernard, G.R. Low 
Levels of Protein C Are Associated With Poor Outcome in Severe Sepsis*. CHEST 
Journal 120, 915-922 (2001). 
144. Fisher, C.J.J. & Yan, S.B. Protein C levels as a prognostic indicator of outcome in 
sepsis and related diseases. Critical Care Medicine 28, S49-S56 (2000). 
145. Zhou, J., et al. Activated protein C improves pial microcirculation in experimental 
endotoxemia in rats. Microvascular Research 83, 276-280 (2012). 
References 
 
Page | 120  
 
146. Bae, J.-S. & Rezaie, A.R. Activated protein C inhibits high mobility group box 1 
signaling in endothelial cells. Blood 118, 3952-3959 (2011). 
147. Cao, C., et al. The efficacy of activated protein C in murine endotoxemia is 
dependent on integrin CD11b. The Journal of Clinical Investigation 120, 1971-
1980 (2010). 
148. Brueckmann, M., et al. Activated protein C inhibits the release of macrophage 
inflammatory protein-1-alpha from THP-1 cells and from human monocytes. 
Cytokine 26, 106-113 (2004). 
149. White, B., et al. Activated protein C inhibits lipopolysaccharide-induced nuclear 
translocation of nuclear factor κB (NF-κB) and tumour necrosis factor α (TNF-α) 
production in the THP-1 monocytic cell line. British Journal of Haematology 110, 
130-134 (2000). 
150. Stephenson, D.A., Toltl, L.J., Beaudin, S. & Liaw, P.C. Modulation of Monocyte 
Function by Activated Protein C, a Natural Anticoagulant. The Journal of 
Immunology 177, 2115-2122 (2006). 
151. Kulkarni, O.P., et al. 4SC-101, A Novel Small Molecule Dihydroorotate 
Dehydrogenase Inhibitor, Suppresses Systemic Lupus Erythematosus in MRL-
(Fas)lpr Mice. The American Journal of Pathology 176, 2840-2847 (2010). 
152. Madhusudhan, T., et al. Cytoprotective signaling by activated protein C requires 
protease-activated receptor-3 in podocytes. Blood 119, 874-883 (2012). 
153. Bock, F., et al. Activated protein C ameliorates diabetic nephropathy by 
epigenetically inhibiting the redox enzyme p66Shc. Proceedings of the National 
Academy of Sciences 110, 648-653 (2013). 
154. Kessenbrock, K., et al. Netting neutrophils in autoimmune small-vessel vasculitis. 
Nat Med 15, 623-625 (2009). 
155. Han, M.H., et al. Proteomic analysis of active multiple sclerosis lesions reveals 
therapeutic targets. Nature 451, 1076-1081 (2008). 
156. Kerschen, E., et al. Activated protein C targets CD8+ dendritic cells to reduce the 
mortality of endotoxemia in mice. The Journal of Clinical Investigation 120, 3167-
3178 (2010). 
157. Kulkarni, O., et al. Anti-Ccl2 Spiegelmer Permits 75% Dose Reduction of 
Cyclophosphamide to Control Diffuse Proliferative Lupus Nephritis and 
Pneumonitis in MRL-Fas(lpr) Mice. Journal of Pharmacology and Experimental 
Therapeutics 328, 371-377 (2009). 
158. Abraham, E., et al. Drotrecogin Alfa (Activated) for Adults with Severe Sepsis and 
a Low Risk of Death. New England Journal of Medicine 353, 1332-1341 (2005). 
159. Germain, R.N. MHC-dependent antigen processing and peptide presentation: 
Providing ligands for T lymphocyte activation. Cell 76, 287-299 (1994). 
160. Zheng, T., et al. Role of cathepsin S-dependent epithelial cell apoptosis in IFN-γ-
induced alveolar remodeling and pulmonary emphysema. The Journal of 
Immunology 175, 2026 (2005). 
161. Samokhin, A.O., Lythgo, P.A., Gauthier, J.Y., Percival, M.D. & Brömme, D. 
Pharmacological Inhibition of Cathepsin S Decreases Atherosclerotic Lesions in 
Apoe-/- Mice. Journal of Cardiovascular Pharmacology 56, 98-105 
110.1097/FJC.1090b1013e3181e1023e1010 (2010). 
162. Allen, C.D.C., et al. Germinal center dark and light zone organization is mediated 
by CXCR4 and CXCR5. Nat Immunol 5, 943-952 (2004). 
163. Victora, G.D., et al. Identification of human germinal center light and dark zone 
cells and their relationship to human B-cell lymphomas. Blood 120, 2240-2248 
(2012).
Abbreviations 
 
Page | 121  
 
9. Abbreviations  
 
ANA Antinuclear antibodies   
APC Antigen presenting cell  
aPC Activated protein C 
BCR B cell receptor  
BSA Bovine serum albumin  
BUN Blood urea nitrogen 
Cat S  Cathepsin S 
cDNA Complementary DNA  
CCL2 Chemokine C-C motif ligand 2  
CCL5 Chemokine C-C motif ligand 5   
CXCL10 Chemokine C-X-C motif ligand 10   
CXCL12 Chemokine C-X-C motif ligand 12  
CT Cycle threshold  
DC Dendritic cell  
DNA Deoxyribonucleic acid  
dNTPs Deoxynucleotide triphosphates 
ELISA Enzyme-Linked Immunosorbent Assay  
FACS Fluorescence activated cell sorting  
FITC Fluorescein isothiocyanate  
GFR Glomerular filtration rate  
IC Immune complex  
ICAM-1 Intercellular adhesion molecule-1 
Ig Immunoglobulin  
IL Interleukin  
IFN-γ Interferon-γ  
kDa kilo Dalton  
lpr Lymphoproliferation 
MCP-1 Monocyte chemoattractant protein-1  
MHC Major histocompatibility complex  
mRNA messenger ribonucleic acid  
O.D. Optical density  
PAS Periodic acid Schiff   
PBS Phosphate buffered saline  
PCR Polymerase chain reaction  
pDCs plasmacytoid dendritic cells   
PE Phycoerythrin  
RNA Ribonucleic acid  
Rnase ribonuclease  
RPM revolutions per minute  
rRNA ribosomal ribonucleic acid  
RT Reverse transcriptase  
SLE Systemic lupus erythematosus  
Sm Smith antigen  
SNP Single nucleotide polymorphism  
SnRNP Small nuclear ribonucleoprotein 
TGF-β transforming growth factor-β  
TLR Toll-like receptor  
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10. Appendix  
 
Collagenase / DNAse solution:   
1 mg/ml Collagenase, 0.1 mg/ml DNAse in 1X HBSS (without Ca, Mg)   
For 10 ml:   
10mg     Collagenase (type I) (Sigma C0130)  
1ml       1 mg/ml DNAse stock solution      
9 ml      1X HBSS          
 
To be preheated in 37ºC water bath before use.   
Caution: Prepare freshly every time (Stable only for few days)   
  
Collagenase solution:   
1 mg/ml Collagenase in 1X HBSS (without Ca, Mg)   
For 10 ml:   
10 mg    Collagenase (type I)        
10ml      HBSS (with Ca, Mg)       
 
To be preheated in 37ºC water bath before use.   
Caution: Prepare freshly every time (Stable only for few days)   
  
FACS buffer:  
500 ml   DPBS   
500 mg  Sodium azide 
1 g         BSA  
  
10X HBSS (Hank’s Balanced Saline Solution) without Ca, Mg:  
 
4 g         KCl  
0.6 g      KH2PO4  
80g        NaCl  
0.621g   Na2HPO4.2H2O   
 
Dissolve in 1000 ml and autoclave. 
 
1X PBS 
  
8 g          NaCl  
0.2 g       KCl  
1.44 g     Na2HPO4  
0.24 g     KH2PO4  
 
Dissolve in 800 ml of distilled H2O.  
Adjust the pH to 7.4 with HCl. Add H2O to 1 liter. 
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